Physiological roles of PKB isoforms in development, growth and glucose metabolism by Dümmler, Bettina
 1
 
Physiological Roles of PKB Isoforms in 








Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 










Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag 
von Dr. Brian Hemmings, Prof. Dr. Nancy Hynes, and Prof. Dr. Christoph 
Moroni. 
 




Prof. Dr. Hans-Peter Hauri   
 (Dekan) 
 3
TABLE OF CONTENT 
 
i. SUMMARY ...................................................................................................................5 
ii. ABBREVIATIONS .......................................................................................................7 
 
I. INTRODUCTION ..........................................................................................................8 
1. PKB isoforms and structure .........................................................................................8 
2. The PI3K/PKB signaling pathway ..............................................................................10 
3. Physiological functions of PKB...................................................................................13 
3.1. Role of PKB in cell proliferation............................................................................13 
3.2. Role of PKB in glucose homeostasis....................................................................18 
 
4. Role of PKB in disease ..............................................................................................22 
4.1 Pathology of type 2 diabetes and molecular mechanisms in insulin 
resistance and β cell failure.........................................................................................22 
4.2 Activation of PKB in cancer ...................................................................................24 
 
5. Insights from PKB mutant mice..................................................................................28 
6. Aims of this thesis ......................................................................................................32 
 
II. RESULTS ..................................................................................................................33 
 
Part 1: ............................................................................................................................33 
Life with a single isoform of Akt: Mice lacking Akt2 and Akt3 are viable 
but display impaired glucose homeostasis and growth deficiencies. 
Dummler B, Tschopp O, Hynx D, Yang ZZ, Dirnhofer S, Hemmings BA.  
Mol Cell Biol, 2006, 26: 8042-8051.  
 
Part 2: ............................................................................................................................34 
Essential role of protein kinase B gamma (PKBgamma/Akt3) in postnatal 
brain development but not in glucose homeostasis.  
Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, 
Michaelis T, Frahm J, Hemmings BA.  
Development 2005, 132: 2943-2954 
 
 4
Part 3: ............................................................................................................................35 
Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and 
Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous 
system development in mice.  
Yang ZZ, Tschopp O, Di-Poi N, Bruder E, Baudry A, Dummler B, Wahli W, Hemmings BA.  
Mol Cell Biol 2005, 25: 10407-10418 
 
III. DISCUSSION............................................................................................................36 
IV. REFERENCES .........................................................................................................41 
V. ACKNOWLEDGEMENTS .......................................................................................522 
 
VI. APPENDIX ...............................................................................................................53 
 
Part 1: ............................................................................................................................53 
Dissecting the physiological functions of CTMP1 and CTMP2 proteins by 
generation and analysis of loss-of-function mice models.  
Dummler B, Brazil DP, Hemmings BA.  
(Fragmental project containing unpublished results)  
 
Part 2: ............................................................................................................................68 
Functional characterization of human RSK4, a new 90-kDa ribosomal S6 
kinase, reveals constitutive activation in most cell types.  
Dummler B, Hauge C, Silber J, Yntema HG, Kruse LS, Kofoed B, Hemmings BA, Alessi DR, 
Frodin M.  
J Biol Chem 2005, 280(14): 13304-13314 
 
Part 3: ............................................................................................................................69 
Vom Labor zum Krankenbett: Wie die Grundlagenforschung zur 
Entwicklung neuer Krebsmedikamente führt.  
Dummler B, Hemmings BA.  
Krebsforschung in der Schweiz 2005, 46-55. Review. 
 
VII. CURRICULUM VITAE.............................................................................................86 
 5
ii. SUMMARY 
Protein kinase B (PKB), also known as Akt, is a serine/threonine protein kinase 
that regulates key events in metabolism, proliferation, cell survival, and 
differentiation. Importantly, PKB is a major downstream effector of IGF1 and 
insulin signaling, implicating this kinase in growth control and insulin action. In 
mammals, there are three isoforms of PKB, PKBα/Akt1, PKBβ/Akt2, and 
PKBγ/Akt3. These are encoded by distinct genes but share similar structural 
organization. It has been proposed that such isoforms are uniquely adapted to 
transmit distinct biological signals. To identify specific physiological functions of 
the individual isoforms, we and others have generated animal models deficient 
in PKBα, PKBβ, and PKBγ: Mice lacking PKBα demonstrate increased 
perinatal mortality and a reduction in body weight, whereas PKBβ-deficient 
exhibit a diabetes-like syndrome with elevated fasting plasma glucose and 
peripheral insulin resistance; the present study shows a role of PKBγ in 
postnatal brain development. 
These observations indicate that the PKB isoforms have some differential, non-
redundant physiological functions. The relatively subtle phenotypes of these 
mice as well as the viability of the animals suggest, however, that for many 
functions PKB isoforms are able to compensate for each other. Certain 
physiological functions of PKB are thus revealed only when total PKB levels are 
below a critical threshold in particular cell types and tissues. In the present 
study we analyzed mice doubly deficient for PKBα/PKBγ and PKBβ/PKBγ, 
respectively, to identify the combined roles of these isoforms in PKB-mediated 
physiological processes. 
We show that mice mutant in both PKBα and PKBγ die around embryonic day 
12 with severe impairments in growth, cardiovascular development, and 
organization of the nervous system. In contrast, we found that PKBβ−/−γ−/− mice 
develop normally and survive with minimal dysfunctions despite a dramatic 
reduction of total PKB levels in all tissues. In PKBβ−/−γ−/− mice only the PKBα 
isoform remains to perform essential PKB functions and we show that minimal 
amounts of PKBα appear to be sufficient for full activation of many downstream 
targets. Interestingly, even the presence of only a single functional allele of 
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PKBα is sufficient for successful embryonic development and postnatal survival 
in mice. However, PKBβ−/−γ−/− mice are glucose and insulin intolerant and 
exhibit a ~25% reduction in body weights compared to wild-type mice. In 
addition, we found a substantial reduction in relative size and weight of brain 
and testis, demonstrating an in vivo role for both PKBβ and PKBγ in the 
determination of whole animal size and individual organ sizes. 
Taken together, our results provide insights into the PKB isoform hierarchy and 





CDK  cyclin-dependent kinase 
4EBP1 eIF4E binding protein 1 
eIF4B  eukaryotic translation initiation factor 4B 
GAP  GTPase activating protein 
GSK3 glycogen synthase kinase 3 
IGF1 insulin-like growth factor 1 
IRS insulin receptor substrate 
mTOR mammalian target of rapamycin 
PDK1 3-phosphoinositide-dependent protein kinase 1 
PH  pleckstrin homology 
PI3K  phosphoinositide-3-kinase 
PI(3,4,5)P3  phosphatidylinositol 3,4,5-triphosphate 
PKB  protein kinase B 
PRK2  protein kinase C-related kinase 2 
PTEN phosphatase and tensin homolog 
Raptor regulatory-associated protein of mTOR 
Rictor rapamycin-insensitive companion of mTOR 
RTK receptor tyrosine kinase 
SH2 Src homology 2 
S6K1 p70 ribosomal protein S6 kinase 1 
TSC tuberous sclerosis complex 
 





1. PKB isoforms and structure 
PKB is a member of a family of protein kinases that originally contained cAMP-
dependent kinase, cGMP-dependent kinase and protein kinase C (PKC), 
termed the AGC family. Other members of the AGC family include p70 
ribosomal protein S6 kinase 1 (S6K1), protein kinase C-related kinase 2 
(PRK2), and serum- and glucocorticoid-inducible kinase (SGK). The protein 
kinases of the AGC family show similarities in many structural and regulatory 
features. Highly similar in all AGC kinases is a flexible peptide loop (activation 
loop) proximal to the catalytic pocket of the kinase domain, and 
phosphorylation of this loop is required for the activation of virtually all AGC 
kinases. PKB is the cellular homologue of the transforming oncogene v-Akt, 
which was found in a retrovirus termed AKT8. This retrovirus was originally 
isolated from mice with a high incidence of spontaneous lymphoma. Close 
homologues of PKB have been identified in a variety of species, including birds, 




Fig, 1. (A) Domain structure and regulatory phosphorylation sites of PKB. All isoforms contain a pleckstrin 
homology (PH) domain, a catalytic domain and a C-terminal regulatory domain containing the 
hydrophobic motif. Phosphorylation of the activation loop and the hydrophobic motif (Thr308 and Ser473 
in PKBα) are critical for kinase activation. (B) Phylogenetic tree of the PKB family. PKB has a high level of 
evolutionary conservation; mouse and human genomes encode three PKB genes (PKBα, PKBβ, PKBγ), 
the C.elegans genome encodes two (Akt1 and Akt2) and the drosophila genome only one (dPKB) 
(Adapted from Riehle et al., 2003). 
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There are three isoforms of PKB in mammals, termed PKBα (Akt1), PKBβ 
(Akt2), and PKBγ (Akt3). These are products of distinct genes but highly related, 
exhibiting greater than 80% sequence identity and sharing the same structural 
organization (Fig. 1A). Each isoform possesses an amino-terminal pleckstrin 
homology (PH) domain that binds to 3-phosphoinositides, a central catalytic 
domain, and a carboxy-terminal regulatory domain. Furthermore, all three 
isoforms possess two conserved phosphorylation sites, and phosphorylation of 
both sites is required for full activation of the kinase. The first one (Thr308 in 
PKBα) lies within the activation loop of the kinase domain and its 
phosphorylation induces a catalytically active conformation of the kinase. The 
second one lies within the regulatory domain in a 6-amino acid long sequence 
termed the hydrophobic motif (FPQFS473Y).  
 
 
Fig. 2. Structure of activated PKB. The ribbon diagram shows an activated PKBβ ternary complex with 
GSK3-peptide (red) bound in the substrate-binding site and AMP-PNP (a hydrolysis-resistant ATP 
analogue) bound in the ATP-binding site. To obtain an active conformation, the hydrophobic motif of PKB 
was replaced with that of another AGC kinase, PRK2, and T309 in the activation segment (blue) was 
phosphorylated by PDK1. The hydrophobic motif of PRK2 contains an acidic residue (D474) in place of a 
phosphorylatable serine and binds constitutively to the N-lobe without needing phosphorylation. (Adapted 
from Yang et al., 2002). 
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Phosphorylation at Ser473 enables the hydrophobic motif to bind into a pocket1 
within the small lobe (N-lobe) of the kinase domain and thereby it stabilizes the 
active conformation of PKB. Binding of the phosphorylated hydrophobic motif to 
this pocket increases kinase activity of PKB by tenfold. 
The crystal structure of the kinase domain of PKB has been solved, although 
this required deletion of the PH domain and substitution of the hydrophobic 
motif of PKB with the hydrophobic motif of PRK2 (Fig. 2)(116). All PKB 
isoforms are assumed to have identical or similar substrate specificity. The 
minimal consensus sequence for in vitro phosphorylation by PKB has been 
defined as ArgXArgXXSer/Thr-Hyd, where X is any amino acid and Hyd is a 
bulky hydrophobic residue. 
                                            
1 This structure has been termed the ‘PRK2-interacting factor (PIF)-pocket’ because it was 
initially identified on PDK1 as a binding site for the hydrophobic motif of PRK2. 
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2. The PI3K/PKB signaling pathway 
The typical route of PKB activation is via receptor tyrosine kinases. Binding of 
ligands such as epidermal growth factor (EGF) and platelet-derived growth 
factor (PDGF) to their appropriate receptors leads to autophosphorylation of 
specific tyrosine residues on the intracellular portion of the receptor (Fig. 3). 
Recruitment of phosphoinositide 3-kinase (PI3K)2 then occurs, via binding of 
the Src homology 2 (SH2) domains of its regulatory subunit, p85, to specific 
phosphotyrosine residues on the receptor. For insulin-receptor and IGF-
receptor, recruitment of the p85 subunit to the receptor is largely mediated by 
an adaptor protein called IRS 3  (insulin receptor substrate). Binding of p85 
subunit to phosphotyrosines on the receptor or IRS proteins leads to a 
conformational change in PI3K and consequently to activation of its catalytic 
subunit, p110. Activated PI3K phosphorylates inositol-containing membrane 
lipids at the 3'-OH position of the inositol ring, generating phosphatidylinositol 
3,4,5-trisphosphate (PI(3,4,5)P3). Subsequently, inactive PKB is recruited from 
the cytosol to the membrane via binding of its PH domain to PI(3,4,5)P3.  
Membrane recruitment brings PKB in close proximity to 3-phosphoinositide-
dependent protein kinase (PDK1). PDK1 possesses a PH domain in its 
carboxy-terminus, which binds PI(3,4,5)P3 and localizes PDK1 at the 
membrane. Co-localization of the two proteins and the conformational change 
induced in PKB upon lipid binding then enable PDK1 to phosphorylate PKB on 
Thr308 in the activation loop. For full kinase activation, PKB requires 
phosphorylation of an additional site, Ser473, which is located in the 
                                            
2 There are several classes of phosphoinositide kinases. For growth factor signaling, the predominant 
enzymes that produce second messengers belong to the 3’ family of phosphoinositide kinases, 
specifically the Class I subdivision. Class I PI3K is a heterodimeric complex comprising a 85-kDa 
regulatory subunit and a 110-kDa catalytic subunit. At least eight isoforms of p85 have been identified, 
which are derived from three distinct genes. The most ubiquitous regulatory subunit is p85α from the 
Pik3r1 gene. Furthermore, there are three different catalytic subunits, p110α, β, and δ, which are derived 
from three different genes and show different tissue distribution. The p110α and p110β forms are almost 
ubiquitous, whereas p110δ is restricted to leukocytes. 
3  IRS proteins have both PH domains and phosphotyrosine-binding domains (PTB domains) near the N-
terminus that account for the high affinity of these proteins to the receptors. The centre and the C-
terminus of the IRS proteins contain up to 20 potential tyrosine-phosphorylation sites that, after 
phosphorylation by the receptor, bind to intracellular molecules that contain SH2 domains. 
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hydrophobic motif domain. The identity of the kinase(s) mediating Ser473 
phosphorylation on PKB is still controversial. Recent work has identified two 
kinases that can phosphorylate PKB on the hydrophobic motif: the mTOR-rictor 
complex and DNA-PK (DNA-dependent protein kinase) (33, 94). Most likely, 
these two upstream kinases mediate PKB activation in response to different 
stimuli. Following activation, PKB is detached from the plasma membrane and 




Fig. 3. Mechanism of PKB activation and downstream targets. PKB is activated via receptor tyrosine kinases (RTK) 
in a PI3K-dependent manner and phosphorylated on Thr308 and Ser473 by upstream kinases. Representative 
substrates of PKB in cytoplasm and nucleus are grouped according to their function. Activation (+) or inhibition (-) of the 
targets upon PKB-mediated phosphorylation is indicated. Abbreviations: BAD: Bcl-2 antagonist of cell death; BRF1: 
Butyrate response factor1; CTMP: C-terminal modulator protein; eNOS: endothelial cell nitric oxide synthase; 
FOXO1/3a/4: Forkhead Box O1/3a/4 (FOXO1/FKHR, FOXO3a/FKHRL1, and FOXO4/AFX); IKK: inhibitor kappa B 
kinase; Mdm2: mouse double minute 2; Myt1: membrane associated and tyrosine/threonine specific 1; NF-κB: nuclear 
factor-kappa B; PHLPP: PH domain and leucine rich repeat protein phosphatase; 6-PF2K: 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase; Plk1: Polo like kinase1; PP2A: protein phosphatase 2 subunit A; WNK1: with no 
lysine [K]1. (Adapted from Fayard et al., 2005) 
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3. Physiological functions of PKB 
Up to date over 40 proteins have been identified as substrates for PKB 
(although some of them only in vitro) and the list is still increasing. The 
identification of PKB substrates and the role PKB-mediated phosphorylation 
plays in the regulation of these molecules have been a major focus of research 
in recent years. The long list of PKB substrates reflects the widely divergent 
cellular processes that PKB is implicated in, such as metabolism, differentiation, 
cell survival, and cell growth/proliferation. In the following, PKB function in cell 
growth/proliferation and in glucose metabolism is described. 
 
3.1. Role of PKB in cell proliferation 
Cell proliferation involves two distinct but intertwined processes: cell growth 
(increase in cell size) and cell division (i.e. progression through the cell cycle). 
Cell growth is characterized by elevated production of the translational 
apparatus that is needed to cope with the increasing demand for protein 
synthesis. A favourable metabolic state is necessary to accumulate enough cell 
mass and organelles to establish two daughter cells. Cell cycle progression 
includes activation of cyclin-dependent kinases (CDKs) that, in association with 
different cyclins, turn key switches throughout the cell cycle. PKB-mediated 
control of both cell growth and cell cycle progression is well established and 
involves regulation of many different targets (Fig. 4). 
The PI3K/PKB pathway in cell cycle progression 
PKB triggers a network that positively regulates G1/S cell cycle progression 
(59). For instance, PKB regulates the cell cycle inhibitors p21Cip1 and p27Kip1 
(60, 109, 120). In quiescent cells p27Kip1 and p21Cip1 are localized in the 
nucleus and inhibit cell cycle progression by binding to cyclin-CDK complexes. 
Mitogenic stimuli activate PKB, which then phosphorylates p21Cip1 and p27Kip1 
at specific sites within their nuclear localization sequences. Phosphorylation at 






Fig. 4. Networks integrating growth, survival, and cell cycle progression signals. PKB controls key 
nodes in cell growth, survival, and cell cycle G1/S transition. Important PKB downstream targets are 
FOXO transcription factors, mTOR, GSK3β, and the CDK inhibitors p21Cip1 and p27Kip1. (Adapted from 
Massague et al., 2004) 
 
Another mechanism, by which PKB promotes cell cycle progression, is the 
indirect regulation of cyclin D1 protein stability. In quiescent cells cyclin D1 
protein is unstable, as glycogen synthase kinase-3β (GSK3β)-mediated 
phosphorylation targets cyclin D1 for degradation by the proteasome. Active 
PKB negatively regulates GSK3 activity by phosphorylation and thereby 
prevents cyclin D1 degradation (30). Recent data also implicated PKB in G2/M 
transition. Okumura et al. found that PKB phosphorylates and thereby 
inactivates the Wee1 family kinase Myt1 in starfish oocytes (78). Myt1 mediates 
inhibitory phosphorylation of CDK1, which keeps the cyclin B-CDK1 complex in 
an inactive state. When Myt1 is inactivated, Cdc25 phosphatase can 
dephosphorylate CDK1 and the cyclin B-CDK1 complex can drive G2/M 
transition. 
The TSC1/TSC2 complex connects the nutrient-mTOR and the PI3K/PKB 
growth pathways 
Effective cell growth is a prerequisite for the cell cycle machinery to proceed 
through G1/S phase and initiate cell division. The major regulator of cell growth 
is a distinct signaling network, termed the mTOR (mammalian target of 
rapamycin) pathway. mTOR is a large protein with homology to members of the 
lipid kinase family and is active in presence of high nutrient levels (glucose and 
amino acids) in the cell. mTOR exists in two distinct multi-protein complexes 
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(93). One is composed of mTOR as well as GβL (G-protein β-subunit-like) and 
raptor (regulatory-associated protein of mTOR). The other complex contains 
also mTOR and GβL but, instead of raptor, a different protein called rictor 
(rapamycin-insensitive companion of mTOR). The mTOR-raptor complex is 
rapamycin sensitive, as rapamycin-FKBP12 can bind to it and inhibit mTOR 
kinase activity, whereas the mTOR-rictor complex is rapamycin-insensitive. The 
two complexes have different functions: mTOR-rictor has been shown to 
function as an upstream kinase for PKB (94) and regulator of cytoskeletal 
reorganization (47), whereas mTOR-raptor positively regulates cell growth and 
modulates a stunning number of other processes, including mRNA translation, 
ribosome biogenesis, nutrient metabolism and autophagy (37, 71). 
The discovery of a regulatory link between PKB and mTOR-raptor revealed 
how mitogenic stimuli can promote mTOR-mediated cell growth via the 
PI3K/PKB pathway. Tuberous sclerosis complex (TSC) is an autosomal 
dominant disorder that is characterized by benign tumors (hamartomas) 
involving multiple organ systems. TSC is due to inactivating mutations in either 
of two genes, tuberous sclerosis complex 1 (TSC1) and tuberous sclerosis 
complex 2 (TSC2) (17, 58). The protein products of these genes form a 
complex, TSC1/TSC2, that inhibits growth. During the past few years enormous 
progress has been made in understanding the biochemical and signaling 
function of this complex. TSC2 is a GTPase-activating protein (GAP), and in 
unstimulated conditions the TSC1/TSC2 complex has a highly specific GAP 
activity towards a small G protein called Rheb (Ras homolog enriched in brain) 
(44, 95, 119). Rheb-GTP levels play a major role in regulating the state of 
activation of the mTOR-raptor complex: in the GTP-bound state, Rheb leads to 
an increase in the activation of the mTOR-raptor complex, whereas a functional 
TSC1/TSC2 complex maintains GDP-bound Rheb and thereby low levels of 
mTOR-raptor activity (63). In cells lacking either TSC1 or TSC2, there is 
absence of a functional TSC1/TSC2 complex and concomitantly an elevation of 
Rheb-GTP levels. This leads to high levels of growth factor-independent, 
deregulated mTOR-raptor activity and consequently to the growth and 
differentiation defects that are seen in TSC hamartomas. Several groups have 
now shown that TSC2 is directly phosphorylated by PKB on several sites and 
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that this PKB-mediated phosphorylation inhibits TSC1/TSC2 function as a 
Rheb-GAP (27, 45, 68, 84). The TSC1/TSC2 complex constitutes therefore the 
converging node through which PKB can connect with the mTOR pathway and 
regulate cell growth. 
How does the mTOR pathway promote cell growth? Two mammalian proteins, 
eIF4E binding protein 1 (4EBP1) and S6K1, are known to link the mTOR-raptor 
complex to the control of mRNA translation. 4EBP1 is a repressor of 
translation; when hypophosphorylated in the absence of nutrients or growth 
factors, 4EBP1 associates with eIF4E4 (eukaryotic translation initiation factor 
4B), the mRNA cap binding protein, to inhibit cap-dependent translation. 
Binding of 4EBPs to eIF4E is regulated by ordered phosphorylation of critical 
residues on 4EBP1. The mTOR-raptor complex catalyzes phosphorylation of 
4EBP1 on specific Ser/Thr sites, which leads to release of eIF4E from 4EBP1 
and permits its participation in translation initiation complexes (75). In parallel, 
mTOR-raptor activates S6K1 (and likely the related S6K2) by phosphorylating it 
within the hydrophobic motif conserved in the AGC family of kinases (12). 
Although activation of S6K requires phosphorylation on many sites by several 
distinct kinases, mTOR-mediated phosphorylation on the hydrophobic motif site 
is absolutely required for S6K activity. How S6K1 substrates exactly contribute 
to cell size control remains to be determined but numerous reports have shown 
that absence or inactivation of S6K1 causes smaller cells, whereas activation of 
S6K1 stimulates cell growth (73, 90, 102). Several S6K1 substrates have been 
described, including the ribosomal S6 protein and the translational regulators 
eEF2 kinase and eIF4B (88). In addition, translational activation of 5’TOP 
mRNAs has been attributed to S6K activity (48). 5’TOP mRNAs encode many 
components of the translational apparatus (ribosomal proteins, elongation 
factors eEF1A and eEF2, and poly(A)-binding protein). Translational repression 
of 5’TOP mRNAs is apparent when proliferation of vertebrate cells is blocked 
by a wide variety of physiological signals (terminal differentiation, contact 
                                            
4 Initiation of translation is considered to be the rate-limiting step of translation. In the most 
general mechanism of translation initiation, the assembly of the eIF4F complex on the mRNA 5’ 
cap structure is essential for the recruitment of the 40S small ribosomal subunit to the mRNA. 
The eIF4F complex is comprised of three polypeptides, among these is the cap-binding protein 
eIF4E, which is present in limiting amounts relative to other initiation factors. The availability of 
eIF4E is regulated by its interaction with the inhibitory proteins 4EBP1-3. 
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inhibition, serum starvation) or by cell cycle inhibitors (aphidicolin and 
nocodazole). More recent work however does not support a role of S6K1 in this 
process; Stolovich et al. found that translational activation of 5'TOP mRNAs 




Fig. 5. The PI3K/PKB pathway promotes cell growth and translation via activation of the mTOR-raptor complex.  
In response to mitogens, activated PKB phosphorylates TSC2 on Ser939, Ser1130, and Thr1462, thereby inhibiting 
GAP function of the TSC1/TSC2 complex on Rheb and relieving inhibition on the mTOR-raptor complex. (Adapted from 
Um et al., 2006). 
 
Taken together, these results suggest the following model for growth signaling 
(Fig. 5). In the absence of growth-stimulatory signals, hypophosphorylated 
TSC1/TSC2 inhibits mTOR-raptor, so that translation regulated by eIF4E and 
S6K1 is minimal. When stimulated by growth factors, activated PI3K/PKB 
signaling results in the phosphorylation and inhibition of the TSC1/TSC2 
complex and thus the derepression of mTOR-raptor. mTOR-raptor then 
phosphorylates S6K1 and 4EBP1, translation rates increase and growth 
ensues. Interestingly, the mTOR-raptor complex also initiates feedback 
inhibition of PKB which is, at least in part, mediated by an inhibitory effect of 
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S6K on IRS1 (38). Although up to date rather speculative, another mechanism 
of feedback inhibition could occur via a shift in the equilibrium between mTOR-
raptor and mTOR-rictor complex formations. PKB-mediated inhibition of 
TSC1/TSC2 complex may promote the assembly of active mTOR-raptor 
complexes and thereby antagonize formation of mTOR-rictor complexes. As 
mentioned above, mTOR-rictor complex may be the principal Ser473 kinase in 
PKB activation following growth factor stimulation, and reduction of mTOR-
rictor complex formation would therefore also reduce PKB activity. 
Of note, the TSC1/TSC2 complex receives inputs from at least two other major 
signaling pathways, besides the PI3K/PKB pathway, that regulate its function 
as a GTPase activating protein by kinase-mediated phosphorylation events. 
First, there is regulation of the mTOR pathway by the MAP (mitogen-activated 
protein) kinase pathway at the TSC1/TSC2 level; both ERK (extracellular 
signal-regulated kinase) and its downstream target RSK1 (p90 ribosomal 
protein S6 kinase 1) phosphorylate TSC2 (at sites distinct from the major PKB 
sites) and thereby negatively regulate the Rheb-GAP activity of the TSC1/TSC2 
complex (64, 89). Second, the cellular energy-sensing kinase AMPK (AMP-
activated protein kinase) can also phosphorylate TSC2 but, in contrast to the 
phosphorylation of TSC2 by PKB, AMPK-mediated phosphorylation somehow 
enhances the ability of TSC1/TSC2 to act as a Rheb-GAP and therefore blocks 
Rheb-dependent mTOR activation under conditions of energy stress (46). 
Apparently, the TSC1/TSC2 complex serves as the converging point for the 
AMPK (nutrient) and PKB (growth factor) signaling in higher eukaryotes. 
 
3.2. Role of PKB in glucose homeostasis 
In humans as well as in other species, the ingestion of food provides the 
fundamental source of energy for various cellular activities. The intake of food 
and the ability of controlling the plasma levels of substrates for energy 
production involve complex mechanisms that ensure a constantly adequate 
supply of metabolites both in fasting and fed state. Postprandial blood glucose 
levels are mainly controlled by secretion of the peptide hormone insulin, which 
acts as a highly potent physiological anabolic agent. It promotes the storage 
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and synthesis of lipids, protein, and carbohydrates and inhibits their breakdown 
and release into circulation (Fig. 6). 
The first step by which insulin increases energy storage or utilization involves 
the regulated transport of glucose into the cells. In muscle and adipose tissues, 
a unique member of the facilitative glucose transporter (GLUT) family, GLUT4, 
is highly expressed and responsible for insulin-stimulated glucose uptake in 
these tissues (11). In unstimulated cells, GLUT4 is stored in intracellular 
vesicles. Binding of insulin to its receptor initiates translocation of GLUT4 from 
its storage vesicles to the plasma membrane and thereby increases glucose 




Fig. 6. Insulin regulates energy metabolism following food intake.  Insulin (I) secretion from pancreatic β-
cells depends on the abundance of ingested and circulating nutrients. In its target tissues (mainly liver, fat, 
and skeletal muscle) it promotes the uptake and storage of glucose (G), amino acids, and fat, whilst 
simultaneously antagonizing the catabolism of fuel reserves. In target cells, the PI3K/PKB pathway is a major 
mediator of the metabolic actions of insulin.  (Adapted from Mayo Foundation for Medical Education and 
Research). 
 
The PI3K/PKB pathway is a major mediator of the metabolic actions of insulin 
and plays an essential role in glucose uptake and GLUT4 translocation. PKB 
becomes strongly activated upon insulin stimulation and overexpression of PKB 
was shown to be sufficient to drive GLUT4 translocation (54). Although it is still 
not clear how PKB impinges on GLUT4 cycling, there is evidence for at least 
two PKB substrates to be involved in insulin-stimulated glucose transport. The 
first is AS160 (Akt substrate 160), a Rab-GAP that contains five sites that 
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conform to the PKB substrate consensus sequence (RXRXX[pS/pT]) and 
whose phosphorylation has been shown to be increased by insulin. Rab 
GTPases are key players in membrane trafficking events and have been shown 
to have critical roles in vesicle formation, fusion, and movement. The Rab 
protein regulated by AS160 is yet to be identified; however, it has been 
demonstrated that a mutant AS160 lacking the PKB phosphorylation sites 
blocks the ability of insulin to stimulate the exocytosis of GLUT4 (91). A second 
PKB substrate that plays a role in insulin-regulated GLUT4 trafficking is PI5-
kinase (PIKfyve) (10). PIKfyve may have a role in the sorting of GLUT4 from 
internalized endosomes into GLUT4 storage vesicles. Another PKB substrate 
that seems to be involved in the regulation of insulin-stimulated GLUT4 
translocation is Synip (115). However, the relevance of Synip phosphorylation 
is controversial because substitution of the PKB-phosphorylated residue to 





Fig. 6. Schematic model for PKB-mediated insulin actions. In muscle and fat cells, GLUT4 
redistributes from intracellular storage vesicle to the plasma membrane, resulting in increased glucose 
flux into the cells. Protein synthesis is promoted via the mTOR pathway and glycogen synthesis is 
stimulated via activation of glycogen synthase (GS). In liver, PKB suppresses transcription of 
phosphoenolpyruvate carboxykinase (PEPCK), which is the rate limiting enzyme in gluconeogenesis. 
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Furthermore, in response to insulin, PKB promotes glycogen synthesis via 
phosphorylation and inactivation of GSK3 (26). In unstimulated cells, glycogen 
synthase, the enzyme mediating incorporation of glucose from uridine 
diphosphoglucose into glycogen, is kept in an inactive state via GSK3-mediated 
phosphorylation. Activated PKB phosphorylates and thereby inactivates GSK3, 
thus promoting dephosphorylation of glycogen synthase and increased 
glycogen synthesis. 
Of note, atypical members of the protein kinase C family (ζ and λ) have been 
proposed as alternative mediators of insulin induced glucose transport (55). 
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4. Role of PKB in disease 
Aberrant signaling via the PI3K/PKB pathway plays a central role in the 
development and progression of two major diseases, type 2 diabetes mellitus 
and cancer (Fig. 7). 
 
 
Fig. 7. Aberrant PKB activity in disease. Hypoactivation of PKB is implicated in type 2 diabetes mellitus 
and hyperactivation of PKB is one of the most common molecular alterations in human malignancy. 
 
4.1 Pathology of type 2 diabetes and molecular mechanisms in 
insulin resistance and β cell failure 
Type 2 diabetes mellitus is a polygenic, multifactorial disease with a pathology 
that includes both a diminished ability of cells to respond to insulin (termed 
“insulin resistance”) and defective insulin secretion by pancreatic β cells. It 
afflicts an estimated 6% of the adult population in Western society and its 
worldwide frequency is expected to continue to grow (39). Insulin resistance 
typically heralds the onset of type 2 diabetes; it can often be detected years 
prior to onset of clinical disease (111). In pre-type 2 diabetic individuals, 
pancreatic β cells are capable of secreting increased amounts of insulin as a 
compensatory response to overcome the defect in insulin action; 
hyperinsulinemia ensues to maintain normal blood glucose levels. Ultimately, 
however, this balance between insulin resistance and insulin secretion can 
exhaust, and the full phenotype of type 2 diabetes develops (34). Dysfunctional 
glucose uptake into muscle and adipose tissue, in conjunction with an 
oversupply of glucose from the liver, results in high circulating plasma glucose 
levels that cause many severe complications. Untreated type 2 diabetes can 
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result in renal failure, vascular disease (including coronary artery disease), and 
vision damage.  
The molecular defects underlying peripheral insulin resistance and relative 
failure of the pancreatic β cells in type 2 diabetes are still unclear and may be 
diverse. Most likely, a combination of acquired and genetic alterations accounts 
for the development of the disease. Functional studies have demonstrated 
numerous quantitative and qualitative abnormalities in the insulin signaling 
pathways of patients displaying insulin-resistance, including down-regulation of 
the insulin receptor, decreased insulin receptor phosphorylation and tyrosine 
kinase activity, reduced levels of active intermediates in the insulin signaling 
pathway, and impairment of GLUT4 translocation (15, 79, 83).  
A relatively new area in type 2 diabetes research is the regulation of β cell 
mass plasticity and its relevance in the onset of disease. Decreased β cell 
mass is a universal observation in both human patients and rodent disease 
models with obesity-linked type 2 diabetes (85). It is caused by a marked 
increase in β cell apoptosis that outweighs the rate of β cell replication and 
neogenesis. Currently, it is unclear what instigates an increased rate of β cell 
apoptosis during the pathogenesis of type 2 diabetes; however, both chronic 
exposure to elevated levels of fatty acids and prolonged fluctuations of high 
circulating glucose levels have a prominent influence. Recent studies have 
implicated signal transduction via IGF1→ IRS25 (insulin receptor substrate 2)→ 
PI3K/PKB as critical to the control of β cell survival (100). For instance, 
targeted disruption of IRS2 in mice results in both peripheral insulin resistance 
and and increased rate of pancreatic β-cell apoptosis; ultimately these mice 
become profoundly diabetic (113). In contrast, IRS1−/− mice also display 
peripheral insulin resistance but do not become diabetic, because the β cell 
mass can in presence of functional IRS2 signaling expand and compensate for 
                                            
5 Several insulin receptor substrate (IRS) proteins have been identified in mammals (IRS1-
IRS6). IRS1 and IRS2 are widely distributed, whereas IRS3 is largely limited to adipocytes and 
brain, and IRS4 is expressed primarily in embryonic tissues or cell lines. Although they are 
highly homologous, studies in knockout mice and cell lines indicate that the various IRS 
proteins serve complementary, rather than redundant, roles in insulin/IGF1 signaling. Of note, 
IRS proteins also undergo serine phosphorylation in response to stimuli, which in general seem 
to negatively regulate IRS signaling. Serine phosphorylation of IRS1 is increased in insulin-
resistant states but its exact role in the pathophysiology of insulin resistance is still not 
completely understood.  
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the insulin resistance (106). PKB appears to be a key downstream mediator of 
IRS signaling in both β cell survival and insulin sensitivity. Activation of PKB 
provides protection from apoptosis through phosphorylation and inhibition of 
pro-apoptotic proteins, such as BAD, and increases expression of PDX1 
(pancreas-duodenum homeobox-1), an important proliferation and survival 
factor in β cell (49, 85). 
 
4.2 Activation of PKB in cancer 
The PI3K/PKB pathway is an important driver of cell proliferation, cell growth, 
and cell survival, all events that favor tumorigenesis. Accordingly, constitutive 
or increased activity of the PI3K/PKB-dependent signaling cascade presents a 
major means whereby tumor cells achieve uncontrolled proliferation - and PKB 
is one of the most frequently hyperactivated protein kinases in human cancer 
(Table1). Hyperactive PKB is, due to its anti-apoptotic activity, also linked to the 
resistance of many cancers to treatment with cytotoxic agents. Aberrant 
activation of PKB in human cancer can occur by diverse mechanisms. PTEN 
(phosphatase and tensin homolog) is a lipid phosphatase that negatively 
regulates the PI3K singnaling pathway and normally limits PKB activation. In a 
large number of cancers PTEN is mutated, deleted, or otherwise inactivated, 
which results in accumulation of high levels of PI(3,4,5)P3 and constitutive 
activation of PKB. PTEN inactivation occurs with a high incidence in prostate 
and endometrial cancers, glioblastoma, and melanoma (14, 28, 92). 
Amplification and overexpression of the gene encoding the p110α catalytic 
subunit of PI3K is also observed in a subset of human cancers (13, 81, 101), as 
well as increased receptor tyrosine kinase activation (e.g. heterodimeric ErbB-
2/ErbB-3 receptor activation) (3, 96); both leading to deregulated PKB 
activation. Lastly, PKB gene amplification as well as mRNA or protein 
overexpression has been found in a variety of human cancers (21, 77, 114). 
The observed dependence of certain tumors on PKB signaling for survival and 
growth make components of the PI3K/PKB pathway appealing targets for novel 
anticancer therapies. In the last several years, through combinatorial chemistry 
and high-throughput screening, a number of inhibitors of the PKB pathway 
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have been identified. Potential targets for selective inhibition include upstream 
receptor tyrosine kinases, PI3K, PDK1, PKB itself, and mTOR kinase (20, 57); 
the different therapeutic targets of the PI3K/PKB pathway are summarized in 
Fig. 8.  
 
Table 1. PKB activation in human cancers 
Tumor type % Tumors with hyperactive PKB 
Glioma ~55 
Thyroid carcinoma 80-100 
Breast carcinoma 20-55 
Small-cell lung carcinoma ~60 
Non-small-cell lung carcinoma 30-75 
Gastric carcinoma ~80 
Gastrointestinal stromal tumors ~30 
Pancreatic carcinoma 30-70 
Bile duct carcinoma ~85 
Ovarian carcinoma 40-70 
Endometrial carcinoma >35 
Prostate carcinoma 45-55 
Renal cell carcinoma ~40 
Anaplastic large-cell lymphoma 100 
Acute myeloid leukemia ~70 
Multiple myeloma ~90 
Malignant mesotheliomaa ~65 
Malignant melanomab 43-67 
a Altomare et al., 2005; b Reviewed in Robertson, 2005; remaining cancer 
types reviewed in Bellacosa et al., 2005. (Adapted from Altomare et al., 2005). 
  
Most small molecule inhibitors against kinases bind in the enzyme active site 
and display ATP-competitive behavior. So far, due to the fact that there is a 
high degree of homology in the ATP-binding pockets between PKB, PKA and 
PKC, no ATP-competitive inhibitors have been identified that are specific 
against PKB. However, recently a group from Merck research laboratories 
described novel allosteric PKB inhibitors that are highly specific for PKB and 
even isoform-selective (5, 61). Binding of these inhibitors appears to promote 
an inactive conformation of the kinase. Although promising results were 
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achieved in cell culture experiments, the poor solubility and pharmacokinetic 





Fig. 8. Therapeutic targeting of the PI3K/PKB pathway. Receptor tyrosine kinase inhibitors (RTK inhibitors) include 
small-molecule tyrosine kinase inhibitors and humanized antibodies against the extracellular receptor domains. 
Farnesyltransferase inhibitors (FTI) and geranylgeranyltransferase inhibitors (GGTI) and are a new class of anticancer 
drugs (inhibitors of prenylation); the mechanism of their antitumor activity is still unclear. PI3K inhibitors include 
Wortmannin and LY294002, which are relatively non-specific for members of the PI3K family, and several new, more 
selective compounds. Wortmannin inhibits PI3K activity by binding covalently to a conserved lysine residue in the ATP-
binding site of the enzyme whereas LY294002 is a reversible ATP-competitive inhibitor. PDK1 inhibitors include the 
staurosporine derivative UCN-01, which forms a complex with the kinase domain of PDK1. PIP3 competitors bind to the 
PH domain of PKB and decrease its localization at the plasma membrane. Recently, highly specific allosteric PKB 
inhibitors were identified that seem to stabilize PKB in an inactive conformation that is not capable of being activated by 
PDK1. mTOR inhibitors include rapamycin and its derivatives. Rapamycin binds to FKBP-12 and this complex can 
inhibit mTOR kinase activity. (Adapted from Cheng et al., 2005). 
 
Two mTOR inhibitors, the rapamycin derivatives CCI-779 (Wyeth Ayerst) and 
RAD001 (Novartis Pharma) are currently being assessed in clinical trials in 
phase III and phase I/II, respectively (7). They appear to have anti-tumor 
activity for a wide range of malignancies; it seems that the maintenance of 
tumors that harbour hyperactive PI3K/PKB signaling requires intact mTOR 
signaling. Furthermore, three small-molecule PDK1 inhibitors (BX-795, BX-912, 
and BX-320) have recently been identified that may have clinical utility as 
anticancer agents, and a staurosporine derivative (UCN-01) which also potently 
inhibit PDK1 is currently in clinical trials. A recent study found several modified 
phosphatidylinositol ether lipid analogues that could act as PI(3,4,5)P3 
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competitors and bind to the PH domain of PKB (and presumably to other PH-
domain containing proteins). These PI(3,4,5)P3 competitors can inhibit PKB 
and selectively induce apoptosis in cancer cell lines with high levels of 
endogenous PKB activity (16). 
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5. Insights from PKB mutant mice 
Targeted deletion of PKB isoforms in mice and as well the generation of 
transgenic mice expressing constitutively active PKB in specific organs (i.e. in 
heart, thymus, mammary gland, pancreas, and prostate) have made it possible 
to identify biological processes controlled by individual PKB isoforms. The three 
PKB isoforms appear to have some differential, non-redundant physiological 
functions. PKBα (and to a lesser extent also PKBβ and PKBγ) seems to be an 
essential regulator of cell proliferation and cell size. Mice lacking PKBα display 
a reduction in body weight of 20-30%, whereas an increase in PKBα activity in 
specific organs or tissues increases cell number and cell size (9, 19, 23, 24, 67, 
69, 103, 108, 118). In addition, PKBα was shown to be an important regulator 
in adipocyte differentiation (6). PKBβ appears to be required for the 
maintenance of normal glucose homeostasis. PKBβ-deficient mice display 
glucose intolerance, insulin resistance, dyslipidemia, and hyperglycemia – and 
in a substantial portion of PKBβ-deficient mice this phenotype progresses to a 
severe form of diabetes that is accompanied by β cell failure. Interestingly, PKB 
isoforms are not functionally redundant in glucose homeostasis. Studies in 
embryonic fibroblasts derived from PKBα and PKBβ knockout mice, as well as 
knockdown studies in 3T3L1 adipocytes using siRNA, indicate that PKBβ is the 
major isoform mediating insulin-induced glucose uptake and loss of PKBβ 
function cannot be rescued by expression of PKBα (4, 22, 35, 50). The 
phenotypes of different PKB mutant mice are summarized in Table 2 and the 
phenotypes of mice deficient in PKBγ, PKBα/PKBγ, and PKBβ/PKBγ are 
described in detail in the result section.  
 
Table 2. Phenotypes of PKB mutant mice 
Targeted 
tissues 
PKB General findings and references 
all PKBα-deficient Increased neonatal lethality, small body size, placental defect, 
and impaired adipogenesis (6, 19, 23, 118) 
all PKBβ-deficient Fasting hyperglycemia, glucose intolerance, insulin resistance, 
and age-dependent loss of adipose tissue (22, 35). 
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all PKBγ-deficient Reduced brain weight (decreases in both cell size and cell 
number) (32, 107). 
all PKBαβ-deficient 
Mice die shortly after birth with multiple defects: small body size, 
impaired skin development, skeletal muscle atrophy, delayed 
bone development, and impeded adipogenesis (82). 
all PKBαγ-deficient 
Lethal at embryonic stage (day E12). Severe impairments in 
growth, cardiovascular development, and organization of the 
nervous system (117). 
all PKBβγ-deficient Mice are viable but exhibit impaired glucose homeostasis and 




Increased basal glucose uptake and myocardial contractility, 
cardiac hypertrophy, increased cell size of cardiomyocytes. In 
some cases cardiac dilatation and death. α-myosin heavy chain 
promoter was used for tissue-specific expression. (24, 25, 52, 
69, 70, 103) 
Thymus 
constitutively active 
PKBα; (one study 
with constitutively 
active PKBβ) 
Active PKB prevents apoptosis in T cells. Tumor induction 
(thymomas and lymphomas) and larger cell size of thymocytes; 
isolated thymocytes display increased cell cycle progression. 
CD2 promoter and lck promoter were used for T cell-specific 





Increased fat content in milk, delayed involution after lactation; 
constitutively active PKB contributes to tumor development 
when co-expressed with ErbB2. MMTV promoter was used for 




Larger islets due to increase in cell size and cell number, 
elevated insulin secretion. Rat insulin promoter was used for 




Impaired glucose tolerance due to defective insulin secretion; 




Prostatic intraepithelial neoplasia (PIN) (66). Probasin promoter 
was used for prostate-specific expression. 
Two forms of PKBα have been commonly used for plasmid construction to generate mice with constitutively active PKB: a 
myristylated version (Myr-PKB) engineered by adding a Lck or Src myristylation signal sequence to the N-terminus of PKB, 
which leads to a hyperactivated form of the kinase; and a constitutively active variant of PKB in which the two regulatory sites 
of PKB are mutated to acidic residues to mimic the doubly phosphorylated form of the kinase (i.e. T308D /S473D in PKBα). 
The kinase-dead mutant of PKB has a mutation in the ATP-binding site (K179M) and acts in a dominant negative manner. 
Abbreviations: lck: lymphocyte-specific kinase; MMTV: mouse mammary tumor virus. 
 
Although mice deficient in individual PKB isoforms show distinct phenotypes, 
these differences have yet to be correlated to differences at the level of 
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substrate selectivity or signaling functions of the different isoforms. It is likely 
that there are some isoform-specific substrates but the abundance of each PKB 
isoform in a given cell type or tissue (Fig. 9) and perhaps specific intracellular 
localizations may also in part account for the different phenotypes observed in 
the mutant mice.  
 
 
Fig. 9. Tissue distribution of PKB isoforms in adult mice. (A) Quantitative PCR analysis of mRNA 
encoding the three PKB isoforms (adapted from Yang et al., 2003). (B) Protein expression of PKB 
isoforms in various tissues as detected by isoform-specific antibodies (PKBα expression blot is adapted 
from Yang et al., 2003; PKBβ and PKBγ blots are from B.Duemmler, unpublished). 
 
Although constitutively active PKB alone leads only in rare cases to 
tumorigenesis (lymphomas and prostatic intraepithelial neoplasia have been 
observed (66, 67, 72, 87) ), a recent study demonstrated that PKB deficiency 
can markedly decrease the incidence and development of tumors in PTEN+/− 
mice. Haplodeficiency of PTEN elicits in mice a wide range of tumors with a 
high tumor incidence in prostate, endometrium, thyroid, adrenal medulla, and  
the intestine (29, 105). Chen et al. crossed these mice with PKBα-deficient 
mice and could show that PKBα-deficiency markedly decrease the incidence 
and development of tumors in all of the above tissues (18). Considered that 
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PTEN inactivation occurs at a high frequency in human cancers, these results 
have important implications for cancer therapy. They provide genetic evidence 
that a deficiency in PKBα is effective in inhibiting neoplasia induced by PTEN 
inactivation. Partial inhibition of PKB activity or inhibition of individual PKB 
isoforms could thus potentially be used for cancer therapy without severe side 
effects. 
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6. Aims of this thesis 
The general aim of this thesis is to identify physiological functions of PKB by 
generation and analysis of loss-of-function mouse models. Emphasis is placed 
on identifying isoform-specific functions and as well functional overlap in-
between the isoforms. Because the three isoforms have overlapping 
expression patterns in mice (Fig. 9), absence of one isoform may be 
compensated by the remaining other isoform(s). Some physiological functions 
of PKB are thus only revealed in mice with combined deficiencies in PKB 
isoforms. The mice generated and analyzed here are deficient in PKBβ/PKBγ, 
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To address the issues of isoform redundancy and isoform specificity of the Akt family of protein kinases in
vivo, we generated mice deficient in both Akt2 and Akt3. In these mice, only the Akt1 isoform remains to
perform essential Akt functions, such as glucose homeostasis, proliferation, differentiation, and early devel-
opment. Surprisingly, we found that Akt2/ Akt3/ and even Akt1/ Akt2/ Akt3/ mice developed
normally and survived with minimal dysfunctions, despite a dramatic reduction of total Akt levels in all tissues.
A single functional allele of Akt1 appears to be sufficient for successful embryonic development and postnatal
survival. This is in sharp contrast to the previously described lethal phenotypes of Akt1/ Akt2/ mice and
Akt1/ Akt3/ mice. However, Akt2/ Akt3/ mice were glucose and insulin intolerant and exhibited an
25% reduction in body weight compared to wild-type mice. In addition, we found substantial reductions in
relative size and weight of the brain and testis in Akt2/ Akt3/ mice, demonstrating an in vivo role for both
Akt2 and Akt3 in the determination of whole animal size and individual organ sizes.
The coordination between signal specificity and kinome re-
dundancy is a fundamental issue in cell biology that is not yet
fully understood. Although most of the major kinase families
are conserved among metazoans, the vertebrate genome con-
tains distinctly more genes encoding protein kinases than do
those of worms or flies (24). Duplications of gene loci in ver-
tebrates have led to the expansion of individual kinases into
several homologous isoforms and brought about a concomitant
increase in signaling complexity. It has been proposed that
such isoforms are uniquely adapted to transmit distinct biolog-
ical signals.
The Akt protein signaling kinase (also known as protein
kinase B [PKB]) has a high level of evolutionary conservation
and plays a key role in the conserved phosphoinositide 3-ki-
nase (PI3K) signaling pathway (27). In mammals, Akt is im-
plicated in the regulation of widely divergent cellular pro-
cesses, such as metabolism, differentiation, proliferation, and
apoptosis (3, 20). Accordingly, activation of Akt is promoted
by numerous stimuli, including growth factors, hormones, and
cytokines. There are three isoforms of Akt in mammals,
termed Akt1/PKB, Akt2/PKB, and Akt3/PKB. These iso-
forms are products of distinct genes but are highly related,
exhibiting 80% protein sequence identity and sharing the
same structural organization. To understand the specific physio-
logical functions of the individual isoforms, animal models
deficient in Akt1, Akt2, or Akt3 have been generated. Mice
lacking Akt1 demonstrate increased perinatal mortality and
reductions in body weight of 20 to 30% (6, 8, 38). In contrast,
Akt2-deficient mice are born in the expected Mendelian ratio
and display normal growth, but they exhibit a diabetes-like
syndrome with an elevated fasting plasma glucose level, ele-
vated hepatic glucose output, and peripheral insulin resistance
(7, 15). Akt3-deficient mice exhibit a reduction in brain weight
resulting from decreases in both cell size and cell number but
maintain normal glucose homeostasis and body weights (13,
33). These observations indicate that the three Akt isoforms
have some differential, nonredundant physiological functions.
The relatively subtle phenotypes of mice lacking individual Akt
isoforms as well as the viability of the animals suggest, how-
ever, that for many functions Akt isoforms are able to com-
pensate for each other. To address the issue of isoform redun-
dancy, mice with combined Akt deficiencies have been
generated. Mice lacking both Akt1 and Akt2 develop to term
but die shortly after birth and display multiple defects. They
exhibit a severe growth deficiency (body weights at birth are
50% of normal weights), skeletal muscle atrophy, impaired
skin development, and a delay in ossification (25). Mice mutant
in both Akt1 and Akt3 die around embryonic day 12, with
severe impairments in growth, cardiovascular development,
and organization of the nervous system (37). Such data ob-
tained from double knockout mice argue strongly for partially
overlapping functions of Akt isoforms in vivo. Certain physio-
logical functions of Akt are thus revealed only when total Akt
levels are below a critical threshold in particular cell types and
tissues. Here we report the generation of Akt2/ Akt3/
mice to determine the combined roles of these isoforms in
Akt-related physiological processes, such as glucose metabo-
lism, development, and growth. It was surprising to us that
compound Akt2/ Akt3/ mice and even mice retaining only
* Corresponding author. Mailing address: Friedrich Miescher Insti-
tute for Biomedical Research, Maulbeerstrasse 66, Basel CH-4058,
Switzerland. Phone: 41 61 697 4872. Fax: 41 61 697 3976. E-mail:
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† Supplemental material for this article may be found at http://mcb
.asm.org/.














one functional allele of Akt1 (Akt1/ Akt2/ Akt3/) were
viable and did not display any gross abnormalities. The body
size of Akt2/ Akt3/ mice was reduced at birth and
throughout postnatal life, and they exhibited severe glucose
and insulin intolerance.
MATERIALS AND METHODS
Mice. Akt3 mutant mice were generated as described previously (33). For the
generation of Akt2 mutant mice, an 9.4-kb mouse genomic DNA fragment
containing exons 3 and 4 of the Akt2 gene was subcloned into pBluescript, and
a NotI site was generated in exon 4 by PCR. An 5-kb IRES-lacZ-Neor cassette
was inserted into the NotI site, resulting in partial deletion of exon 4 and a
frameshift in the open reading frame of the Akt2 gene. The resulting targeting
vector was linearized with SalI and electroporated into 129/Ola embryonic stem
(ES) cells. Screening of ES cell clones was performed by Southern blotting.
DNAs were digested with EcoRI and probed with an external probe (see Fig.
S2a, probe A, in the supplemental material). An internal probe (see Fig. S2a,
probe B, in the supplemental material) was then used on BamHI-digested DNAs
for further characterization of ES cell clones positive for homologous recombi-
nation. Correctly targeted ES cells were used to generate chimeras. Male chi-
meras were mated with wild-type C57BL/6 females to obtain Akt2/ mice,
which were intercrossed to produce Akt2 homozygous mutants. Progeny were
genotyped for the presence of a targeted Akt2 allele by multiplex PCR. The
following primers were used for genotyping: P1-as, 5-CTCAGGGACACCCAT
GTGTGGCTGC-3; P2/KO-s, 5-GCTGCCTCGTCCTGCAGTTCATTC-3;
and P3/WT-s, 5-CCACAGGCAGCAGAAAGGAA-3. One primer set ampli-
fies a 600-bp fragment from the targeted allele, and the second primer set
amplifies a 360-bp fragment from the wild-type allele. Akt2/ Akt3/ mice
were crossed with Akt2/Akt3/ mice to obtain Akt2/ Akt3/ offspring,
which were mated to generate Akt2/ Akt3/ mice as well as the wild-type,
Akt2/, and Akt3/ littermates used in the study. Both starting strains were on
a mixed 129 Ola and C57BL/6 background. For the generation of Akt1/
Akt2/ Akt3/ mice, Akt2/ Akt3/ mice were mated with Akt1/ Akt3/
mice (37), and resulting Akt1/ Akt2/ Akt3/ progeny were intercrossed.
Mice were housed according to the Swiss Animal Protection Laws in groups with
12-h dark-light cycles and with free access to food and water. All procedures were
conducted with the relevant approval of the appropriate authorities.
Cell culture. Cerebellar granule cells were isolated and cultured as previously
described (28). Cells were counted and plated on poly-D-lysine-coated six-well
plates in culture medium (basal Eagle medium containing 10% fetal bovine
serum, 100 U of penicillin-streptomycin, 2 mM glutamine, and 25 mM KCl).
After 24 h, 10 	M cytosine arabinoside was added to the medium to inhibit the
proliferation of nonneuronal cells. After 2 days in culture, cells were starved by
serum deprivation for 12 h and then stimulated with 100 nM insulin.
Western blot analysis. For Western blot analysis, protein lysates were pre-
pared by homogenization of various organs in lysis buffer (50 mM Tris-HCl, pH
8.0, 120 mM NaCl, 1% NP-40, 40 mM -glycerophosphate, 10% glycerol, 4 	M
leupeptin, 0.05 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 50 mM
NaF, 1 mM Na3VO4, 5 mM EDTA, 1 	M Microcystin LR). Homogenates were
centrifuged twice (13,000 rpm for 10 min at 4°C) to remove cell debris. Protein
concentrations were determined using the Bradford assay. Proteins (50 	g per
sample) were separated by 15%, 10%, or 6% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and then transferred to Immobilon-P polyvinylidene
difluoride membranes (Millipore). Akt isoform-specific antibodies were obtained
by immunizing rabbits with isoform-specific peptides as previously described
(38). Antibodies against total Akt, phospho-Akt (Ser473), phospho-glycogen
synthase kinase 3/ (phospho-GSK3/ [Ser21/9]), phospho-GSK3 (Ser9),
total GSK3, phospho-TSC2 (Thr1462), phospho-p70 S6K (Thr389), and total
4E-BP1 were purchased from Cell Signaling Technologies. Anti-Foxo3a and
anti-phospho-Foxo3a (Thr32) antibodies were obtained from Upstate Biotech-
nology. A rat monoclonal anti--tubulin (YL1/2)-producing hybridoma cell line
was obtained from the American Type Culture Collection. Anti-TSC2 antibody
was generated as previously described (35) and kindly provided by K. Molle
(Biozentrum, University of Basel, Switzerland). For quantitation, Western blots
were scanned using a GS-800 Bio-Rad densitometer with a resolution of 63.5 	m
by 63.5 	m, and bands were quantified using Proteomweaver 4.0.0.5 (Bio-Rad).
As shown in Fig. S1 in the supplemental material, the anti-total Akt and anti-
phospho-Akt (Ser473) antibodies utilized in this study show equal affinities
towards Akt1 and Akt3 but a lower affinity towards Akt2. As a consequence, the
total Akt and phospho-Akt levels that were detected in our study with these
antibodies may slightly understate the magnitude of the differences between
wild-type and Akt2/ Akt3/ mice.
Histology and TUNEL assays. For histological analysis, organs were dissected
and fixed in 4% paraformaldehyde–phosphate-buffered saline overnight at 4°C.
After dehydration in ethanol, samples were embedded in paraffin. Tissues were
cut into 6-	m-thick sections and stored for staining. For hematoxylin-eosin
(Sigma) and cresyl violet (Sigma) staining, sections were deparaffinized and
stained. A terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end
labeling (TUNEL) assay was performed as previously described (37). For quan-
titation of apoptosis in testes, sections of testes derived from wild-type and
Akt2/ Akt3/ mice were subjected to TUNEL assay, and the number of
TUNEL-positive cells per area was counted (for each mouse, an area of 20 to
40 mm2 of stained testis sections was analyzed).
Testosterone measurement. Blood samples were collected from tail veins of
10-week-old male mice. Samples were allowed to clot at room temperature, and
serum was separated by centrifugation. To account for the pulsatile secretion of
testosterone, three separate samples were taken from each mouse on the same
day (spaced 3 h apart) and pooled. A commercial enzyme-linked immunosorbent
assay kit (DRG Instruments GmbH, Marburg, Germany) was used to measure
testosterone in serum following the manufacturer’s recommendations.
Glucose and insulin tolerance test. All mice used for glucose and insulin
tolerance tests were offspring from doubly heterozygous parents. Note that
glucose and insulin tolerance was not affected in doubly heterozygous mice, and
an influence of the mother on the diabetic phenotype of the offspring could
therefore be excluded. Three-month-old mice of the selected genotypes were
made to fast overnight; for glucose tolerance tests, glucose (2 g/kg of body
weight) (D-()-glucose anhydrous; Fluka) was given orally, and for insulin tol-
erance tests, insulin (1 U/kg) (human recombinant insulin; Sigma) was admin-
istered by intraperitoneal injection. Blood samples were collected at the indi-
cated times from tail veins, and glucose levels were determined using
Glucometer Elite (Bayer). Similarly, random-fed and fasting blood glucose levels
were determined for 3-month-old mice by the collection of blood samples from
tail veins, with glucose levels determined as described above. Blood insulin levels
were measured with an ultrasensitive mouse insulin enzyme-linked immunosor-
bent assay (Immunodiagnostic Systems).
In vivo insulin stimulation. In vivo insulin stimulation was performed on
8-week-old male mice. Following an overnight fast, a bolus of insulin (1 mU/g
or 10 mU/g, as indicated) (human recombinant insulin; Sigma) or saline solution
was injected via the inferior vena cava into terminally anesthetized mice. White
adipose tissue, liver, skeletal muscle, and whole brain were harvested after 12
min of stimulation and immediately snap frozen in liquid nitrogen. Tissues were
homogenized thereafter and lysed as described above.
Statistics. Data are provided as arithmetic means 
 standard errors of the
means (SEM), and n represents the number of independent experiments. All
data were tested for significance using one-way analysis of variance (ANOVA)
and a paired or unpaired Student t test, as applicable. Only results with P values
of 0.05 were considered statistically significant.
RESULTS
A single functional allele of Akt1 is sufficient for successful
embryonic development and postnatal survival in mice lacking
Akt2 and Akt3. Considering the lethal phenotypes and multiple
developmental defects of Akt1/ Akt2/ and Akt1/
Akt3/ mice, Akt isoforms appear to play essential roles in
various aspects of embryonic development (25, 37). Moreover,
the Akt genes seem to compensate functionally for one another
in vivo, as no developmental deficiencies have been observed
in any mice lacking only one isoform of the Akt family (6–8, 13,
15, 33). We wanted to evaluate the impact of combined Akt2
and Akt3 deficiencies on the viability and embryonic develop-
ment of mice. Akt2/ mice were generated by targeted dis-
ruption of exon 4 of the Akt2 gene (see Fig. S2a in the sup-
plemental material). In mice homozygous for the targeted
allele, expression of the Akt2 protein was not detectable with
isoform-specific antisera (see Fig. S2c in the supplemental ma-
terial). Thus, the targeted disruption resulted in a functional
null allele. Akt2/ Akt3/ mice were crossed with Akt2/













Akt3/ mice to obtain Akt2/ Akt3/ mice. These doubly
heterozygous mice were intercrossed to generate Akt2/
Akt3/ mice. Surprisingly, Akt2/ Akt3/ offspring were
viable and showed no obvious abnormalities, except for their
smaller size (Fig. 1A). Examination of 500 pups from mat-
ings between Akt2/ Akt3/ mice showed the expected Men-
delian distribution for Akt2/ Akt3/ progeny and the other
resulting genotypes (see Table S1 in the supplemental mate-
rial). We investigated whether upregulation of the remaining
Akt isoform in these mice, Akt1, could account for the mild
phenotype of Akt2/ Akt3/ mice. Immunoblotting of pro-
tein extracts from various tissues of 4-day-old Akt2/ Akt3/
FIG. 1. (A) Top view of wild-type (WT), Akt2/ Akt3/ (DKO), and Akt1/ Akt2/ Akt3/ (Akt1/DKO) mice (12-week-old male mice;
the WT and DKO mice were from the same litter). Note that the pictures are illustrative of the viability of mutant mice rather than a size
comparison. (B) Akt1 protein levels in 4-day-old wild-type (WT) and Akt2/ Akt3/ (DKO) pups. The indicated tissues from wild-type and DKO
pups were lysed and blotted with antibodies specific for Akt1, Akt2, and Akt3. As a loading control, the expression of -tubulin was detected on
the same membrane. Duplicates are from independent samples. (C) Stepwise reduction of total Akt levels in wild-type (WT), Akt2/ Akt3/
(DKO), and Akt/ Akt2/ Akt3/ (Akt/DKO) mice. Tissues from 3-month-old mice of the indicated genotypes were lysed and blotted with
an Akt antibody that recognizes all three isoforms. As a loading control, the expression of -tubulin was detected on the same membrane. Bands
were quantified, and indicated values represent total Akt expression relative to wild-type expression levels, normalized to the -tubulin control.
The experiment was performed twice with independent samples and with similar results.













mice with an isoform-specific antibody against Akt1 re-
vealed no significant increase in Akt1 protein levels com-
pared to those in wild-type littermates (Fig. 1B). Since we
had previously observed that in neonates the tissue distri-
bution of Akt isoforms differs from that in adult mice (37),
we also examined Akt1 expression levels in tissues of adult
Akt2/ Akt3/ mice. As in neonates, Akt1 was not up-
regulated in tissues of adult Akt2/ Akt3/ mice (data not
shown). We therefore excluded the possibility that a com-
pensatory upregulation of Akt1 could influence the pheno-
type of Akt2/ Akt3/ mice.
Next, we asked the question of whether Akt1 affects mouse
development in a dose-dependent fashion. To evaluate the
impact of a decrease in the Akt1 dose, we crossed our Akt2/
Akt3/ mice with Akt1/ Akt3/ mice (38). Resulting
Akt1/ Akt2/ Akt3/ mice were subsequently intercrossed
to obtain mice containing only one functional allele of Akt1
(Akt1/ Akt2/ Akt3/ mice). We did not obtain any
Akt1/ Akt2/ Akt3/ mice, as a combined deficiency of
Akt1 and Akt3 is lethal at embryonic stage E12 (37). However,
we obtained viable Akt1/ Akt2/ Akt3/ mice from these
crosses (Fig. 1A; see Table S2 in the supplemental material).
Approximately 14% of the mice in the analyzed cohort (n 
105) were Akt1/ Akt2/ Akt3/ mutants. As shown in Fig.
1C, a stepwise reduction in functional Akt alleles was reflected
by a concomitant reduction in total Akt protein levels. For
instance, in both brain and liver, there was an 3-fold reduc-
tion of total Akt levels in Akt2/ Akt3/ mice and an 10-
fold reduction of total Akt levels in Akt1/ Akt2/ Akt3/
mice compared to wild-type levels (Fig. 1C). Akt1/ Akt2/
Akt3/ mice developed normally, with no obvious defects
except for a severe growth deficiency, with body weights at the
age of 12 weeks reduced40% compared to those of wild-type
mice (17.1
 1.7 g versus 29.1 
 0.7 g, respectively [n 5]; P
0.01). Taken together, these findings demonstrate that Akt1
(even in the case where only one allele is present) is sufficient
to enable successful embryonic development and postnatal sur-
vival in mice lacking Akt2 and Akt3.
Growth deficiency and substantially reduced brain and testis
mass in Akt2/ Akt3/ mice. It was previously shown that
disruption of the Akt1 gene in mice leads to growth retardation
(6, 8, 38), and Akt3-deficient mice were shown to have a
reduction in brain size (13, 33). In progeny of Akt2/ Akt3/
intercrosses, we observed that the combined deletion of Akt2
and Akt3 resulted in a growth deficiency in both male and
female Akt2/ Akt3/ mice. One-week-old male Akt2/
Akt3/ mice were 28% smaller than their wild-type litter-
mates (3.81 
 0.21 g versus 5.26 
 0.14 g; P  0.001), and an
average decrease in body weight of 25% persisted throughout
the examined 3-month life period of male Akt2/ Akt3/
mice (Fig. 2). For female Akt2/ Akt3/ mice, a significant
decrease in body weight was evident only from the fourth week
of age onward, with an average decrease of 14% compared to
wild-type littermates. Consistent with previous reports, single
knockouts of either Akt2 or Akt3 did not significantly affect
animal size compared to wild-type littermates (data not shown)
(7, 33). Comparisons of selected organ weights (brain, heart,
lung, thymus, liver, spleen, kidney, and testis) from 3-month-
old Akt2/ Akt3/, Akt2/, Akt3/, and wild-type litter-
mate mice revealed an 35% reduction in brain weights of
Akt2/ Akt3/ mice (0.31 
 0.01 g versus 0.49 
 0.01 g; P 
0.001) and an 40% reduction in testis weights (0.12 
 0.01 g
versus 0.20
 0.01 g; P 0.001) compared to those of wild-type
mice (Fig. 3A and B). While most organs of Akt2/ Akt3/
mice were decreased proportionally to the reduced body
weights, the relative weights of brains and testes were reduced
by 18.8% 
 1.7% and 28.5%
 2.7%, respectively (Fig. 3A and
B). The prominent size reduction in the testes prompted us to
measure serum testosterone levels in 10-week-old male
Akt2/ Akt3/ and wild-type mice. In Akt2/ Akt3/ mice,
testosterone levels were 70% lower than those measured in
wild-type mice (1.4 
 0.5 ng/ml versus 4.7 
 1.2 ng/ml [n  5];
P 0.05). In addition, we compared ovary weights in 3-month-
old Akt2/ Akt3/ and wild-type females. We observed an
26% reduction in absolute weights of ovaries of Akt2/
Akt3/ mice (13.3
 1.3 mg versus 18.2 
 1.0 mg [n 5]; P 
0.05); however, there was no significant difference from the
wild type in the organ/body weight ratio.
The PI3K/Akt pathway also plays a critical role in cell sur-
vival and apoptosis, and therefore we assessed whether an
increased rate of spontaneous apoptosis could account for the
smaller sizes of testes in Akt2/ Akt3/ mice. TUNEL assays
were performed on testis sections from adult Akt2/ Akt3/
FIG. 2. Growth deficiency in Akt2/ Akt3/ (DKO) mice. Body
weights of male (upper panel) and female (lower panel) wild-type
(filled triangles) and Akt2/ Akt3/ (open diamonds) littermate
mice were determined at the indicated time points. The graph depicts
arithmetic means 
 SEM (n  8 for each group). Significantly differ-
ent values for Akt2/ Akt3/ mice versus the wild type, as deter-
mined by one-way ANOVA, are indicated (*, P  0.05).













mice and their wild-type littermates. Generally, the rate of
spontaneous apoptosis was low for both genotypes, but the
testes of Akt2/ Akt3/ mice showed an 1.5-fold increase
in TUNEL-positive cells compared to wild-type littermates
(Fig. 3D). In addition, areas of seminiferous tubules were
reduced 24% in Akt2/ Akt3/ mice compared to those in
wild-type littermates (0.76 
 0.05 versus 1.0 
 0.05 [n  4];
P  0.05). However, histopathological analysis of testes from
Akt2/ Akt3/, Akt2/, Akt3/, and wild-type littermate
mice (3-month-old mice; n  5 to 8 mice per genotype) re-
vealed no morphological abnormalities (Fig. 3C). Further-
more, both male and female Akt2/ Akt3/ mice were fer-
tile, although litter sizes from such crossings were smaller (data
not shown).
FIG. 3. Selective reduction of brain and testis size in Akt2/ Akt3/ mice. (A) Brains were dissected from 3-month-old male wild-type (WT)
and Akt2/ Akt3/ (DKO) littermate mice (left). Mean absolute brain weights (middle) and brain weights relative to body weight (right) of
3-month-old male mice of the indicated genotypes are shown (n  8; *, P  0.001). (B) Testes were dissected from 3-month-old wild-type and
Akt2/ Akt3/ littermate mice (left). Mean absolute testis weights (middle) and testis weights relative to body weight (right) of 3-month-old mice
of the indicated genotypes are depicted (n  14; *, P  0.001). Relative weights are percentages relative to the wild type (WT  1). Error bars
represent SEM. (C) Morphology of testes from wild-type and Akt2/ Akt3/ littermate mice. Representative sections stained with hematoxylin
and eosin show morphologically normal seminiferous tubules. (D) Spontaneous apoptosis in testes of Akt2/ Akt3/ mice. The graph shows a
comparison of TUNEL-positive cell numbers in testis sections from Akt2/ Akt3/ mice and their wild-type littermates (n  3; *, P  0.05).













Akt1 is sufficient for phosphorylation of key downstream
targets in brains and testes of Akt2/ Akt3/ mice. We were
interested to know how Akt signaling was affected in the brains
and testes of Akt2/ Akt3/ mice. First, we assessed steady-
state phosphorylation/activation levels of Akt in brains and
testes of adult Akt2/ Akt3/ and wild-type mice by immu-
noblotting protein extracts with an antibody against phospho-
Ser473. This phosphorylation site is a distinctive indicator of
Akt activation status, and the antibody detects phosphorylation
of this site in all three Akt isoforms. In the testes of Akt2/
Akt3/ mice, steady-state phosphorylation of Akt was re-
duced 10-fold compared to that in wild-type littermate con-
trols and represented residual Akt1 activity (Fig. 4A and B).
Interestingly, we found that in vivo insulin stimulation could
increase the phosphorylation of Akt in testes of wild-type mice,
although this induction was less prominent than that in a clas-
sical insulin-responsive tissue, such as the liver, and was
scarcely detectable in Akt2/ Akt3/ mice (see Fig. S3 in the
supplemental material). Similarly, phosphorylation of Akt in
the brain was severely reduced (Fig. 5C shows phospho-Akt
under fasting and insulin-stimulated conditions; data for steady
state not shown).
Next, we generated primary cultures of cerebellar granule
cells to study inducible Akt activation in an in vitro cellular
system. In wild-type cerebellar granule cells, the expression of
all three Akt isoforms could be detected by isoform-specific
antibodies (data not shown), and there was no compensatory
upregulation of Akt1 in cells of Akt2/ Akt3/ mice (Fig.
4C). Cerebellar granule cell cultures were deprived of serum
for 12 h and then stimulated with 100 nM insulin. After serum
deprivation, phospho-Akt levels were 10-fold lower in
Akt2/ Akt3/ cells than in wild-type cells, and after stimu-
lation, phospho-Akt levels increased in both wild-type and
Akt2/ Akt3/ cells but remained 2-fold lower in Akt2/
Akt3/ cells (Fig. 4C). We then assessed the phosphorylation
levels of several downstream targets of Akt. GSK3 is a key
molecule implicated in neuronal survival, protein synthesis,
and glycogen synthesis (10–12), whereas tuberous sclerosis
complex 2 (TSC2) is a critical target of Akt in mediating cell
growth (17, 23, 26) and p70 S6 kinase (S6K) is a downstream
component of the PI3K/Akt/TSC pathway (19, 22). Both GSK3
and TSC2 are well-established Akt substrates. In contrast, the
regulation of S6K is more complex, as both PI3K-dependent
and -independent signaling pathways are involved in its acti-
vation (5, 9, 14). Upon insulin stimulation, a clear induction in
phosphorylation of all three downstream targets could be ob-
served in cerebellar granule cells, but interestingly, no differ-
ences in phosphorylation levels were apparent in Akt2/
Akt3/ cells compared to wild-type cells (Fig. 4C). Similarly,
no significant differences in phosphorylation levels of these
downstream targets were apparent in the testis (Fig. 4B). We
also assessed phosphorylation of the Akt substrate Foxo3a and
of the mammalian target of rapamycin (mTOR) substrate 4E-
binding protein 1 in testes of Akt2/ Akt3/ mice but found
no marked differences compared to the wild type (see Fig. S3
in the supplemental material). In summary, residual Akt1 ac-
tivity appears be sufficient to phosphorylate these downstream
targets under both steady-state and induced conditions in
Akt2/ Akt3/ mice.
Perturbation of glucose metabolism in Akt2/ Akt3/
mice. The Akt2 isoform of the Akt family has a major role in
the regulation of glucose metabolism (36). It is the predomi-
nant isoform expressed in insulin-responsive tissues and is in-
FIG. 4. Phospho-Western blot analysis of downstream targets of Akt.
(A) Representative blot showing steady-state phosphorylation of down-
stream targets of Akt in testes of wild-type (WT), Akt2/, Akt3/, and
Akt2/ Akt3/ (DKO) littermate mice. (B) Quantification of phosphor-
ylated Akt and downstream targets. Values are the means for three mice
per genotype, error bars depict SEM, and phospho-protein/total protein
ratios are relative to the wild-type ratio. Phospho-Akt values were nor-
malized to -tubulin. (C) Primary cerebellar granule cell cultures of wild-
type (WT) and Akt2/ Akt3/ (DKO) mice were serum starved over-
night and then stimulated with 100 nM insulin for 12 min. Lysates were
analyzed for the phosphorylation status of the indicated downstream
targets of Akt. Phospho-Akt bands (P-Ser473) were quantified, and indi-
cated values represent the means for two mice per genotype. Values are
relative to stimulated phospho-Akt levels in the wild type and were nor-
malized to the -tubulin control.













FIG. 5. Glucose metabolism in Akt2/ Akt3/ mice. (A) A glucose tolerance test was performed on 12-week-old male (upper panel) and
female (lower panel) mice of the indicated genotypes. The graph depicts arithmetic means 
 SEM (n  8 to 12 for each group) of plasma glucose













volved in the regulation of insulin-stimulated glucose trans-
port, lipogenesis, and glycogen synthesis (1, 7, 15). To
investigate glucose metabolism in Akt2/ Akt3/ mice, glu-
cose tolerance and insulin tolerance tests were performed on
3-month-old mice obtained from doubly heterozygous inter-
crosses (Fig. 5A and B). For the glucose tolerance test, glucose
(2 mg/g of body weight) was administered orally to fasted
Akt2/ Akt3/, Akt2/, Akt3/, and wild-type littermate
mice. For all four genotypes, blood glucose levels peaked 15 to
30 min after glucose administration and returned to baseline
after 3 h. Akt3/ mice had similar glucose excursions as wild-
type mice. However, in male Akt2/ Akt3/ mice, blood
glucose levels rose faster, and at 30 min they were 50%
higher than those of wild-type mice (21.8 
 1.3 mM versus
14.8 
 1.2 mM; P  0.01) (Fig. 5A). Akt2/ mice had similar
blood glucose levels as Akt2/ Akt3/ mice at all time
points. The susceptibility to glucose intolerance was gender
dependent because in female mice of all four genotypes, blood
glucose levels were not statistically different (P  0.05). Gen-
erally, female mice manifest better glucose tolerance than do
male mice (16). For assessment of insulin sensitivity, insulin (1
mU/g of body weight) was administered by intraperitoneal
injection to fasted Akt2/ Akt3/, Akt2/, Akt3/, and
wild-type littermate mice. In wild-type and Akt3/ mice, in-
sulin elicited a 50% decrease in blood glucose levels 60 to 90
min after administration. After 90 min, glucose levels began to
recover and reached baseline values 3 h after insulin adminis-
tration. In contrast, blood glucose levels remained close to
baseline levels at all measured time points in Akt2/ Akt3/
and Akt2/ mice. The reduced insulin sensitivity was evident
in both male and female mice of the Akt2/ Akt3/ and
Akt2/ genotypes.
To further explore the observed differences in glucose dis-
posal, fasting and fed blood glucose and plasma insulin levels
were examined in 3-month-old male Akt2/ Akt3/,
Akt2/, and wild-type littermate mice. Plasma insulin levels
were significantly higher in Akt2/ Akt3/ mice than in the
wild type, under both random feeding (4.6- 
 1.6-fold; P 
0.05) and fasting (1.9- 
 0.3-fold; P  0.05) conditions (see
Table S3 in the supplemental material). In addition, hypergly-
cemia was observed in Akt2/ Akt3/ mice under random
feeding conditions (1.7-fold 
 0.2-fold increase; P  0.05),
whereas fasting blood glucose levels were not significantly dif-
ferent from the wild-type levels. We also assessed the percent-
age of nonenzymatically glycated hemoglobin (hemoglobin
A1c [HbA1c]) in male mice of all four genotypes. This value
provides an integrated measure of blood glucose levels during
a period of approximately 1 month prior to sample removal.
Despite the defects in glucose homeostasis, HbA1c levels were
similar in both Akt2/ and Akt2/ Akt3/ mice to those in
wild-type mice (see Table S3 in the supplemental material).
Next, we performed in vivo insulin stimulation in these mice to
investigate the induction of Akt phosphorylation in insulin-
responsive tissues. Wild-type and Akt2/ Akt3/ mice were
made to fast overnight and then injected with a bolus of insulin
(10 mU/g) or a saline control. Twelve minutes after injection,
insulin-responsive tissues (liver, skeletal muscle, and white fat
tissue) were collected. In wild-type mice, Akt became strongly
phosphorylated upon insulin stimulation in all three tissues
(Fig. 5C). In Akt2/ Akt3/ mice, inducible Akt could also
be detected, but phospho-Akt levels were 10- to 20-fold
lower than those in wild-type mice (see Fig. S4 in the supple-
mental material for quantitation). As a readout for Akt1 ac-
tivity in Akt2/ Akt3/ mice, we assessed phospho-GSK3
levels in insulin-responsive tissues. Phosphorylation of GSK3
was induced robustly in the liver and skeletal muscle following
insulin stimulation, and phosphorylation levels were similar in
both Akt2/ Akt3/ and wild-type mice. There was no ap-
parent induction of phospho-GSK3 in white fat in our exper-
imental settings. Peripherally injected insulin was recently
shown to also induce Akt phosphorylation in the brain, sug-
gesting an in vivo regulation of the Akt signaling pathway in
mouse brain in response to changes in glucose metabolism
(29). However, within 12 min of intravenous insulin injection,
we could not detect any induction of phospho-Akt in the brain
(Fig. 5C), although phospho-Akt levels were consistently lower
in Akt2/ Akt3/ mice than in wild-type mice.
DISCUSSION
In order to fully evaluate the impact of the Akt kinase
pathway on physiological processes, combined ablation of its
isoforms is necessary. Complete inhibition of Akt activity ap-
pears to be incompatible with cell survival, but we were able to
generate viable Akt mutant mice that contain only a single Akt
isoform. Our results provide strong genetic evidence that the
Akt1 isoform of the Akt family is sufficient to perform all
essential Akt functions in embryonic development and postna-
tal survival. We observed that Akt2/ Akt3/ mice and even
Akt1/ Akt2/ Akt3/ mice, which retain only one func-
tional allele of Akt1 and have total Akt levels that are up to
10-fold lower than those in wild-type mice, can develop nor-
mally and survive with minimal dysfunctions. This is in sharp
contrast to the lethal phenotype of mice that contain only Akt3
(Akt1/ Akt2/ mice) or Akt2 (Akt1/ Akt3/ mice) (25,
37). These mice have multiple developmental defects that cul-
minate in lethality at embryonic stage E12 (Akt1/ Akt3/
mice) or the neonatal stage (Akt1/ Akt2/ mice).
concentrations following per os glucose administration (2 g/kg body weight). (B) An insulin tolerance test was performed on 15-week-old male
(upper panel) and female (lower panel) mice of the indicated genotypes. The graph depicts arithmetic means 
 SEM (n  8 to 10 each group)
of plasma glucose concentrations following intraperitoneal injection of insulin (1 mU/g body weight). All genotypes were littermate offspring of
Akt2/ Akt3/ matings. Significantly different values obtained for Akt2/ Akt3/ mice (DKO) versus wild-type mice (WT), as determined by
one-way ANOVA, are indicated (*, P  0.05). In all four graphs, differences in Akt2
/ Akt3/ versus Akt2/ mice were not significant. (C)
Active Akt and GSK3 in insulin-responsive tissues of wild-type and Akt2/ Akt3/ mice after in vivo insulin stimulation. Three-month-old male
mice were made to fast overnight and injected with either saline () or insulin (10 mU/g body weight). After 12 min, the indicated tissues were
harvested. Lysates were immunoblotted with the indicated antibodies. Samples are from individual mice (n 3 for saline controls; n 4 for insulin
stimulation).













Significantly, combined deficiency of Akt2 and Akt3 affects
the determination of whole animal size and individual organ
sizes, indicating that Akt1 is not able to fully compensate for
the lack of the other isoforms in growth signaling. Akt is a
crucial downstream effector of IGF-1 signaling (2, 21). Con-
sistent with a function in cell growth and proliferation, various
reports have shown that the expression of activated Akt in
specific mouse organs increases organ size (18, 30, 34), whereas
ablation of Akt can cause reductions in whole animal growth
and/or specific organ sizes (6, 8, 13, 15, 33). In Akt2/ Akt3/
mice, we observed a substantial reduction (25% in males) in
body weights compared to those of wild-type mice. Interest-
ingly, no growth deficiencies have been observed in either Akt2
or Akt3 single-knockout phenotypes for the same strain back-
ground. However, a mild growth deficiency was shown for
Akt2/ mice with a pure DBA/1lacj background (16%) (15).
In addition, Akt2 and Akt3 appear to be involved in the reg-
ulation of brain and testis size, as the weights of both organs
were severely reduced in Akt2/ Akt3/ mice. A testicular
phenotype has also been described for Akt1/ mice, which
exhibit several morphological abnormalities in the testis (6). In
contrast, we found no morphological abnormalities in testes of
Akt2/ Akt3/ mice but observed a severe reduction in se-
rum testosterone levels. Interestingly, relative to body weight,
brain size was not further reduced in Akt2/ Akt3/ mice
compared to Akt3-deficient mice, despite a high expression of
Akt2 in the brain (25% of total Akt [13]) which is abrogated
in Akt2/ Akt3/ mice. This argues for a selective influence
of Akt3 on the regulation of brain size, rather than the size
being a result of the total Akt dose in the tissue. Furthermore,
Akt3 appears not to contribute to glucose homeostasis in mice,
as a combined disruption of Akt2 and Akt3 did not noticeably
exacerbate the glucose and insulin intolerance observed in
Akt2/ mice.
Detection of active Akt by a phospho-Ser473 antibody
showed substantially reduced levels of total active Akt in var-
ious tissues of Akt2/ Akt3/ mice both at the steady state
and when induced. Surprisingly, phosphorylation levels of crit-
ical downstream targets, such as GSK3, TSC2, and S6K, were
similar in the Akt2/ Akt3/ mice to those in wild-type
controls. Very low levels of active Akt1, the residual isoform,
appear to be sufficient to phosphorylate certain downstream
targets. However, we cannot formally exclude that these tar-
gets may be phosphorylated by another compensatory mecha-
nism. For instance, S6K and p90 ribosomal S6 kinases (RSK)
are two other insulin-stimulated protein kinases that can cat-
alyze the phosphorylation of GSK3 in vitro (10, 31, 32). Al-
though Akt appears to be the major kinase phosphorylating
GSK3 in vivo upon insulin stimulation (4, 11), S6K and/or RSK
may constitute a compensatory mechanism by which GSK3
becomes phosphorylated in Akt-deficient mice.
In conclusion, we provide genetic evidence for a dominant
role of Akt1 in embryonic development and postnatal survival.
We show that minimal amounts of Akt1 appear to be sufficient
for full activation of many downstream targets. In addition, we
identify redundant and nonredundant functions of the Akt2
and Akt3 isoforms in growth and glucose metabolism and
provide insights into Akt isoform hierarchy.
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Introduction
Protein kinase B (PKB/Akt) is a second messenger-regulated
kinase that has been implicated in many crucial cellular
processes, such as glucose metabolism, transcription, cell
proliferation, apoptosis, migration and growth (Brazil and
Hemmings, 2001; Chan et al., 1999; Datta et al., 1999; Kandel
and Hay, 1999; Scheid and Woodgett, 2001). Deregulation of
PKB activity contributes to cell transformation and diabetes
(Brazil and Hemmings, 2001; Nicholson and Anderson, 2002).
In mammalian cells, three closely related isoforms of the PKB
family have been identified and termed PKBα/Akt1,
PKBβ/Akt2 and PKBγ/Akt3 (Brodbeck et al., 1999; Cheng et
al., 1992; Jones et al., 1991a; Jones et al., 1991b; Masure et
al., 1999; Nakatani et al., 1999). These proteins are products
of three separate genes located on distinct chromosomes and
are widely expressed with a few isoform-specific features
(Altomare et al., 1998; Yang et al., 2003). All three members
of the PKB family contain a highly conserved N-terminal
pleckstrin homology (PH) domain, a central catalytic domain
and a short C-terminal regulatory domain (Hanada et al., 2004).
PKB is activated by numerous stimuli, including growth
factors, hormones and cytokines (Brazil and Hemmings, 2001;
Chan et al., 1999; Datta et al., 1999). Activation of PKB occurs
in response to signalling via phosphoinositide 3 kinase (PI3K)
and requires the membrane-bound second messenger
phosphatidylinositol-3,4,5-triphosphate [PtdIns(3,4,5)P3 or
PIP3] (Burgering and Coffer, 1995; Cross et al., 1995; Franke
et al., 1995). The current model for PKB regulation proposes
that PtdIns(3,4,5)P3, generated following PI3K activation,
interacts with the PH domain of PKB, recruiting the inactive
kinase from the cytoplasm to the plasma membrane
and promoting a conformational change that allows
phosphorylation on two regulatory sites by upstream kinases
at the plasma membrane. One of these critical phosphorylation
sites resides in the activation loop of the kinase domain
(Thr308 in PKBα) and the other is located in the C-terminal
regulatory domain (Ser-473 in PKBα), termed the hydrophobic
motif (Alessi et al., 1996; Brodbeck et al., 1999; Meier et al.,
1997). The upstream kinase that phosphorylates Thr308 in the
activation loop of the kinase domain of PKBα in a PIP3-
dependent-manner has been identified and termed 3-
phosphoinositide-dependent kinase 1 (PDK1) (Alessi et al.,
1997; Stokoe et al., 1997). Thr308 phosphorylation is
necessary and sufficient for PKB activation; however, maximal
activation requires additional phosphorylation at Ser473
(Alessi et al., 1996; Yang et al., 2002a; Yang et al., 2002b).
Several different protein kinases and mechanisms have been
proposed for the phosphorylation of the hydrophobic motif
(Brazil and Hemmings, 2001; Yang et al., 2002b).
Mice with targeted disruption of Pkbα and/or Pkbβ have
been obtained recently with Pkbα mutant mice displaying an
increased neonatal lethality and a reduction in body weight of
~30% (Chen et al., 2001; Cho et al., 2001b; Yang et al., 2003).
Moreover, loss of Pkbα leads to placental hypotrophy with
impaired vascularisation (Yang et al., 2003). By contrast,
Pkbβ-deficient mice are born with the expected Mendelian
ratio and exhibit a diabetes-like syndrome with elevated fasting
plasma glucose, hepatic glucose output, peripheral insulin
resistance and an compensatory increase of islet mass (Cho et
Protein kinase B is implicated in many crucial cellular
processes, such as metabolism, apoptosis and cell
proliferation. In contrast to Pkbα and Pkbβ-deficient mice,
Pkbγ –/– mice are viable, show no growth retardation and
display normal glucose metabolism. However, in adult Pkbγ
mutant mice, brain size and weight are dramatically
reduced by about 25%. In vivo magnetic resonance
imaging confirmed the reduction of Pkbγ –/– brain volumes
with a proportionally smaller ventricular system.
Examination of the major brain structures revealed no
anatomical malformations except for a pronounced
thinning of white matter fibre connections in the corpus
callosum. The reduction in brain weight of Pkbγ –/– mice is
caused, at least partially, by a significant reduction in both
cell size and cell number. Our results provide novel insights
into the physiological role of PKBγ and suggest a crucial
role in postnatal brain development.
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al., 2001a). Compared with Pkbα mutant mice, Pkbβ-deficient
mice are only mildly growth retarded (Cho et al., 2001a;
Garofalo et al., 2003). However, mice lacking both isoforms
die after birth, probably owing to respiratory failure (Peng et
al., 2003). Pkbαβ double mutant newborns display a severe
reduction in body weight (≈50%), prominent atrophy of the
skin and skeletal muscle, as well as impaired adipogenesis and
delayed ossification.
Here, we report the generation and characterisation of mice
with targeted disruption of the Pkbγ gene. Compared with
Pkbα–/– and Pkbβ–/– mice, Pkbγ mutant mice display a distinct
phenotype without increased perinatal mortality, growth
retardation or altered glucose metabolism. However, loss of
PKBγ profoundly affects postnatal brain growth. Brains from
adult Pkbγ mutant mice show a dramatic reduction in size and
weight. Taken together, our results reveal a novel and important
physiological role for PKBγ in postnatal brain development.
Materials and methods
Targeted disruption of the Pkbγ gene by homologous
recombination
An ~11-kb HindIII fragment was subcloned containing exons 4 and 5
of Pkbγ. A NcoI site was generated in exon 4 for insertion of a ~5-kb
IRES-lacZ-Neo cassette. The targeting vector was linearised with SalI
and electroporated into 129/Ola ES cells. An external probe was used
for ES cell screening following XbaI digestion. An internal probe and
a lacZ-Neo probe were used to characterize ES clones positive for
homologous recombination (data not shown). Correctly targeted ES
cells were used to generate chimeras. Male chimeras were mated with
wild-type C57BL/6 females to obtain Pkbγ +/– mice. Pkbγ +/– mice
have been backcrossed twice with pure C57BL/6 mice and the
progeny of Pkbγ +/– intercrosses have ~75% C57BL/6 genetic
background. Progeny were genotyped by multiplex PCR with the
following three primers: (1) P35, GGTTCTGTGGGAGGTA-
GTTCTC; (2) Neo-2, GCAATCCATCTTGTTCAATGGCCG; and
(3) E4γ, CCATCGGTCGGCTACGGCTTGG.
Quantitative real time PCR
The levels of PKB isoforms in wild-type and mutant mice were
determined by quantitative Q-RT-PCR. The experiment was
performed as described previously (Yang et al., 2003). Briefly, total
RNA was purified using Trizol Reagent (Invitrogen). For the Q-PCR
reaction, 50 ng total RNA was mixed with 5′ and 3′ primers, Taqman
probe, MuLV reverse transcriptase, RNase inhibitor and the
components of the TaqMan PCR reagent kit (Eurogentec) in a total
volume of 25 µl following the TaqMan PCR reagent kit protocol.
Western blot analysis
For Western blot analysis, protein lysates were processed as
previously described (Yang et al., 2003). PKB isoform-specific
antibodies were obtained by immunizing rabbits with isoform-specific
peptides as previously described (Yang et al., 2003). Antibodies
against phospho-PKB (Ser473), phospho-GSK3α/β (Ser21/9),
phospho-TSC2 (Thr1462) and phospho-p70S6K were purchased from
Cell Signalling Technologies. Antibodies against p27 and ERK were
purchased from Santa Cruz Biotechnology. The antibody against
phospho-ERK (Thr202/Tyr204) was purchased from Promega and the
Pan-Actin antibody was obtained from NeoMarkers. Western blots
were scanned using a GS-800 BioRad densitometer with a resolution
of 63.5 µm  63.5 µm and bands were quantified using
Proteomweaver 3.0.0.6 (Definiens).
Histological examination
For histological analysis, animals were perfused with phosphate-
buffered saline and 4% paraformaldehyde in phosphate-buffered
saline. Organs were dissected and kept in the same fixation solution
overnight at 4°C. Samples were embedded in paraffin following
dehydration in ethanol. Tissues were cut into 6 µm sections and stored
for staining. For Haematoxylin-Eosin and Cresyl-Violet (Sigma)
staining, sections were freed of paraffin and stained.
Cell number determination
To determine the number of cells in a whole brain, the DNA content
was determined as described by Labarca and Paigen (Labarca and
Paigen, 1980). This method is based on the enhancement of
fluorescence after binding of bisbenzimid (Riedel-de Haen) to DNA.
A linear standard curve (1-10 µg/ml) was prepared to calculate the
DNA concentration. The relative cell size in posterior cortex was
measured on plane-matched, parasagittal brain sections stained with
DAPI (Biotium). Image-Pro® Plus (Media Cybernetics) was used to
count the cell number and to calculate the mean area occupied by one
cell. The relative cell size is expressed as percent of wild type.
In vivo magnetic resonance imaging (MRI)
MRI studies of 4-month-old female Pkbγ wild-type (n=5) and mutant
mice (n=5) were performed at 2.35 T using a MRBR 4.7/400 mm
magnet (Magnex Scientific, Abingdon, England) equipped with
BGA20 gradients (100 mT m–1) and a DBX system (Bruker Biospin,
Ettlingen, Germany). For in vivo examinations, animals were
anaesthetized (1.0-1.5% halothane in 70:30 N2O:O2) and treated as
previously described (Natt et al., 2002). Briefly, radiofrequency (rf)
excitation and signal reception were accomplished with use of a
Helmholtz coil (∅ 100 mm) and a surface coil (∅ 2012 mm),
respectively. Three-dimensional T1-weighted (rf-spoiled 3D FLASH,
repetition time TR=17 mseconds, echo time TE=7.6 mseconds, flip
angle 25°, measuring time 84 minutes) and T2-weighted MRI data sets
(3D fast spin-echo, TR/TE=3000/98 mseconds, measuring time 58
minutes) were acquired with an isotropic resolution of 117 µm.
Volumetric assessments were obtained by analysing T1-weighted
images using software provided by the manufacturer (Paravision,
Bruker Biospin, Ettlingen, Germany). After manually outlining the
whole brain and the ventricular spaces in individual sections,
respective areas were calculated (in mm2), summed and multiplied by
the section thickness.
Neuronal cell culture
E16.5 murine hippocampal neurons were isolated from timed matings.
Cells were kept in culture for 7 days on polylysine coverslips coated
with B27/Neurobasal (GIBCO Life Technologies). At day 7, cultures
were treated with glutamate (15 mM/24 hours), staurosporine (50
nM/12 hours) or were left untreated. For the detection of apoptotic
cells, five fixed cultures per genotype were stained using a TUNEL-
assay (Roche) according to the manufacturer’s instructions and
counterstained with DAPI (Biotium). At least 200 cells per culture
were counted and the percentage of apoptotic cells was calculated.
Glucose and insulin tolerance test
Mice were housed according to the Swiss Animal Protection Laws in
groups with 12 hours dark/light cycles and with free access to food
and water. All procedures were conducted with the approval of the
appropriate authorities.
Random-fed and fasting blood glucose levels were determined in
5- to 6-month-old mice. Blood samples were collected from tail veins
and glucose levels were determined using Glucometer Elite (Bayer).
Mice (aged 5-6 months) were fasted overnight before the start of the
glucose and insulin tolerance tests. Glucose (2 g/kg) was given
orally to conscious mice. Insulin (1 U/kg) was administered by
intraperitoneal injection to conscious mice. Blood samples were
collected at indicated times from tail veins and glucose levels were
determined using Glucometer Elite (Bayer). Blood glucose levels
were expressed as percentage of initial value. Blood insulin levels
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were measured with a Mouse ultra-sensitive insulin ELISA
(Immunodiagnostic Systems).
Microarray analysis
Microarray analysis was performed using murine MOE430A
GeneChips™ (Affymetrix). Total RNA (10 µg) was reverse
transcribed using the SuperScript Choice system for cDNA synthesis
(Life Technologies) and biotin-labelled cRNA generated using the
Enzo BioArray High Yield RNA transcript labelling kit (Enzo
Diagnostics) following the manufacturer’s protocol. cRNA
fragmentation and hybridisation were performed as recommended
by Affymetrix. Expression data were calculated using the RMA
algorithm from BioConductor (Irizarry et al., 2003). A gene was
considered to be significantly altered in its expression if it had an
Affymetrix change P-value of less than 0.003 for either increase or
decrease in at least two-thirds of replicate comparisons and it had a
minimum expression value of 100 in at least one condition. A fold-
change threshold of 1.5 was then applied and the resulting genes were
subjected to a one-way ANOVA with a P-value cut-off of 0.05. A
Benjamini and Hochberg multiple testing correction and a Tukey post-
hoc test were applied.
Statistical analysis
To compare body weight, brain weight and volume, brain/body weight
ratio, DNA content, cell number and percentage of apoptotic cells
between Pkbγ +/+ and Pkbγ –/–, an unpaired Students t-test was
performed. P values under 0.05 were considered as significant and
values below 0.01 as highly significant.
Results
Targeting strategy and confirmation of genotype
Pkbγ –/– mice were generated by targeted disruption of exon 4
as shown in (Fig. 1A). The ablation of Pkbγ was confirmed
by PCR, Q-RT-PCR and Western blot analysis using brain
tissue samples from Pkbγ wild-type (Pkbγ +/+), heterozygous
(Pkbγ +/–) and mutant (Pkbγ –/–) mice (Fig. 1B). Quantitative
RT-PCR displayed complete ablation of the PKBγ mRNA in
brain samples of Pkbγ mutant mice (n=3, data not shown). To
confirm the absence of PKBγ at the protein level, Western blot
analysis was performed with an isoform-specific anti-PKBγ
antibody. In contrast to Pkbγ+/+ brain tissue samples, PKBγ was
not detectable in samples derived from mutant mice (Fig. 1C).
In addition, Western blot analysis with antibodies specific for
PKBα and PKBβ, respectively, showed no compensatory
upregulation of PKBα and/or PKBβ, respectively, in the brain
of Pkbγ –/– mice (Fig. 1D).
Distribution of PKBγ in wild-type tissues
It has been reported that the PKBα and β isoform are widely
expressed in all organs, but with some isoform-specific features
(Altomare et al., 1998; Yang et al., 2003). Less is known about
the tissue distribution of the PKBγ isoform. Previous reports
suggest that PKBγ has a more restricted distribution with high
levels in the adult brain and foetal heart and low levels in liver
and skeletal muscle (Brodbeck et al., 1999; Masure et al., 1999;
Yang et al., 2003). We assessed the distribution of PKBγ
mRNA in 15 major tissues of adult mice by quantitative RT-
PCR and normalised to the level of PKBγ in the brain (Fig.
2A). PKBγ mRNA was found at the highest level in brain and
testis, and at lower levels in lung, mammary gland, fat and
spleen.
To investigate whether PKBγ ablation leads to compensatory
increase in PKBα and/or PKBβ, total RNA isolated from brain,
testis, lung, mammary gland, fat and spleen of three Pkbγ wild-
type and three mutant mice was subjected to quantitative RT-
PCR. The levels of PKBα and β were normalised to the level
of PKBα in wild-type brain and set as 100%. Overall, no
marked upregulation of PKBα and/or PKBβ was observed,
including the brain (Fig. 2B,C). These results are consistent
with Western blot analysis of protein extracts of brains from
Pkbγ wild-type and mutant mice (Fig. 1D). To investigate the
distribution and levels of individual PKB isoforms within the
brain, protein lysates were prepared from ten anatomically and
functionally different regions. In general, all three isoforms
were expressed in all examined regions but with certain
isoform-specific features (Fig. 2D). PKBα is expressed in all
regions at similar levels, whereas PKBβ is expressed at
moderate levels in cortex, cerebellum, hippocampus and
olfactory bulb, and at lower levels in the hypothalamus,
midbrain, brain stem and spinal cord. PKBγ is expressed in all
examined regions but at higher levels in the cortex and in the
cerebellum.
Fig. 1. Targeting strategy and confirmation of genotype. (A) The
genomic organization of the Pkbγ wild-type allele (top) was
disrupted using a targeting vector with an IRES-lacZ-Neo-cassette
(middle). Targeting of the wild-type allele leads to disruption of exon
4 of the Pkbγ gene (bottom). Arrowheads indicate the localization of
the primers for the PCR reaction. (B) The genotype of mice was
determined by PCR. Representative results from Pkbγ +/+, Pkbγ +/–
and Pkbγ –/– mice are shown. (C) The levels of PKBγ in the brains of
Pkbγ +/+, Pkbγ +/– and Pkbγ –/– mice were determined by western blot
analysis using a PKBγ-specific antibody. (D) The levels of PKBα
and PKBβ, respectively, were determined in brain lysates from










Signalling in Pkbγ mutant mice
The phosphorylation/activation state of PKB in protein extracts
from brains of 3-month-old Pkbγ +/+ and Pkbγ –/– mice was
analysed using an antibody specific for the phosphorylation
site (anti-phospho-Ser-473) in the hydrophobic motif of the
regulatory domain of all three isoforms (Fig. 3A). As expected,
levels of activated PKB (quantification was done using actin as
loading control) in Pkbγ –/– mice was significantly lower than
in Pkbγ +/+ littermate controls (100% versus 38%), but was not
completely abolished (Fig. 3B). The phosphorylation levels
of glycogen synthase kinase 3 (GSK3), tuberous sclerosis
complex 2 (TSC2), p70S6K, ERK and p27 in Pkbγ –/– mice
were not significantly changed when compared with wild-type
littermate controls (levels of phosphorylated protein were
normalised with the level of unphosphorylated protein). We
repeated this experiment using brain samples of 14 days old
mice and obtained comparable results with significantly
reduced levels of total phosphorylated PKB and unchanged
levels of phosphorylated substrates (data not shown). 
Several recent studies emphasize the importance of insulin-
like growth factor 1 (IGF1) signalling in the survival and
proliferation of oligodendrocytes and myelination in the
central nervous system (D’Ercole et al., 2002). Mice lacking
IGF1 also have reduced brain weight and reduced size of the
corpus callosum and anterior commissure (Ye et al., 2002).
Therefore, we performed a western blot analysis with cell
lineage-specific markers using antibodies against myelin
basic protein (oligodendrocytes), glial fibrillary acidic protein
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Fig. 2. Tissue distribution of PKBγ and levels of PKBα and PKBβ in
Pkbγ mutant mice. (A) The mRNA level of PKBγ was determined in
15 different organs from adult Pkbγ +/+ mice. Total RNA was isolated
from three adult mice and the levels were normalized to the level of
PKBγ in the brain (100%). MG, mammary gland. Error bars
represent s.d. mRNA levels of (B) PKBα and (C) PKBβ were
determined using total RNA from six different organs of adult Pkbγ
wild-type (n=3; black bars) and mutant mice (n=3; white bars).
mRNA levels of PKBα and PKBβ were normalized to the level of
PKBα in wild-type brain (100%). Error bars represent s.d. 
(D) Western blot analysis of PKBα, β and γ within ten different brain
regions using isoform specific antibodies.
Fig. 3. Phospho-western blot analysis of brains from Pkbγ mutant
mice. (A) Brains of three wild-type and three mutant mice were
analysed for phosphorylation status of proteins involved in PKB
signalling. p, indicates phosphorylated protein. (B) Western blot
quantification. Levels of p-Ser473 and p27 were normalized to the
level of actin, all phosphorylated proteins were normalized to the
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(astrocytes) and M-neurofilaments (neurons). Significantly, no
obvious differences in the expression levels of these marker
proteins were observed when comparing samples of Pkbγ +/+
and Pkbγ –/– mice (n=5 per genotype, data not shown).
PKBγ is not required for postnatal survival, fertility,
body weight and glucose metabolism
There was no evidence for increased mortality of Pkbγ –/– mice
after birth in an analysis of more than 400 pups (aged 3-4
weeks) [Pkbγ +/+: Pkbγ +/–: Pkbγ –/–=104 (25.6%): 206 (50.7%):
96 (23.6%)]. As PKBγ is highly expressed in the testis, fertility
of mutant mice was tested using male Pkbγ –/–  female
Pkbγ +/+ and female Pkbγ –/–  male Pkbγ +/+ matings. Both
male and female mutant mice matings gave normal pregnancies
and births, indicating that fertility is not impaired in either male
or female Pkbγ mutant mice (data not shown).
As PKB has been implicated in the regulation of cell and
organ growth, body weight was measured in male Pkbγ mutant
mice and wild-type littermate controls (n=5-8 per group) at
different time points (Chen et al., 2001; Cho et al., 2001b; Peng
et al., 2003; Yang et al., 2003). Body weight did not differ
significantly between male Pkbγ mutant mice and wild-type
controls at any time point (Fig. 4A). A similar result was
obtained with female Pkbγ –/– mice and Pkbγ +/+ controls (n=5-
8 per group, data not shown), indicating that PKBγ does not
play a significant role in the overall growth of mice.
To investigate a potential role of PKBγ in the regulation of
glucose metabolism, blood glucose levels were measured in
adult (5-6 months) Pkbγ mutant mice under random-fed and
fasting condition, and compared with age- and gender-matched
wild-type controls. Interestingly, both random-fed and fasting
blood glucose levels, were not significantly different between
wild-type and mutant mice (Fig. 4B). Additionally, blood
insulin levels in random-fed condition did not differ
significantly between Pkbγ +/+ and Pkbγ –/– mice (1.32±0.08
µg/l versus 1.30±0.13 µg/l; n=6). To further investigate glucose
metabolism, overnight fasted mice were challenged with
insulin (insulin tolerance test) or glucose (glucose tolerance
test). To test the insulin responsiveness, insulin (1 U/kg) was
applied by intraperitoneal injection und blood glucose levels
were measured at indicated time points using blood from tail
veins. No obvious differences of blood glucose levels in the
insulin tolerance test were found between the groups with
mutant and control mice (Fig. 4C). Additionally, mice were
challenged with orally applied glucose (2 g/kg) and blood
glucose levels were measured at indicated time. Compared with
wild-type mice, Pkbγ –/– mice displayed a very similar response
to the glucose load (Fig. 4D). Taken together, these results
suggest that PKBγ does not play a significant role in the
maintenance of glucose homeostasis.
Essential role of PKBγ in postnatal brain
development
Next, adult Pkbγ +/+ and Pkbγ –/– mice were dissected and all
major organs were investigated macroscopically. Compared
with Pkbγ +/+ littermate controls, the overall size of brains from
Fig. 4. Dispensable role of PKBγ for
body weight and glucose metabolism.
(A) Body weights of male Pkbγ +/+
(white bars) and Pkbγ –/– (black bars)
mice were measured at different
points in time (n=5-8 animals per
genotype). Error bars represent s.d.
NB, newborn. (B) Blood glucose
concentrations from random-fed (RF)
and overnight fasted (ONF) mice
(n=8; 6 months old; Pkbγ +/+ white
bars and  Pkbγ –/– black bars). Error
bars represent s.d. (C) Insulin
tolerance test. Animals (n=6; 6
months old; Pkbγ +/+ white triangles
and  Pkbγ –/– black circles) were
fasted overnight and insulin (1 U/kg)
was administered by intraperitoneal
injection. (C) Glucose concentrations
were determined at indicated time
points from whole blood collected
from tail veins. Values were
normalized to the starting glucose
concentration at the administration of
insulin. Error bars represent s.d. 
(D) Glucose tolerance test. Animals
(n=6; 5-6 months old; Pkbγ +/+ white
triangles and  Pkbγ –/– black circles)
were fasted overnight and glucose (2
g/kg) was orally administered. Blood
glucose concentrations were sampled
at the indicated times. Values were
normalized to the starting glucose
concentration at the administration of












































































































adult Pkbγ –/– mice was strikingly reduced. A representative
example is shown in Fig. 5B-D. Furthermore, the weights of
freshly dissected brains of Pkbγ wild-type and Pkbγ mutant
mice were measured at different ages (Fig. 5A). Compared
with age- and gender-matched wild-type littermate controls,
brains from adult Pkbγ –/– mice (3-12 months old) exhibited a
highly significant reduction in weight of about 25% (range
22%-29%), affecting both males and females (data for females
not shown, n=5-8). Interestingly, at birth, brain weight did not
differ significantly between Pkbγ+/+ and Pkbγ –/– mice. The
reduction in brain size and weight was first observed at the age
of 1 month, but was less pronounced compared with adult mice
(≈18%). In contrast to Pkbα, Pkbβ and IgfI-null mutant mice
(Beck et al., 1995; Cheng et al., 1998; Garofalo et al., 2003;
Powell-Braxton et al., 1993), the brain/body weight ratio of
Pkbγ mutant mice was also significantly reduced to a similar
extent.
In vivo magnetic resonance imaging (MRI) of Pkbγ –/–
mice
MRI is an excellent non-invasive technique for studying brain
anatomy in transgenic and mutant mice (Kooy et al., 2001; Natt
et al., 2002). For further characterization of Pkbγ mutant brain
anatomy, five adult female mutant and five age and gender
matched wild-type littermate controls (with the same genetic
background) from Pkbγ +/– matings were examined using high-
resolution 3D MRI as previously described (Natt et al., 2002).
Fig. 5E-J shows representative T2-weighted images of Pkbγ +/+
and Pkbγ –/– brains in a sagittal, horizontal, and coronal section
orientation. Complementary in vivo volumetry based on T1-
weighted 3D MRI confirmed the much smaller brain size of all
five Pkbγ mutant mice. Compared with wild-type littermates,
whole brain volume in Pkbγ –/– mice was significantly reduced
by about 24% (513±14 mm3 versus 391±16 mm3, P<0.01;
n=5). Although several brain regions were affected, including
olfactory bulb, cortex and hippocampal formation, no
alteration in the structural organization of the brain was
observed, confirming the macro-pathological findings.
Moreover, because the volume of the ventricular spaces in 
Pkbγ –/– mice was reduced (7.85±2.2 mm3 versus 5.55±2.8
mm3) in proportion to that of the whole brain and MRI revealed
no enlargement of the subarachnoid space, the occurrence of
an internal or external hydrocephalus is excluded as a cause of
reduced brain size. Interestingly, in contrast to any wild-type
littermate controls, all five Pkbγ –/– mice presented with a
marked thinning of the corpus callosum (downward
arrowheads in Fig. 5E,F). White matter fibres connections are
depicted as hypointense structures in T2-weighted images.
Although unequivocally identifiable in Pkbγ +/+ mice (Fig.
5E,G,I), the corpus callosum is partly indistinguishable from
surrounding grey matter in Pkbγ –/– mice (Fig. 5F,H,J). Anterior
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Fig. 5. Reduced brain weight and size of Pkbγ mutant mice. 
(A) Weight of freshly dissected brains of male Pkbγ +/+ (white bars)
and Pkbγ –/– (black bars) mice were measured at different points in
time (n=5-8 animals per genotype). *P<0.05. Error bars represent
s.d. NB, newborn. (B) Cranial, (C) caudal and (D) lateral views of
brains from adult Pkbγ wild-type (left side) and knockout (right side)
mice. Co, cortex; CE, cerebellum; OB, olfactory bulb; BS,
brainstem; HY, hypothalamus. (E-J) Representative sections from T2-
weighted 3D MRI data sets acquired in vivo from the brains of
Pkbγ +/+ (E,G,I) and Pkbγ –/– mice (F,H,J) from Pkbγ +/– matings in
sagittal (E,F), horizontal (G,H) and coronal (I,J) orientation. CC,
corpus callosum; AC, anterior commissure; PC, posterior
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and posterior commissures as well as
the hippocampal fimbria are less
prominently affected.
Histology of Pkbγ –/– mouse
brains
Histological examination of Pkbγ –/–
brain was performed to investigate
changes at the microscopic level.
Various brain regions, including
cerebellum, hippocampus and corpus
callosum, were examined following
Haematoxylin/Eosin staining (Fig.
6A-F). With the exception of the
reduced size of all regions, no abnormalities in the overall
structure of the different brain regions were observed. In line
with the in vivo MRI findings, the thickness of the corpus
callosum in Pkbγ mutant mice was markedly reduced
(downward arrowheads in Fig. 6G,J). Additionally, myelin
staining with luxol Fast Blue revealed not only a reduction in
thickness of the corpus callosum but also less intense staining
of the structure (Fig. 6H,K).
Cell number in the brains of Pkbγ –/– mice
Next, we indirectly assessed the cell number by measuring the
amount of DNA in whole brains derived from Pkbγ +/+ and
Pkbγ –/– mice. The amount of DNA is considered as an
indicator of cell number, whereas the amount of DNA per gram
of tissue is an indicator of cell density which is reciprocal to
cell volume (Zamenhof, 1976). The DNA contents of brains
from newborns and 1-month-old mice were determined using
the method described by Labarca and Paigen (Labarca and
Paigen, 1980). Briefly, this method is based on the
enhancement of fluorescence after binding of bisbenzimid to
DNA. Compared with wild-type control samples, whole brain
DNA content of Pkbγ –/– newborns did not differ significantly,
indicating that cell number was not changed. Similarly, the
DNA content per gram of brain tissue was comparable between
Pkbγ wild-type and mutant mice, indicating a comparable cell
size. In contrast to newborns, the DNA content in brains of 1-
month-old Pkbγ mutant mice was slightly, but significantly,
reduced compared with the Pkbγ +/+ controls (Table 1).
However, the DNA content per gram of tissue was,
significantly increased in samples from Pkbγ –/– compared with
wild-type littermate controls, indicative of increased cell
density (and reduced cell size).
Additionally, the relative cell size in the posterior cortex of
adult mice (3 months) was determined based on histological
slides stained with DAPI. Cells were analysed using Image-Pro
Plus in a defined field of view (≈1000 per field), and the area
occupied by one cell was subsequently calculated. In line with
the results of the DNA content experiment, the relative cell size
was significantly and consistently reduced in Pkbγ mutant mice
(100±10% versus 80±7%; n=5 per genotype; P<0.05). Taken
together, the results show that both cell size and cell number
contribute to the reduction in brain size observed in mutant
mice, but the relative contribution of cell size reduction plays
a more important part.
Susceptibility to glutamate and staurosporine
induced cell death
It is established that the PI3K/PKB pathway plays a crucial role
in cell survival in the central nervous system (Datta et al., 1999;
Dudek et al., 1997; Kim et al., 2002). To investigate the
potential role of PKBγ in apoptosis, primary cell cultures were
established from Pkbγ +/+ and Pkbγ –/– hippocampal neurons.
Immunocytochemistry at day 28 using antibodies against tau
(for axons) and Map2C (for dendrites) did not reveal any
obvious defects in the differentiation of Pkbγ –/– hippocampal
neurons (Fig. 7A-D). Consistent with the analysis of the
expression pattern of PKB isoforms in various brain regions
(Fig. 2D), we found that PKBα, PKBβ and PKBγ, respectively,
were expressed in cultured wild-type primary hippocampal
neurons. In accordance with the result of Fig. 1D, we did not
Fig. 6. Histology of brains from Pkbγ
mutant mice. Representative sections (HE
staining) of the cortex (A,D),
hippocampus (B,E) and cerebellum (C,F)
from adult Pkbγ +/+ (A-C) and Pkbγ –/– (D-
F) mice in parasagittal orientation.
Representative sections stained for myelin
(Luxol-Fast Blue/Eosin) of whole brain
(G,J), corpus callosum (H,K) and anterior
commissure (I,L) from Pkbγ +/+ (G-I) and
Pkbγ –/– mice (J-L) in coronal orientation.
White matter structures are labelled as










find a compensatory upregulation of PKBα and PKBβ in Pkbγ-
deficient cells (Fig. 7E). To test the potential role of PKBγ in
the survival of hippocampal neurons, cell cultures were
challenged with glutamate (15 mM/24 hours) or staurosporine
(50 nM/12 hours) after 7 days in culture. Apoptotic cells were
detected using the TUNEL assay. In untreated cells cultures,
no significant difference in the percentage of apoptotic cells
between Pkbγ +/+ and Pkbγ –/– hippocampal neurons was
observed (Fig. 7F). After treatment with glutamate or
staurosporine, the percentage of apoptotic cells was
significantly increased (51% and 24%, respectively, P<0.01) in
cultures from Pkbγ –/– hippocampal neurons (Fig. 7F).
Additionally, we analysed the number of apoptotic cells from
adult brains (n=5 per genotype) using TUNEL staining on
parasagittal sections. Similar to the results of untreated
cultures, we did not find any difference between Pkbγ +/+ and
Pkbγ –/– mice (data not shown).
Microarray analysis of Pkbγ –/– brains
In the CNS, a considerable amount of cellular and
physiological events occur during postnatal development, such
as neuronal outgrowth, differentiation, synaptogenesis and
maturation. To investigate a potential role of PKBγ in these
events, we analyzed gene expression patterns in brains of
Pkbγ +/+ and Pkbγ –/– mice at different time points during
postnatal brain development, i.e. day 1, day 7 and day 30. RNA
was extracted from whole mice brains and microarray analysis
was performed on three individual brains per genotype and
time point using murine Affymetrix GeneChips™. Changes
below 1.5-fold increase were considered insignificant, and
differentially regulated genes were subjected to a one-way
ANOVA analysis (Table 2). As the brain consists of various
heterogeneous cell populations, any change of expression
occurring in a specific cell type will be quenched in the pool
of whole brain RNA. It is therefore likely that the real
expression changes in specific tissues are higher than apparent
in this experiment. Among the 17,000 expressed genes, we
found 37 genes to be differentially expressed in Pkbγ–/– brains
versus Pkbγ+/+ brains. Of these, 16 genes were upregulated and
21 genes downregulated. Among the genes with changed
expression are several transcription factors and genes
implicated in cell cycle and proliferation. Significantly, one of
the most interesting findings is that at P30, several genes
involved in synaptic transmission (pre- and postsynaptic),
including ionotropic glutamate receptor (NMDAR1),
potassium-chloride co-transporter 2 (KCC2), chapsyin 110
[channel-associated protein of synapses, 110 kDa (DLG2)] and
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Table 1. Cell number in the brain of Pkbγ wild-type and mutant mice
Age
Newborns One month old
Pkbγ +/+ Pkbγ –/– Pkbγ +/+ Pkbγ –/–
Body weight (g) 1.21±0.23 1.31±0.14 (107%) 14.1±2.5 13.0±2.3 (92%)
Brain weight (g) 0.071±0.001 0.069±0.006 (98%) 0.41±0.03 0.32±0.03 (78%)*
Brain/body weight ratio 0.059±0.011 0.054±0.008 (90%) 0.030±0.004 0.025±0.003 (85%)*
DNA/brain (mg) 0.59±0.04 0.56±0.12 (96%) 1.38±0.03 1.29±0.07 (93%)*
DNA/g of tissue (mg) 8.53±1.64 8.11±1.29 (95%) 3.38±0.20 4.04±0.47 (119%)*
The cell number in whole brains of Pkbγ+/+ and Pkbγ–/– mice was determined in newborns and 1-month-old animals. Brain weight, brain/body weight and DNA
content (parameter of cell number) per brain were significantly reduced in Pkbγ–/– mice at 1 month, but not in newborns. The DNA content per gram of tissue, a
parameter of cell density, was significantly increased in Pkbγ mutant mice at 1 month, but not in newborns (*P<0.05).
Fig. 7. Increased susceptibility to glutamate and staurosporine
induced cell death. (A-D) Primary hippocampal neurons were
established from E16.5 embryos and kept in culture for 28 days.
Immunocytochemistry was performed using antibodies against
dendritic (Map2C) or axonal (tau) proteins. (E) PKBα, PKBβ and
PKBγ expression in Pkbγ wild-type and mutant hippocampal
neurons. (F) Seven-day-old cultures were treated with glutamate (15
mM/24 hours) or with staurosporine (50 nM/12 hours) or were left
untreated (Pkbγ +/+ white bars and Pkbγ –/– black bars). Apoptotic
cells were identified by TUNEL-assay and at least 200 cells per
culture were counted (n=5 cultures per treatment and genotype).
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synaptotagmin 2 (SYT2), have significantly reduced
expression levels in Pkbγ mutant brains. Additionally, Ca2+/
calmodulin-dependent protein kinase II α (CaMKII), an
enzyme that is essential in synaptic plasticity and memory
formation, was found at reduced expression levels (Ninan and
Arancio, 2004).
Discussion
Here, we report the phenotypic consequences of the ablation
of the Pkbγ gene. Mice with targeted disruption of all single
PKB isoform were generated and all demonstrated a distinct
phenotype. Mice deficient in Pkbα are smaller with a 30%
reduction in body size and partial neonatal lethality, which
might be caused by placental insufficiency (Chen et al., 2001;
Cho et al., 2001b; Yang et al., 2003). By contrast, Pkbβ
knockout mice exhibited a diabetes-like syndrome with
hyperglycemia and impaired insulin action in fat, liver and
skeletal muscle and, depending on the genetic background,
mild growth retardation (Cho et al., 2001; Garofalo et al.,
2003). Recently, Peng and colleagues reported the generation
of Pkbαβ double mutant mice with severe intrauterine growth
retardation that die shortly after birth with multiple defects in
skin, bone and fat tissue (Peng et al., 2003). However, our
results demonstrate that Pkbγ-deficient mice display a distinct
phenotype without increased mortality, growth retardation and
altered glucose homeostasis. Inactivation of the Pkbγ gene
leads to a considerable reduction in total phosphorylated/
activated PKB in the mutant brain without any compensatory
increase of the α and β isoforms (assessed at the mRNA and
protein levels), suggesting a failure to fully compensate for the
loss of PKBγ. This result is consistent with findings in Pkbα
and Pkbβ mutant mice, where no compensatory upregulation
of 2 remaining isoforms was found (Cho et al., 2001b; Garofalo
et al., 2003; Yang et al., 2003). It has been speculated that the
distinct phenotypes of Pkbα and Pkbβ mutant mice are due to
specific and distinct functions of the different PKB isoforms.
By contrast, Peng and colleagues proposed that the individual
phenotypes are due to loss of the dominant isoform in a specific
tissue, which leads to significant reduction of total activated
PKB below a crucial level (Peng et al., 2003). For example, the
observed diabetes mellitus-like syndrome of Pkbβ–/– mice
could be due to ablation of the dominant isoform in the
classical insulin-responsive tissues such as fat, liver and
muscle. Moreover, the loss of a second isoform would have an
additive effect in reducing the level of total PKB and, therefore,
would intensify the phenotype. This possibility is supported by
the observation of Pkbαβ double knockout mice (Peng et al.,
2003) and our unpublished data on the Pkbαγ double mutant
mice (Z.-Z.Y. and B.A.H., unpublished). Ablation of a single
copy of Pkbγ in Pkbα-deficient mice (Pkbα–/– Pkbγ +/–) led to
a higher perinatal mortality compared with Pkbα single mutant
Table 2. Microarray analysis of Pkbγ mutant brain
Fold change in expression
GenBank Accession 
Gene name Number Day 1 Day 7 Day 30 Function
RIO kinase 3 (yeast) AK004748 5.47* 0.59 1.52* Chromatin condensation
Kinesin family member 5B BF099632 2.24* 0.72 1.03 Microtubule based transport
Small EDRK-rich factor 1 AA709993 1.69* 1.14 1.06
CD24a antigen BB560574 1.57* 1.33 1.12 Cell proliferation
SRp20, splicing factor, arginine/serine-rich 3 AV135383 1.53* 1.32 0.91 mRNA splicing
WNK1 (protein kinase, lysine deficient 1) BI692255 1.53* 1.00 0.93 Blood pressure
ATPase, Na+/K+ transporting, alpha 2 polypeptide BQ175915 2.23* 2.93* 1.71* Nt uptake, K+ uptake
SRY-box containing gene 11 BG072739 0.96 1.82* 0.95 Transcription
Histone 1, H2af W91024 1.04 1.60* 1.16 Nucleosome structure
Upstream transcription factor 1 AF479773 1.53* 1.55* 1.45 Transcription
Early B-cell factor 3 AK014058 1.13 1.54* 0.76 Transcription
RNA-binding region (RNP1, RRM) containing 2 BB436856 1.40 1.53* 1.46 Transcription
CDC28 protein kinase regulatory subunit 2 NM_025415 1.09 1.53* 1.20 Cell cycle
Procollagen, type III, alpha 1 BG968894 1.08 1.09 2.10* Cell adhesion
Surfeit gene 4 AI788623 1.20 1.23 1.83* Membrane protein
GABAA receptor, subunit alpha 6 NM_008068 1.06 0.57* 0.92 Synaptic transmission
ATPase, Na+/K+ transporting, alpha 2 polypeptide AI845177 0.72 0.66* 0.56* Nt uptake, K+ uptake
Kinesin family member 5A NM_008447 1.04 0.80 0.53* Microtubule based transport
ADP-ribosylation factor 3 NM_007478 1.05 0.80 0.56* Protein transport
Contactin associated protein 1 NM_016782 0.96 0.96 0.57* Cell adhesion
Fibroblast growth factor 1 BM932451 0.86 0.95 0.59* Angiogenesis, cell  proliferation
Growth arrest specific 7 NM_008088 0.89 0.89 0.59* Neurite outgrowth
Ca2+/calmodulin-dependent protein kinase II alpha X14836 1.04 0.69 0.59* Cell cycle, synaptic plasticity
K+/Cl– co-transporter (KCC2/SLC12A5) AF332064 1.13 0.90 0.62* Synaptic transmission
Glutamate receptor, ionotropic, NMDA1 (ζ1) NM_008169 0.96 0.80 0.63* Synaptic transmission
Synaptotagmin 2 AF257304 1.02 1.00 0.64* Synaptic transmission
Fascin homolog 1, actin bundling protein BE952057 1.06 0.86 0.64* Actin binding
Potassium voltage-gated channel, beta member 2 L48983 0.87 0.86 0.64* Ion transport
Protein tyrosine phosphatase, receptor type, F NM_011213 0.98 1.03 0.65* Cell adhesion
Coronin, actin binding protein 1C AW548837 0.97 0.94 0.65* Actin assembly
Chapsyn-110 [discs, large homolog 2 (DLG2)] BB622767 1.29 0.80 0.65* Synaptic transmission
Genes with altered expression in male Pkbγ –/– mice (n=3) compared with Pkbγ +/+ animals at different time points during postnatal brain development. 










mice and the ablation of both Pkbγ alleles in Pkbα–/– mice led
to more pronounced dwarfism and intra-uterine death of all
Pkbα–/–Pkbγ–/– double mutant animals. However, it cannot be
confirmed yet whether the observed phenotypes are due to a
combination of reduced level of activated PKB and the loss of
isoform-specific functions.
The IGF1/PI3K/PKB pathway plays a crucial role in
mammalian brain development and function (D’Ercole et al.,
2002; Rodgers and Theibert, 2002). Besides the severe growth
retardation, adult mice with IGF1 deficiency exhibit a
significant (38%) brain weight reduction (Beck et al., 1995).
Similar to the Pkbγ mutant mice, all brain parts of the Igf1–/–
mice were affected but the general anatomical organisation was
normal. Furthermore, ablation of IGF1 resulted in a cell type-
dependent loss of neurons, as well as a reduced total number
of oligodendrocytes and hypomyelination (Beck et al., 1995;
Ye et al., 2002). In addition, targeted deletion of IRS2 in mice
also produced a pronounced brain growth deficiency, but in
contrast to Pkbγ mutants, the reduction was already apparent
during embryonic (E15.5) development (Schubert et al., 2003).
By contrast, an increased brain mass was observed in mice
overexpressing IGF1 (Mathews et al., 1988; Ye et al., 1995).
Moreover, mice with brain-specific deletion of PTEN, a
negative regulator of the PI3K/PKB pathway, exhibited an
enlarged brain with seizures and ataxia resembling Lhermitte-
Duclos disease (Backman et al., 2001; Kwon et al., 2001). Less
is known about the consequences of Pkbα and Pkbβ
inactivation for mouse brain development. Compared with
Pkbγ–/– mice, adult Pkbα and Pkbβ mutant mice showed only
a slight decrease in brain weight (Garofalo et al., 2003; Yang
et al., 2004). In both Pkbα and Pkbβ mutant mice, no changes
in the gross brain morphology were reported.
However, inactivation of the Pkbγ gene resulted in a
significant reduction of brain weight and size. Interestingly,
Pkbγ deficiency did not affect the general anatomical
organization of the brain. In vivo 3D MRI and histological
analysis excluded the absence of a specific brain region as the
main cause of the weight reduction, consistent with the result
of the broad expression profile among brain regions. More
specifically, the proportionally reduced ventricular system
rules out major disturbances in production, circulation and
absorption of cerebrospinal fluid as a cause of reduced cell
size/number in Pkbγ –/– mice. The biological relevance of the
MRI signal alterations in white matter such as the corpus
callosum requires further investigation. Nevertheless, it should
be noted that the in vivo MRI results are consistent with a
pronounced, but not complete, deficit in myelin deposition
(Boretius, 2003), which is also strongly supported by the
histological findings for myelin staining. In agreement with our
results, mice deficient in IGF1, a potent activator of PKBγ, the
myelin-rich white matter regions, including corpus callosum
and anterior commissure, were overproportionally reduced by
about 70% (Beck et al., 1995). By contrast, mice
overexpressing IGF1 display an increased brain weight and the
corpus callosum of the Igf1 transgenic mice was increased in
excess of proportionality (Carson et al., 1993).
The PI3-K/PKB signalling pathway plays a crucial role in
the determination of cell size (Scanga et al., 2000; Shioi et al.,
2002; Tuttle et al., 2001; Verdu et al., 1999). Results from
transgenic mice overexpressing PKB show larger cardiac
myocytes and thymocytes, or hypertrophy and hyperplasia in
the pancreas (Kovacic et al., 2003; Mangi et al., 2003). An
increase in neuronal soma size was observed in mice with
brain-specific deletion of PTEN (Backman et al., 2001; Kwon
et al., 2001). By contrast, the size of skeletal muscle cells in
Pkbαβ double mutant mice was dramatically reduced (Peng et
al., 2003). Our results show that both cell number and cell size
are affected, but that reduced cell size contributes more than
the reduced cell number. Additionally, it has been shown that
the mTOR signalling pathway is also involved in the
determination of cell size (Montagne et al., 1999; Oldham et
al., 2000; Zhang et al., 2000). PKB modulates mTOR activity
by phosphorylating TSC2, with a subsequent disruption of the
TSC1-TSC2 interaction (Inoki et al., 2002; Potter et al., 2003). 
Recent publications have linked PI3-K/PKB with synaptic
plasticity and memory (Dash et al., 2004; Kelly and Lynch,
2000; Lin et al., 2001; Robles et al., 2003; Sanna et al., 2002).
Wang and colleagues demonstrated that the A-type γ-
aminobutyric acid receptors (GABAAR), which mediate fast
inhibitory synaptic transmission, is phosphorylated by PKB
(Wang et al., 2003). Phosphorylation of GABAAR leads to an
increased number of receptor on the cell membrane and an
increased synaptic transmission. Additionally, Lin et al.
established a role of the PI3-K/PKB pathway in fear
conditioning in the amygdala (Lin et al., 2001). As we found
several genes involved in neuronal circuit activity in
our microarray experiment, future behavioural and
electrophysiological studies of Pkbγ mutant brains will
elucidate the specific role of PKBγ in synaptic transmission,
learning and memory.
In summary, we have demonstrated that Pkbγ-deficient mice
display a phenotype distinct from Pkbα and Pkbβ mutant mice.
Our results provide novel insights into the physiological
function of PKBγ and suggest a crucial role in postnatal brain
development of mammals. Identification of PKBγ specific
substrates involved in postnatal brain development is now of
critical importance.
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Akt/protein kinase B (PKB) plays a critical role in the regulation of metabolism, transcription, cell migra-
tion, cell cycle progression, and cell survival. The existence of viable knockout mice for each of the three
isoforms suggests functional redundancy. We generated mice with combined mutant alleles of Akt1 and Akt3
to study their effects on mouse development. Here we show that Akt1/ Akt3/ mice display multiple defects
in the thymus, heart, and skin and die within several days after birth, while Akt1/ Akt3/ mice survive
normally. Double knockout (Akt1/ Akt3/) causes embryonic lethality at around embryonic days 11 and 12,
with more severe developmental defects in the cardiovascular and nervous systems. Increased apoptosis was
found in the developing brain of double mutant embryos. These data indicate that the Akt1 gene is more
essential than Akt3 for embryonic development and survival but that both are required for embryo develop-
ment. Our results indicate isoform-specific and dosage-dependent effects of Akt on animal survival and
development.
In mammals, Akt1, Akt2, and Akt3 (also called protein kinase
B [PKB], PKB, and PKB) proteins have similar domain
structures and can be activated by numerous growth factors in a
phosphatidylinositol 3-kinase-dependent manner (1, 3, 4, 15, 23).
Once activated, Akt phosphorylates and controls the activities of
a diverse group of substrates involved in many cellular and phys-
iological processes, such as cell survival, cell cycle progression, cell
growth, metabolism, and angiogenesis (3, 10, 17, 23).
Although many proteins have been identified as Akt sub-
strates, the challenge that remains is to show that they actually
have an important impact on physiological processes in organ-
isms. Recently, targeted deletion of specific isoforms of Akt in
mice has proved to be a powerful tool for elucidating the
physiological roles of Akt proteins (5, 7, 8, 13, 16, 25, 27, 28).
Characterization of such knockout mice has yielded intriguing
and surprising results. We and others found that 40% of Akt1
knockout mice die at a neonatal stage with growth retardation,
but the other 60% of Akt1 knockout mice survive apparently
normally. This suggests that the other two remaining Akt iso-
forms can, in part, compensate for the loss of one Akt. Knock-
out of each single isoform gives rise to a distinct phenotype. In
general, Akt1 null mice are growth retarded, which may result
from placental insufficiency, while Akt2-deficient mice suffer
from a type 2 diabetes-like syndrome and Akt3 null mice show
impaired brain development (5, 7, 8, 13, 16, 25, 27, 28). These
observations indicate that the three Akt isoforms have different
nonredundant physiological functions. The relatively normal de-
velopment and distinct physiological functions exhibited by
single knockouts may be explained by differences in the tissue
distribution and expression levels of these isoforms. We found
that Akt1 is the major isoform in placenta and that placenta
lacking this protein cannot form a proper vascular labyrinth;
this may restrict nutrient supply to the fetus and impair growth
(28). Similarly, in the major insulin-responsive tissues of fat,
skeletal muscle, and liver, Akt2 is the predominant isoform (2,
7, 28). In the case of Akt3, which shows a more restricted level
of expression with the brain containing the highest levels and
has lower levels of expression in other tissues, ablation of this
isoform affects postnatal brain development (13, 25).
We predicted that simultaneous inactivation of two Akt iso-
forms in mice would severely affect development and survival.
To test this hypothesis, we crossed Akt1 with Akt3 knockout
mice to generate compound (combined mutation of four al-
leles of Akt1 and Akt3) and double knockout (DKO) mice. Our
results show that the Akt1 gene is more essential than the Akt3
gene for survival and that both proteins are required for nor-
mal embryo development. Our studies demonstrate isoform-
specific and dosage-dependent effects of Akt genes on animal
survival and development.
MATERIALS AND METHODS
Preparation of murine embryonic fibroblasts (MEFs) and Western analysis.
MEFs were prepared from embryonic day 10.5 (E10.5) to E13.5 embryos as
previously described (14). Western analysis and the antibody that recognizes
both mouse Akt1 and Akt3 have been described previously (25, 28). The isoform-
specific antibodies for mouse Akt1, Akt2, and Akt3 have been described already
(25). Antibodies for pSer473 were purchased from Cell Signaling Technology.
Actin antibody was purchased from Neomarkers.
Mice. Mice were housed in accordance with the Swiss Animal Protection
Ordinance in groups with 12-h dark-light cycles and with free access to food and
* Corresponding author. Mailing address: Friedrich Miescher Insti-
tute for Biomedical Research, P.O. Box 2543, Maulbeerstrasse 66,















FIG. 1. Expression Akt isoforms in neonates, Akt1/Akt3 localization in E11.5 to E12.5 embryos, generation of Akt1/Akt3 compound, and
double knockout mice. (A) Expression patterns of Akt isoforms in neonates. Four wild-type mice from two litters were sacrificed, and their tissues
were pooled for lysate preparation. Forty micrograms of total protein was used for Western analysis with the indicated isoform-specific antibodies.
(B) Akt1/Akt3 antibody specificity. Mouse Akt1, Akt2, and Akt3 cDNAs cloned in pCMV5 were expressed in HEK293 cells, and cell lysates were
prepared for Western analysis. Immunoblot analysis was carried out with an affinity-purified Akt1/Akt3 antibody that recognizes Akt1 and Akt3.
Actin levels were determined to control for equal loading. (C) Absence of Akt1 and Akt3 proteins in DKO mouse embryonic fibroblasts (MEFs).
MEFs were prepared from wild-type, Akt1/Akt3 DKO, or Akt2/Akt3 DKO embryos, and cell lysates derived from these cells were used for Western
analysis using the antibody as described in the legend to panel B with actin as control. (D) PCR genotyping for Akt1 and Akt3 loci. WT, wild type;
DKO, double knockout. (E) Absence of Akt1 and Akt3 proteins in DKO mouse tissue (placenta). Total phospho-Akt is substantially decreased.
(F to I) HE and immunohistochemical staining of E11.5 and E12.5 embryos with the Akt1/Akt3 antibody. Panels F and G are for the E11.5 embryo
and H and I are for the E12.5 embryo; F and H show hematoxylin and eosin staining, and G and I show immunohistochemical staining. Akt1 or
Akt3 (or both) is expressed in both the central and peripheral nervous systems of brain, neural tube, and heart. Arrowheads indicate various
ganglia. Abbreviations: HB, hindbrain; MB, midbrain; FB, forebrain; BA, branchial arch; H, heart; NT, neural tube; CG, cranial ganglia; DRG,
dorsal root ganglia; Li, liver; T, tongue.













FIG. 2. Defects in the thymus from Akt1/ Akt3/ mice. (A) Thymi from P3 Akt1/ Akt3/ and Akt1/ Akt3/ littermates. (B to E) HE
staining of the thymus from panel A. Panels B and C are lower-magnification images of panels D and E. Arrowheads in panel E indicate the
Hassall’s corpuscle-like structures in the Akt1/ Akt3/ mice which are not found in wild-type mouse thymus. Cap, capillary blood vessel.
Magnification for panels B and C, 40; for panels D and E, 400.
TABLE 1. Progeny of Akt1/ Akt3/ matingsa
Genotype 1/ 3/ 1/ 3/ 1/ 3/ 1/ 3/ 1/ 3/ 1/ 3/ 1/ 3/ 1/ 3/ 1/ 3/
No. of animals 27 34 20 31 74 37 11 3 0
% 11.3 14.3 8.4 13 31 15.5 4.6 1.3 0
Theoretical % 6.3 12.5 6.3 12.5 25 12.5 6.3 12.5 6.3
a Total number analyzed, 237.


























water. All procedures were conducted with relevant authority approval. Akt1/
and Akt3/ mice have been described previously (25, 28). All mice had a 129
Ola and C57BL/6 mixed background.
BrdU incorporation. E10.5 to E11.5 pregnant mice were injected intraperi-
toneally with bromodeoxyuridine (BrdU) (1 mg per 20 g of body weight). The
mice were sacrificed 2 h later, and embryos together with placenta were
dissected (25, 28).
Hematoxylin-eosin (HE) and immunohistochemisty (IHC). The HE and IHC
protocols were as described previously (25, 28). For IHC, sections were incu-
bated at 4°C overnight with antibodies for Akt1 and Akt3, BrdU (AbCam Ltd.),
platelet endothelial cell adhesion molecule (PECAM) (Pharmingen), skin mark-
ers of keratin 10 (K10) and K14, and involucrin (BABCO). The sections were
then processed as described in the protocol of the Vectastain ABC kit (Vector
Laboratories).
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end label-
ing (TUNEL staining). Paraffin-embedded sections were treated with 20 g/ml
proteinase K for 10 min at 37°C (omitted for cryosections). Endogenous peroxidase
was inactivated by treatment with 3% H2O2 in 100% methanol for 30 min at room
temperature. The sections were then equilibrated with 1 terminal deoxynucleotidyl
transferase (TdT) buffer for 15 min at room temperature and incubated with TdT
and biotinylated dUTP (TdT reaction) for 1 h at 37°C. The reaction was stopped by
washing with 1 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate). A
Vectastain ABC kit (Vector Laboratories) was used as described by the manufac-
turer for color development.
Quantification and statistics. Quantification of skin thickness and hair follicles
was performed with three double-heterozygous (DH) (Akt1/ Akt3/) and
three Akt1/ Akt3/ mice as described previously (11). For the TUNEL assay
of heart, five fields of each section were counted for apoptotic cells. The t test was
used for statistical analysis. Similar scoring was performed for placental vascu-
lature.
RESULTS
Tissue distribution of Akt isoforms in neonates and mid-
gestation embryos. We first investigated the expression pat-
terns of the three isoforms in neonates and surprisingly show
that the expression of the Akt3 isoform is more widely ex-
pressed than it is in adults (Fig. 1A). Similar to adult mice,
Akt3 is highest in the brain and Akt2 is highest in fat as
reported previously (7, 13, 25, 28). However, Akt1 and Akt3
are abundant in kidney and skeletal muscle, whereas they are
nearly absent in adult mice (Fig. 1A). The ubiquitous expres-
sion pattern of the three Akt proteins in neonates indicates
that all three isoforms are apparently required for early devel-
opment.
These isoform-specific antibodies could not be used for
immunohistochemistry (IHC) because of nonspecific back-
ground staining. Therefore, we used an antibody that specifi-
cally recognized both Akt1 and Akt3 (labeled Akt1/Akt3 an-
tibody in Fig. 1B and C) that was originally developed against
the carboxyl-terminal peptide sequence of porcine Akt1 (18).
This affinity-purified antibody recognized mouse Akt1 and
Akt3 but not Akt2 (Fig. 1B) and could be used for IHC.
At E11.5, the level of Akt1 or Akt3 protein (or both) is high
in the brain, neural tube, and heart (Fig. 1F and G). At E12.5,
the signals are predominantly localized in the developing brain
and various ganglia, and the levels (indicated by the staining
signal) increased compared to that at E11.5 (Fig. 1H and I).
The tissue distribution patterns indicate that the two proteins
are important for brain and cardiovascular development at
E11.5 to E12.5.
Generation of Akt1 and Akt3 double mutant mice. Akt1,
Akt2, and Akt3 genes have been successfully targeted in our lab-
oratory by homologous recombination (25, 28; B. A. Du¨mmler,
unpublished data). In the present work, we first mated Akt1/
males with Akt3/ females to generate Akt1/ Akt3/ (DH)
mice. Intercrossing of these DH mice gave rise to offspring with
nine genotypes (Table 1). Genotyping of these mice was carried
out by independent PCR for the Akt1 and Akt3 loci as previously
described (25, 28) (Fig. 1D). Western blot analysis confirmed the
absence of the two proteins in the MEFs and tissues from Akt1/
Akt3 DKO mice (Fig. C and 1E).
Akt1/ Akt3/ mice die at an early age and Akt1/Akt3
double knockout mice are embryonic lethal. Among the nine
genotypes, only Akt1/ Akt3/ and DKO mice had survival
problems, whereas all others were produced in numbers con-
sistent with the expected Mendelian ratio (Table 1). More than
90% of Akt1/ Akt3/ mice were lost by the time of geno-
typing, and we did not observe any DKO mice at the time
of genotyping (Table 1). We next determined at what stage
Akt1/ Akt3/ mice and DKO mice die. For Akt1/
Akt3/ mice, we set up matings between Akt1/ Akt3/
males and Akt1/ females. Theoretically, offspring of this
mating are half Akt1/ Akt3/ and half DH (1:1). Of the 20
newborns collected from four litters, 8 were DH and 12 were
Akt1/ Akt3/, which is consistent with the expected Men-
delian ratio. Therefore, Akt1/ Akt3/ mice appear to de-
velop to term. In a follow-up study, we found that the majority
of Akt1/ Akt3/ mice died several days after birth.
We next determined the stage of DKO embryonic lethality.
No double knockout embryos were found at E14.5. At E12.5,
some double knockout embryos had already decayed, leaving
only the placenta and body remnants (progeny of Akt1/
Akt3/ intercross mice were the following: for genotype
Akt1/ Akt3/, 15 mice; for genotype Akt1/ Akt3/, 12
mice; for genotype Akt1/ Akt3/, 13 mice [7 of the Akt1/
Akt3/ mice were dead and partially decayed). DKO embryos
dissected at E11.5 displayed severely retarded development
(data not shown). When E10.5 embryos were dissected and
genotyped, double knockout embryos were found with mor-
phology comparable to that of Akt1/ Akt3/ littermates.
These data indicate that double knockout mutants die around
E11 to E12.
Thus, Akt3 appears to be redundant for the survival of Akt1
mutant mice. In contrast, Akt1 mutant mice (Akt1/) showed
a 40% loss after birth, with the mortality of Akt1/ Akt3/
mice increased to more than 90%.
FIG. 3. Structural defects in the heart from Akt1/ Akt3/ mice. (A) The hearts of Akt1/ Akt3/ mice are smaller than those of the
controls, but the atria are as big as those of the controls. (B to D) Sagittal sections of the hearts. (B to D) HE staining of hearts from panel A.
(C and D) Enlargement of the right side of Akt1/ Akt3/ hearts and apparent atria septum defects in Akt1/ Akt3/ hearts (P3). The wall
of the right atrium of the Akt1/ Akt3/ heart is thin due to enlargement (C and D). The arrowhead in panel D indicates atria septum defects.
(E and F) TUNEL assay. Arrowheads indicate apoptotic cells. (G) Quantification of apoptosis. Error bars indicate standard deviation. , P	 0.01.
RA, right atrium; RV, right ventricle; LA, left atrium. Magnification for panels B to D, 40; for panels E and F, 400.


























Multiple defects in the thymus, heart, and skin of Akt1/
Akt3/ mice. Nearly all Akt1/ Akt3/ mice died within a
few days after birth. To determine possible causes of death, we
first performed systemic anatomic organ analysis of postnatal
day 3 (P3) viable Akt1/ Akt3/ mice and their DH litter-
mates (the latter mice survive normally and were, therefore,
used as the control). Generally, most organs from Akt1/
Akt3/ mice analyzed were proportionally smaller than those
of DH controls.
Strikingly, Akt1/ Akt3/ mice also displayed nonpropor-
tional hypotrophy of the thymus, heart, and skin. We have
studied the six thymi from two litters of P3 mice (three Akt1/
Akt3/ and three DH). The thymus of Akt1/ Akt3/ mice
is hypotrophic and much smaller than the control (Fig. 2A
to C). There are many Hassall’s corpuscle-like structures (ar-
rowheads in Fig. 2E) formed in the thymus of Akt1/ Akt3/
mice, but they were not seen in the DH control (Fig. 2D).
To analyze heart development, we used eight Akt1/
Akt3/ and three Akt1/ mice (similar numbers for control)
from newborn to P8. The hearts of Akt1/ Akt3/ mice were
smaller than those of controls, the difference being mainly in
the ventricles (Fig. 3A). Further histological study of these P3
hearts and other P3 hearts from wild-type mice revealed that
Akt1/ Akt3/ hearts had dilated (enlarged) atria and
ventricles, especially on the right side (Fig. 3C and D). In
addition, we found a range of defects in Akt1/ Akt3/
hearts, including atria septum defect, muscular ventricle
septum defect, ventricle septum vascular anomaly, and
thickened valves (data not shown). Small ventricle size and
insufficient contractility of cardiomyocytes of Akt1/
Akt3/ hearts may lead to the retention of blood in the
right side of the heart and cause the atria septum to open.
One Akt1/ Akt3/ mouse that died after 8 days exhibited
a significantly enlarged right atrium and ventricle (data not
shown). Trichrome staining revealed a large area of necrosis
(data not shown). TUNEL staining of the heart identified a
large number of apoptotic cells outside of the necrotic area
(Fig. 3F and G). Histological structure of the lung of
Akt1/ Akt3/ mice was similar to that of controls (data
not shown). The data presented are representative of the
phenotype observed for these mice.
Previously, we observed impaired hair follicle development
in Akt1/ mice by HE staining (11). We performed immuno-
histochemical and HE analyses to evaluate the structure and
development of the skin of Akt1/ Akt3/ mice. We have
analyzed 11 Akt1/ Akt3/ mice (and a similar number for
control) from E16.5 to P8 for skin development. The thin-skin
phenotype observed was found in nearly all the mice examined.
Immunohistochemical staining showed Akt1 and Akt3 to be
localized mainly in the keratinocytes of epidermis and follicles
at P2 (Fig. 4A), which coincided with phospho-Ser473 staining
(Fig. 4B). HE staining revealed a reduction in the thickness of
Akt1/ Akt3/ skin at P2 and P8 (Fig. 4C). Thickness of the
hypodermis and total skin, total number of hair follicles (or
hair follicle density), and hair morphogenesis of skin samples
from three Akt1/ Akt3/ mice and three controls (Akt/
Akt3/) at P3 were all significantly different (Fig. 4G). Cell
differentiation is normal in Akt1/ Akt3/ skin based on
keratin 14 (K14), keratin 10 (K10), and involucrin staining
(data not shown). Although all skin layers were present in
Akt1/ Akt3/ mice, individual skin layers were much thin-
ner than in the wild type. Thus, the skin as a whole was much
thinner. Hair follicles were distinctly reduced in size in Akt1/
Akt3/ animals, and there were fewer (black) hair fibers (data
not shown). The impaired skin development of Akt1/
Akt3/ mice may be attributable to decreased vasculature
revealed by PECAM (CD31) staining (24) (Fig. 4E and F).
This provides further evidence for Akt1- and Akt3-dependent
regulation of angiogenesis and vascular formation.
Abnormal development of DKO embryos. At E11.5, some
DKO embryos displayed apparent vascular defects and hem-
orrhages. E10.5 DKO embryos displayed morphology compa-
rable to that of the control. Therefore, we studied embryonic
development of E10.5 DKO embryos to understand the ensu-
ing embryo lethality. We analyzed four to five mutant embryos
(similar for control) at E10.5 and E12.5. The data presented
are representative of the phenotype observed.
Vascular structure was studied using PECAM staining (24).
We found a significant decrease in vasculature of DKO em-
bryos compared with controls (Fig. 5A to H). Fine (capillary)
vessels were abundant in the head (neuroepithelium) and body
trunk of the control but were not apparent in DKO embryos
(Fig. 5A to D). Furthermore, DKO embryos displayed hypo-
plastic branchial arches (Fig. 5G), fused or dilated arch arter-
ies, and the absence of fine vessels (Fig. 5H).
Previously, we observed reduced vasculature in Akt1/ pla-
centa (28), and a more significant vascular defect was found in
DKO placenta (Fig. 5J and K). In addition, reduced cell pro-
liferation was detected in DKO placenta (Fig. 5M).
The predominant expression of Akt1 or Akt3 (or both) in
the nervous system at E11.5 to E12.5 suggests an important
role of these two proteins in the maintenance of brain devel-
opment. However, there was no significant difference between
DKO and wild-type control mice with cell proliferation dis-
played by BrdU staining (data not shown).
An increase of apoptotic cells was detected using the TUNEL
assay in the neuroepithelium and in the neurons of various gan-
glia in DKO embryos compared to the wild type (Fig. 6A to H).
These results indicate that Akt1 and Akt3 contribute to the de-
velopment of the nervous system by maintenance of cell survival.
FIG. 4. Histology of Akt1/ Akt3/ skin. (A and B) Immunohistochemical staining of Akt1/Akt3 and phospho-Akt (Ser473) in control skin.
(A) Akt1/Akt3 localization. The two proteins are mainly localized in the keratinocytes of the epidermis (Ep) and hair follicles (arrowheads).
(B) Phospho-Akt (Ser473) in control skin. Localization of phospho-Akt is similar to that of Akt1/Akt3. (C and D) HE staining. Skin of Akt1/
Akt3/ mice is much thinner than that of control littermates and has fewer hair follicles (arrowheads). (E and F) PECAM (CD31) staining to
display the vasculature. Akt1/ Akt3/ skin has fewer vessels than the control. Insets in all panels are lower magnification images showing a larger
part of the skin. (G) Quantification of skin thickness and hair follicles. HE staining sections from three Akt1/ Akt3/ mice and three Akt1/
Akt3/ littermates (P3) were measured for thickness and hair follicle density. Error bars are standard deviation, and two asterisks indicate a
significant difference between the two genotypes (P 	 0.05). Magnification, 200.



























With neonatal mice, we found that the three Akt proteins
are widely expressed in contrast to results obtained in the adult
mice, where the Akt3 protein expression is quite restricted.
Our findings provide important insights and help better under-
stand the developmental defects in Akt1/Akt3 compound mu-
tant mice and Akt1/Akt2 Akt1/Akt3 DKO mice. In the single
knockouts of Akt isoforms, Akt2 and Akt3 null mice have no
neonatal survival disadvantages (7, 16, 25, 27). Nevertheless,
we and others have observed that 40% of Akt1 null mice fail to
FIG. 5. Analysis of the vascular system of DKO embryos. (A to H) Left panels are HE staining to show the morphology, and the right panels
are PECAM staining to display vasculature. (A to D) Fine vessels (capillary) in the neuroepithelium of hindbrain. Arrowheads indicate the small
vessels (capillary). Small vessels are abundant in the control and are evenly distributed, while these vessels are scarce in DKO embryos. (E to H)
Branchial arches and their arteries. In the control, first, second, and third arch arteries can be seen (arrowheads), and small vessels are rich in
mesenchymal tissue (F). However, the branchial arches of DKO mice are hypoplastic, with little mesenchymal tissue, and the large arch arteries
cannot be distinguished (arrowhead). Small vessels are also scarce in DKO branchial arches. Abbreviations: NE, neuroepithelium; BA, branchial
arch; WT, wild type. Magnification, 100. (I to M) Histological analysis of DKO placenta. (I and J) E12.5 placentas. PECAM staining displays
fetal vessels in the labyrinth. In the wild type (I), fetal vessels are well formed and filled with fetal nucleated erythroid cells (arrowheads), while
in DKO mice (J) these vessels are rare, although the epithelial cells can be seen. (K) Quantification of fetal vessels in wild-type and DKO placenta.
The double asterisks indicates a significant difference (P 	 0.05). (L and M) E10.5 placentas. BrdU staining. DKO placenta shows a substantial
reduction of proliferation, especially in the spongiotrophoblast layer (Sp). De, decidua; Lab, labyrinth. Magnification, 40.













FIG. 6. Apoptosis in wild-type (WT) and DKO embryos. The left panels are HE staining, and the right panels are TUNEL staining. In the wild
type, very few apoptotic cells can be seen in the neuroepithelium, but there are many in DKO neuroepithelium (arrowheads indicate apoptotic
cells). (A to D) E10.5; (E to H) E9.5. Magnification for panels A and B, 40; for panels C to F, 200.













survive past the neonatal period (8). This raises the intriguing
possibility that the Akt1 gene is the most critical isoform of
the three for early mouse development. Nearly all Akt1/
Akt3/ mice died at an early age, while Akt1 / Akt3/
mice survived normally. This suggests that the Akt1 gene is
more essential than Akt3 for mouse survival. In a recent report,
Akt1/Akt2 double knockout mice developed to term but died
shortly after birth with severe developmental defects, including
dwarfism, skeletal deformity, and skin abnormalities (22). We
found that Akt1/ Akt3/ mice have severe growth deficien-
cies, and nearly all died young with multiple organ and tissue
pathologies. Mice lacking both Akt1 and Akt3 genes died at
approximately E11 to E12 and displayed multiple fatal devel-
opmental defects. Akt1/Akt2 double knockout mice with only
Akt3 developed to term (22), but Akt1/Akt3 DKO mice (i.e.,
only Akt2 was expressed) did not develop beyond the midterm
(E12). This indicates a more critical role for Akt3 than Akt2 in
early animal development and survival. Thus, the order of
apparent importance of the three Akt genes in mouse devel-
opment and survival is Akt1 
 Akt3 
 Akt2. The phenotypes
observed with Akt1/Akt3 DKO and Akt1/Akt2 DKO mice are
largely due to loss of Akt1 function. Taken together, these
results indicate that the three Akt genes have isoform-specific
and dosage-dependent effects on mouse survival and deve-
lopment.
In this study, we found that Akt1 and Akt3 have essential
roles in cardiovascular development and function. The proba-
ble cause of sudden death of Akt1/ Akt3/ mice is heart
failure, possibly as a result of defective heart development and
cardiomyocyte function (6). Akt1/Akt3 DKO mice embryonic
lethality could also be attributed to cardiovascular anomalies.
These embryos died at around E12, with significant vascular re-
duction in embryo and placenta; large vessels in the branchial
arches and dorsal aorta were also abnormal. As these large
branchial arch and dorsal aorta arteries are converted to aortic
artery and other large arteries, the developmental defects of these
vessels at E12 inhibits further development of mice and enhances
morbidity (9, 20, 21).
Our studies of Akt1/Akt3 DKO mice also indicate that Akt1
and Akt3 are critical for nervous system development. Previ-
ously, we found that Akt3 protein levels are the highest in the
brain, and deletion of this isoform substantially impaired brain
development (13, 25). In Akt1/Akt3 DKO embryos, many ap-
optotic cells were found in the neuroepithelium and neurons of
ganglia. Therefore, Akt1 and Akt3 are indispensable for ner-
vous system development in the embryo through their main-
tenance of cell survival (12, 29, 30).
Another interesting finding is the Hassall’s corpuscle-like
structures in, Akt1/ Akt3/ thymus, as this structure is well
developed in the thymus of humans and guinea pigs but poorly
developed in the thymus of mice and rats (26). In humans, the
Hassall’s corpuscles have been proposed to remove apoptotic
thymocytes (26). Previously, Hay’s group found increased apop-
totic thymocytes in Akt1 null mice (5). The formation and
function of these structures in Akt1/ Akt3/ thymus need
to be studied further.
In conclusion, our results indicate that Akt1 and Akt3 genes
apparently regulate multiple developmental processes in mice.
Akt1 and Akt3 genes share some redundant functions required
to maintain mouse development and survival. However, these
two proteins seem to play distinct roles based on the pheno-
types of the individual knockouts. To rigorously understand
the causes of the different phenotypes, it will be necessary to
identify the specific Akt substrates involved in the development
of the different organs.
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 III. DISCUSSION 
 
 
Since its discovery more than 15 years ago, the signaling kinase PKB has been 
recognized as a central player in a diverse array of cellular processes. PKB lies 
at the crossroads of multiple cellular signaling pathways and acts as a 
transducer of many functions initiated by growth factor receptors that activate 
PI3K. Importantly, deregulation of PKB activity is implicated in human diseases, 
especially in cancer and type 2 diabetes. The members of the PKB family of 
protein kinases are attractive targets for pharmacological intervention and 
knowledge of the precise individual roles of each isoform may be useful for the 
design of PKB-based therapeutics. 
It is still unclear whether PKBα, PKBβ, and PKBγ are functionally redundant or 
whether each isoform performs specific functional roles. To elucidate specific 
physiological roles of the different PKB isoforms, we generated and analyzed 
loss-of-function mouse models of PKBγ, PKBα/PKBγ, and PKBβ/PKBγ.  
 
PKB function in somatic growth and organ size 
Our analysis of the PKBγ−/− phenotype has provided a function for this protein 
kinase in the attainment of normal brain size, influencing both cell size and 
number in the mouse brain. The requirement of functional PKBγ appears to be 
remarkably organ-specific, as PKBγ−/− mice display normal body size and no 
other abnormalities. Furthermore, this appears to be a PKBγ-specific non-
redundant function as (a) neither PKBα−/− (19) nor PKBβ−/− (22, 35) mice exhibit 
reduced brain weights and (b) relative brain weights of the here analyzed 
PKBβ−/−PKBγ−/− mice were not decreased compared to those of PKBγ−/− mice, 
indicating that the absence of an additional PKB isoform does not intensify the 
small-brain phenotype of PKBγ−/− mice. 
Particular organ sizes appear to be regulated by specific isoforms. For instance, 
while PKBγ influences brain size, PKBβ−/−PKBγ−/− mice display reduced relative 
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weights of testes, and PKBα−/−PKBβ−/− mice show decreased myocyte size in 
skeletal muscle and a decreased cell number in skin (82).  There are organ-
specific differences in the modes of mass reduction in PKB mutant mice (i.e. 
decreased cell number, cell size, or both). However, these differences may 
reflect the growth potential for particular organs (e.g. proliferative capacity 
throughout life or postnatal growth exclusively through increases in cell size). 
Comparison of the phenotypes of mice deficient in IGF1 receptor (IGF1r), IRS 
proteins, and PKB isoforms allows some conclusions about the relevant 
signaling pathways for somatic growth and growth of particular organs. Both 
IGF1r−/− and IRS1−/− mice display severely reduced body size (2, 62). In 
contrast, IRS2−/− mice reach nearly normal size but have an impairment of brain 
growth secondary to a decrease in neuronal proliferation (97). Thus, the 
IGF1→IRS2→PKBγ pathway may be responsible for the effects of IGF1 on 
brain size, whereas IRS1 mediates the effect of IGF1 on somatic growth. 
The most important PKB isoform for somatic growth is PKBα. PKBα−/− mice are 
about 20% smaller than wild type littermates and organs weights are reduced 
proportionally to the reduced body weights (19, 23, 118). Interestingly, somatic 
growth is not exclusively influenced by PKBα. Deletion of either PKBβ or PKBγ 
in PKBα−/− mice intensifies the growth deficiency seen in PKBα null mice. 
PKBα−/−PKBβ−/− mice have a birth weight ~50% of that of wild type littermates 
(82) and PKBα−/−PKBγ−/− embryos (lethal at day E12) display severely retarded 
development. In addition, we observed a ~25% reduction in body weights of 
PKBβ−/−PKBγ−/− mice compared to wild types. Thus, all three isoforms influence 
somatic growth, although PKBα appears to be the major contributor, and the 
three isoforms can partial compensation for each other in this function. 
A very recent publication has shown that PKBα and PKBβ may play differential 
and opposing roles in the modulation of p21Cip1 localization and cell 
proliferation. Heron-Milhavet et al. show differential interaction of PKBα and 
PKBβ with the cell cycle inhibitor p21Cip1 (40). Whereas PKBα promotes 
proliferation by mediating phosphorylation of p21Cip1 on Thr145 and its release 
from CDK2, PKBβ binds p21Cip1 in the region of the phosphorylation site, 
induces accumulation of p21Cip1 in the nucleus and ultimately cell cycle exit. 
 38
This data was obtained mainly by siRNA knock down experiments and 
overexpression of the isoforms in mouse myoblasts and fibroblast cell lines. 
The physiological relevance of these findings is still an open question and is 
only partially supported by the phenotypes we observed in our PKB mutant 
mice. Although PKBα appears to be the predominant isoform regulating 
somatic growth, there is no indication for PKBβ being a negative regulator of 
cell proliferation. However, we did not yet investigate p21Cip1 localization in our 
PKB mutant mice. 
 
PKB function in embryonic development and postnatal survival 
PKBα−/− mice display an increased neonatal lethality and about 30% of these 
mice die shortly after birth (19, 118). A potential cause of death in these 
animals may be the growth retardation of PKBα−/− mice, which is resulting from 
placental insufficiency and also embryo-intrinsic mechanisms (118). Mice with a 
PKBα−/−PKBγ−/− genotype display lethality already at embryonic day E12; 
PKBα−/−PKBγ−/− embryos show multiple severe developmental defects in the 
cardiovascular and nervous system. PKBα−/−PKBβ−/− mice finish gestation but 
die shortly after birth with developmental defects in skin, skeletal muscle and 
bone (82). 
Considering the lethal phenotypes and multiple developmental defects of 
PKBα−/−PKBγ−/− and PKBα−/−PKBβ−/− mice, PKB isoforms appear to play 
essential roles in various aspects of embryonic development. However, 
PKBβ−/−PKBγ−/− and even PKBα+/−PKBβ−/−PKBγ−/− mice, which retain only one 
functional allele of PKBα, can develop normally and survive with minimal 
dysfunctions. Interestingly, we found no compensatory upregulation of PKBα 
protein in PKBβ−/−PKBγ−/− mice, neither in adult animals nor in neonates. PKBα 
appears thus to play a dominant role in embryonic development and postnatal 
survival: it is sufficient (even when expressed at very low levels as in 




PKB function in glucose metabolism 
Various lines of evidence have confirmed an isoform-specific role of PKBβ in 
insulin-stimulated glucose uptake. PKBβ−/− mice are glucose and insulin 
intolerant (22, 35) whereas PKBα−/− mice display normal glucose homeostasis 
(23). In accordance with this, studies in adipocytes derived from embryonic 
fibroblasts of PKBα−/−PKBβ−/− mice have shown that impaired glucose uptake 
can be rescued in these cells by re-expression of PKBβ whereas re-expression 
of PKBα at comparable levels was ineffective (4). 
We found that the PKBγ isoform is, like PKBα, dispensable for glucose 
homeostasis. PKBγ−/− mice have similar glucose excursions in glucose and 
insulin tolerance tests as wild type. In addition, absence of PKBγ does not 
intensify the diabetes-like phenotype of PKBβ−/− mice, as PKBβ−/−PKBγ−/− mice 
have similar glucose excursions in glucose and insulin tolerance tests as 
PKBβ−/− mice. 
Of note, PKB signal transduction is also critical for β cell growth and survival. 
We assessed hyperinsulinemia in both PKBβ−/− and PKBβ−/−PKBγ−/− mice, 
indicating that the pancreatic β cells are trying to compensate for the peripheral 
insulin resistance in these mice. Most likely the higher plasma insulin levels are 
due to increased secretion of insulin rather than an increase in β cell mass. 
Garofalo et al. showed that PKBβ−/− mice were not able to increase β cell mass 
in response to the peripheral insulin resistance, and six-month-old male 
PKBβ−/− mice presented increased β cell apoptosis accompanied with β cell 
failure (35). Upstream, the signaling pathway mediating β cell growth and 
survival appears to involve IGF1 receptor and IRS2 (112). IRS2−/− mice are 
insulin resistant and develop diabetes due to a concomitant reduction in β cell 
mass (56, 113). This phenotype is even more severe in IGF1r+/−IRS2−/− mice 
(112). The β cell phenotype of PKBβ−/− mice strongly resembles the one of 
IRS2−/− mice but is less severe, indicating that in PKBβ−/− mice the other PKB 




Downstream signaling of PKB in mutant mice 
Although many downstream targets of PKB that mediate cell growth, 
proliferation, and insulin signaling are known and their functions well 
established, it is not always possible to correlate the deficiencies observed in 
PKB mutant mice with a reduction in phosphorylation of these targets. For 
example, we could not detect any reduction in the phosphorylation levels of the 
growth-relevant downstream targets TSC2 and S6K1 in neither cerebellar 
neurons of PKBβ−/−PKBγ−/− mice nor whole brains of PKBγ−/− mice; although 
these mice exhibit a prominent reduction in neuronal cell size and number. 
However, Peng et al. found reduced TSC2 phosphorylation in primary cultures 
of PKBα−/−PKBβ−/− MEFs (82). 
It has been proposed that PKB isoforms display differential activation in insulin 
responsive tissues. For instance, insulin-stimulated activation of the three 
isoforms of PKB was studied in primary hepatocytes and activation of PKBα 
appeared to be 4-fold higher than PKBβ activity, while PKBγ activity was lowest 
(110). We found that insulin-induced PKB activation, as measured by Ser473 
phosphorylation, was more than 10-fold reduced in livers of PKBβ−/− and 
PKBβ−/−PKBγ−/− mice compared to wild type levels. However, when we 
examined insulin-induced phosphorylation levels of the PKB substrate GSK3β 
in those mice, we found no reduction of phospho-GSK3β levels in PKBβ−/− and 
PKBβ−/−PKBγ−/− mice compared to wild type. It is not quite clear yet why a 
striking decrease in total levels of activated PKB should not be followed by 
reduced phosphorylation of PKB substrates. It may be that in PKBβ−/−PKBγ−/− 
mice the remaining PKBα isoform is even at minimal amounts sufficient to 
phosphorylate many downstream targets. Alternatively, compensation for the 
deletion of PKB isoforms could occur via other kinases or relevant substrates 
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Dissecting the physiological functions of CTMP1 and CTMP2 




Among the plethora of PKB binding partners, our group identified the C-
terminal modulator protein (CTMP1), as a novel PKB-binding protein. Recently, 
we also identified and cloned a CTMP1-related protein, CTMP2. Both CTMP1 
and CTMP2 are conserved in higher eukaryotes but not present in drosophila 





Fig. 1. (Left) Conservation of CTMP proteins across species (from www.ensembl.org, GeneTreeView). 
(Right) Sequence alignment of mouse CTMP1 and CTMP2. The two proteins have ~30% sequence 
identity and >50% similarity. 
 
CTMP1 and CTMP2 have also been termed THEM4 (thioesterase superfamily 
member 4) and THEM5 (thioesterase superfamily member 5), respectively, 
because they contain a putative thioesterase domain called 4HBT6 domain (4-
                                            
6 4HBT is an enzyme found in Pseudomonas and catalyzes the final step in the biosynthesis of 4-
hydroxybenzoate from 4-chlorobenzoate as part of the bacterial 2,4-dichlorobenzoate degradation 
pathway. A 4HBT domain is also present in other mammalian proteins, such as thioesterase superfamily 
member 2 (THEM2) or acyl-CoA thioesterases (Acot7, Acot11, Acot12) that catalyze the hydrolysis of 
acyl-CoAs to free fatty acid and coenzyme A (CoASH).  
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hydroxybenzoyl-CoA thioesterase domain). The most N-terminal ~25 amino 
acid residues of both CTMP1 and CTMP2 are predicted to function as a 
mitochondrial targeting sequence (TargetP software from Emanuelsson et al., 
2000). Cell fractionation and immunoctyochemistry showed clearly that the 
major cellular pool of hCTMP1 protein is localized in the mitochondria (Fig. 2; 
Tintignac et al., unpublished). 
 
 
Fig. 2. The major pool of endogenous CTMP1 is localized in the mitochondria. Endogenous CTMP1 
co-localizes with MitoTracker dye, a mitochondrial-selective fluorescent label (from L.Tintignac). 
 
In most cases, the mitochondrial targeting sequence of an imported protein is 
proteolytically removed during or after the entry of the protein into the 
mitochondrion. Cleavage is mediated by the mitochondrial processing 
peptidase (MPP) that recognizes a consensus sequence characterized by an 
Arg in position -2 or -3 relative to the cleavage site. CTMP1 contains a highly 
probable MPP-cleavage site following the mitochondrial targeting sequence, 
with cleavage occurring after amino acid residue 36 and 27 for hCTMP1 and 
mCTMP1, respectively; in CTMP2 this cleavage site is not conserved and there 
is only a low predicted probability for MPP to cleave after residue 35. Cleavage 
of CTMP1 can be detected by immunoblotting and the introduction of point 
mutations within the MPP cleavage site abolishes proteolytic processing of 
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CTMP1 (Tintignac et al., unpublished). In summary, these findings suggest that 
CTMP1 protein (and very likely also CTMP2), is synthesized as a 27kDa 
precursor in the cytosol, translocated into the mitochondria and processed by 




Fig. 3. Domain structure of CTMP proteins. Both CTMP1 and CTMP2 contain an N-terminal, ~25 amino 
acid residues long, mitochondrial targeting peptide (mTp) and a 4HBT domain. In CTMP1 this peptide is 
followed by a MPP (mitochondrial processing peptidase) cleavage site. Mitochondrial targeting sequences 
do not share distinct consensus sequences but display common physicochemical properties, they are rich 
in positively charged residues (mainly Arg) and have the potential to form an amphiphilic helical structure. 
(*) indicates potential phosphorylation sites. Ser37 and Ser38 were identified as in-vivo phosphorylation 
sites following pervanadate treatment in hCTMP1. 
 
When containing an N-terminal tag, such as FLAG or HA, CTMP proteins do 
not translocate to the mitochondria but remain mostly in the cytosol. 
Presumably, the tag is interfering with recognition of the mitochondrial targeting 
sequence. Such cytosolic CTMP binds to PKB at the plasma membrane and 
reduces PKB activity by preventing its phosphorylation (65). Furthermore, cells 
transformed with v-Akt7 undergo phenotypic reversion when CTMP is stably 
expressed, due to decreased PKB activity, and also exhibit significantly 
                                            
7 The transforming oncogene v-Akt is the viral homolog of PKB. V-akt encodes a fusion protein between 
the viral protein Gag and full-length cellular PKBα. The viral gag domain in v-Akt possesses a 
myristoylation signal that mediates targeting of the fusion protein to the plasma membrane, leading to 
constitutive activation of PKB. CCL64 mink lung cells stably expressing v-Akt (AKT8 cells) form tumors 
when injected into nude mice.  
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reduced tumor-forming ability in nude mice (65). Therefore, CTMP is predicted 
to serve a tumor suppressor-like role by virtue of its negative regulation of PKB 
in cells. A recent report supports this function of CTMP as a tumor-suppressor-
like protein. Knobbe et al. found significantly reduced CTMP1 mRNA 
expression in 40% of primary glioblastomas and reduced mRNA levels were 
closely associated with hypermethylation of the CTMP1 promoter (53). This 
suggests that downregulation of CTMP1 expression is an important molecular 
mechanism involved in the pathogenesis of glioblastoma. 
Biochemical characterization of the interaction between PKB and CTMP1 
showed that CTMP1 binds to the most C-terminal ~15 amino acids of PKB 
(Hanada et al., unpublished). This sequence contains the Ser473 
phosphorylation site, which has to be phosphorylated for maximal activity of 
PKB. It is likely, that binding of CTMP1 to Ser473 blocks the access for 
activating kinases and thereby inhibits Ser473 phosphorylation. Of the three 
PKB isoforms, both CTMP1 and CTMP2 appear to preferentially bind PKBα 
(Hanada et al., unpublished). Furthermore, CTMP1 and CTMP2 form homo- 
and heterodimers in cells through the conserved 4HBT-domain found in both 
proteins (Hanada et al., unpublished).  
 
Results and discussion 
 
Physiological function of CTMP1 
CTMP1 protein is highly expressed in brain, heart, liver, kidney and testis in 
wild type mice (Fig. 4). This protein expression pattern of CTMP1 differs slightly 
from the mRNA expression pattern previously described in human tissues (63) 
but is consistent with high expression in brain, kidney, and testis. 
To dissect CTMP1 gene function in a vertebrate model, we have generated 
mice deficient in CTMP1 (Fig. 5). CTMP1 knockout mice were viable and fertile 
and did not display any gross abnormalities. Histomorphological analysis 
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showed increased erythropoiesis and granulopoiesis in spleen 8  and bone 
marrow of CTMP1−/− mice; in some knockout animals this was accompanied 
with a marked increase in spleen weight (data not shown, collaboration with 




Fig. 4. Detection of CTMP1 protein in tissue and cell lysates shows high expression in brain, liver, 
kidney, heart, and testis. Table (left) summarizes results from various experiments where CTMP1 
expression was detected in wild type tissue and cell line lysates by immunoblotting with anti-CTMP1 
antibody (Ab99390). Expression levels: +++: high; ++: medium; +/- very low; - not detectable. 
 
Interestingly, we could not detect any CTMP1 protein expression in spleen 
tissue lysates, indicating that these findings may be a secondary effect due to 
some other disturbance. So far, changes in the hematopoietic system appear to 
be the major phenotype of CTMP1−/− mice.  
As we have previously observed that CTMP1 can inhibit PKB phosphorylation, 
we expected that the absence of CTMP1 protein in the mutant mice would lead 
to increased phosphorylation of PKB. To investigate this hypothesis, we 
examined steady-state phospho-PKB levels in mutant mice in tissues that 
exhibit high CTMP1 expression in wild type mice. In all examined tissues 
(brain, heart, liver, and kidney) no difference in PKB phospho-Ser473 levels 
                                            
8 In mice hematopoiesis not only occurs in the bone marrow but also at extramedullary sites, especially in 
the spleen. 
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could be observed in CTMP1−/− compared to CTMP1+/+ mice (data not shown). 
Next, we generated primary cultures of mouse embryonic fibroblasts (MEFs) to 
study inducible PKB activation in an in vitro cellular system. MEFs were 
deprived of serum over night and then stimulated with 10% fetal calf serum 
(FCS) which leads to a clear induction of PKB phosphorylation (Fig. 6). 
Induction of PKB phospho-Ser473 and phospho-Thr308 was similar in both 
CTMP1+/+ and CTMP1−/− MEF clones. Thus, CTMP1 ablation does not affect 




Fig. 5. Targeted disruption of CTMP1 in mice (Brazil et al., unpublished). Homologous recombination 
with the targeting vector results in disruption of exon 2 in the CTMP1 gene and introduces a translational 
frame shift (green boxes: internal and external probes). In mice homozygous for the targeted allele, 
expression of CTMP1 protein was not detectable with CTMP1-specific antibody (bottom, Ab99390). Thus, 
the targeted disruption resulted in a functional null allele.  
 
Considering the intracellular localization of CTMP1, we are now investigating 
whether CTMP1-mediated inhibition of PKB may take place upon its release 
from the mitochondria under apoptosis inducing conditions (A. Parcellier and L. 
Tintignac, unpublished). Alternatively, we cannot exclude that the in vivo 
function of CTMP1 differs from its function observed in previous overexpression 




Fig. 6. Activation of PKB in CTMP1−/− MEFs. CTMP1−/− (clone 4 and 12) and CTMP1+/+ (clone 
8 and 9) MEFs were generated from littermate E12.5 embryos. MEFs (passage 4) growing in 
10% FCS (NS), serum-deprived over night (-), and stimulated after serum-deprivation with 10% 
FCS for 20’ (+), were blotted with anti-Phospho-Ser473 (left) and anti-Phospho-Thr308 
antibody (right). Protein expression levels of PKB and CTMP1 were detected with Ab10 and 
Ab99390, respectively. 
 
We also analyzed gene expression patterns in two tissues with high CTMP1 
expression, brain and kidney, to detect whether CTMP1-deficiency leads to 
changes in gene expression (Table 1). In both brain and kidney of CTMP1−/− 
mice, erythroid differentiation regulator (Edr) was upregulated more than 2-fold. 
This is a autocrine factor produced in many tissues and released from cells in 
response to various stressful conditions. It may promote cell survival and 
growth (31). Other genes whose expression was changed in CTMP1−/− mice in 
both organs are growth arrest specific 5 (Gas5) and inactive X specific 
transcripts (Xist), expression of both genes was significantly upregulated. The 
RNAs of these two genes are assumed to be non-protein-coding RNAs. Xist is 
implicated in the process of X-inactivation(74); whether gas5 RNA has any 
regulatory function is not clear (86). Strongly upregulated in CTMP1−/− kidney 
was also 3-β-hydroxy-delta(5)-steroid dehydrogenase type 2. Hydroxy-steroid-
dehydrogenases play crucial roles in the biosynthesis of all classes of hormonal 
steroids; 3-β-hydroxy-delta(5)-steroid dehydrogenase type 2 is mainly 
expressed in liver and kidney. 
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Physiological function of CTMP2 
The mild phenotype observed in CTMP1−/− mice may be due to a compensation 
by the recently identified CTMP1-paralogue CTMP2. We first wanted to assess 
in which tissues CTMP2 is expressed in mice and whether its expression is 
upregulated in CTMP1−/− mice. CTMP2 mRNA levels were analyzed by 




Fig. 7. mRNA expression levels of CTMP2 in various tissues. (Top) A commercial northern blot (RNA 
Master Blot, Clonetech) was hybridized with cDNA probe for mCTMP2. (Bottom) RNA was purified from 
indicated organs (first lane CTMP1−/− and second lane CTMP1+/+). Reverse transcription was performed to 
obtain cDNA from which CTMP2 cDNA was amplified with forward primer 5’-CAC AGA GTC CCT GGT 
TGC AAG AT-3’ and reverse primer 5’-GGC CCT GGA TAT GAT CTC TGT TG-3’. The resulting product 
is ~180 bp; forward primer stretches over exon1/exon2 border. A control PCR on mCTMP2 plasmid DNA 
resulted in a product on the same height as indicating arrow head. In a second wild type mouse, 
expression of CTMP2 in cDNA of heart could also be detected (data not shown). 18s internal control 




CTMP2 expression could be detected in various tissues (mainly liver, kidney, 
stomach, lung, pancreas, thyroid gland) and overall tissue distribution shows 
partial overlap with CTMP1 expression. From the preliminary results it appears 
that CTMP2 mRNA is not generally upregulated in CTMP1−/− tissues (Fig. 7). 
Whether the difference in CTMP2 mRNA levels between CTMP1−/− and 





Fig. 8. Purification of antibody against CTMP2. (A) Crude serum from immunized rabbit (project 
D2515-s, immunization with peptide SPO22501 from hCTMP2 sequence) was purified on peptide column 
(bleed batch 8/14, rabbit #B1391) Low pH elution contained antibody fraction recognizing overexpressed 
CTMP2 of both human and mouse origin. Antibody is specific for CTMP2 and does not recognize CTMP1 
(right). (B) Antibody was tested on indicated tissue lysates of CTMP2+/+ and CTMP−/− mice. It appears not 
to recognize endogenous CTMP2 as no band of appropriate size could be detected that would be absent 
in the CTMP2−/− tissues. Last lane on both blots contains untagged mCTMP2 expressed in 293HEK cells 
as size control. Of note, all visible bands recognized by the purified antibody could be titrated away by 
peptide competition. 
 
To be able to assess CTMP2 protein levels, we generated a polyclonal CTMP2 
peptide antibody. This antibody was purified on a peptide column and 
recognizes both human and mouse CTMP2 when overexpressed in cell lines 
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(Fig. 8). However, in various tests with this antibody we could not reliably detect 
endogenous CTMP2. 
To investigate the physiological function of CTMP2, we generated mice 
deficient in CTMP2 by targeted disruption of the CTMP2 gene. In the targeted 
alleles, the protein coding part of exon 1 and exon 2 are deleted, ablating the 
ATG start codon and introducing a frame shift in the remaining coding 
sequence (Fig. 9). CTMP2−/− mice are viable and fertile and do not display any 
gross abnormalities. These mice are currently analyzed in more detail and 
preliminary observations show prominently enlarged preputial glands in the 
males with high penetrance. Preputial glands are highly modified, paired 
sebaceous glands that are only found in rodents and release pheromones to 
the urine. In males they are located anterior to the male prepuce between body 
wall and skin. The released pheromones have attractant function towards 
females and are connected with the social status of the male: preputial 
hypertrophy correlates with aggressiveness and dominance whereas preputial 





Fig. 9. Targeted disruption of mCTMP2 gene by homologous recombination. (A) Presence 
of mCTMP2 genomic DNA in BAC clone was verified by PCR of individual exons (cloned 
mCTMP2 cDNA is positive control). BAC clone was used as PCR template for generating left 
and right homology region of targeting vector. (B) Transcript structure of mCTMP2 gene in mice. 
White areas represent untranslated regions (from Ensembl database). (C) Targeted mCTMP2 
allele. A targeting vector was generated that contains a 3.7 kb 5’ homology region, an 
IRES/lacZ/neo cassette, and a 5 kb 3’ homology region. A genomic DNA fragment of about 1.3 
kb, including the ATG start codon in exon 1 and the full sequence of exon2, is deleted in the 
targeting vector. The targeting vector was linearized with NotI and electroporated into 129/Ola 
ES cells. Screening of ES cell clones was performed by Southern Blotting. DNA was digested 
with EcoRV and probed with an external probe (green box spanning sequence 16980-17663). 
An internal probe was then used on NdeI digested DNA (green box spanning sequence 9652-
10154) for further characterization of ES cell clones positive for homologous recombination. 
Correctly targeted ES cells were used to generate chimeras. Male chimeras were mated with 
wild type C57BL/6 females to obtain CTMP2+/− mice, which were intercrossed to produce 
CTMP2 homozygous mutants. (D) Progeny were genotyped for the presence of a targeted 
allele by multiplex PCR. The following primers were used for genotyping: P1-as 5’-GCA GCA 
GGC TGA ACT GAC TGA GG-3’; P2/KO-s 5'- GCT GCC TCG TCC TGC AGT TCA TTC-3’'; 
P3/WT-s 5'-CAG GCG GCT GGA TTA AAC TAC C-3’. One reaction amplifies a 500 bp 
fragment from the targeted allele and the second reaction amplifies a 330 bp fragment from the 
wild type allele.   
 
There are several issues to address as next steps in the analysis of these mice. 
First, it needs to be confirmed that mouse CTMP proteins localize to the 
mitochondria as their human orthologues. Next, it is important to obtain an anti-
CTMP2 antibody that recognizes endogenous protein. Also, targeted CTMP2 
alleles contain an NLS-lacZ expression reporter cassette and X-gal staining 
can thus be used to assess CTMP2 gene expression in tissues of these mice. 
As redundancy between CTMP1 and CTMP2 may be the reason for the mild 
phenotypes of the individual knockouts, it would also be interesting to generate 






Table 1. Gene expression analysis in brain and kidney of CMTP1 mutant 
and wild type mice 
Kidney 
Expression lower in CTMP1−/− 
Affymetrix 
Probe 
CTMP1−/−  kidney: 
normalized expression 
average and range 
CTMP1+/+ kidney: 
normalized expression 




104617_at 230.2 (177.6 to 267.6) 845.2 (600.7 to 1,180.5) 0.27 RIKEN cDNA 0610005C13 gene 
93059_at 115.9 (107.2 to 122.4) 260.3 (200.0 to 395.6) 0.45 RIKEN cDNA 2610204K14 gene 
101574_f_at 146.5 (117.9 to 166.2) 310.1 (160.2 to 468.7) 0.47 serine protease inhibitor 1-5 
94338_g_at 275.1 (193.9 to 383.2) 573.2 (502.1 to 670.5) 0.48 growth arrest specific 2 
103421_at 139.5 (106.9 to 191.9) 267.2 (236.1 to 340.8) 0.52 
stromal cell derived factor 
receptor 2 
92252_at 82.2 (63.0 to 120.5) 156.5 (131.9 to 172.5) 0.52 cholecystokinin A receptor 
101572_f_at 120.6 (92.7 to 153.2) 228.0 (113.3 to 386.8) 0.53 serine protease inhibitor 1-1 
94426_at 111.9 (84.4 to 154.5) 198.3 (164.5 to 247.8) 0.56 RIKEN cDNA 6330575P11 gene 




1,872.6 (1,252.3 to 
3,197.5) 
3,233.4 (2,684.5 to 
4,298.3) 
0.58 
ATP-binding cassette, sub-family 
D (ALD), member 3 
93109_f_at 263.6 (262.1 to 265.5) 449.6 (223.1 to 760.3) 0.59 serine protease inhibitor 1-4 
104495_f_at 1,230.4 (956.2 to 1,849.0) 
1,946.2 (1,855.8 to 
2,063.6) 
0.63 kallikrein 5 
101289_f_at 
2,324.6 (1,886.6 to 
3,142.9) 
3,648.7 (3,325.4 to 
3,954.1) 
0.64 kallikrein 1-related peptidase b16  
100061_f_at 
5,452.7 (4,470.4 to 
7,652.1) 
8,497.6 (7,961.0 to 
9,461.3) 
0.64 kallikrein 6 
102947_at 820.5 (665.1 to 1,196.7) 
1,273.2 (1,214.6 to 
1,327.7) 
0.64 
solute carrier family 22 (organic 
cation transporter), member 2 
161637_f_at 458.0 (375.0 to 647.6) 709.1 (635.8 to 775.8) 0.65 kallikrein 5 
101950_at 150.6 (138.9 to 174.1) 232.5 (212.6 to 245.4) 0.65 
semaF cytoplasmic domain 
associated protein 2 
96072_at 
1,999.5 (1,835.9 to 
2,221.2) 
3,062.8 (2,836.9 to 
3,253.7) 
0.65 lactate dehydrogenase 1, A chain 
101565_f_at 317.0 (266.0 to 350.3) 476.7 (305.3 to 658.0) 0.66 serine protease inhibitor 1-3 
95775_f_at 
3,910.8 (3,195.5 to 
4,939.4) 
5,733.4 (5,208.8 to 
6,465.3) 
0.68 kallikrein 1 
100329_at 162.5 (159.4 to 168.0) 237.7 (90.1 to 495.9) 0.68 serine protease inhibitor 1-4 
101576_f_at 270.7 (234.4 to 299.0) 389.8 (208.1 to 705.6) 0.69 serine protease inhibitor 1-2 
Expression higher in CTMP1−/− 
101659_at 
2,490.5 (2,124.3 to 
2,962.8) 
378.1 (248.0 to 534.2) 6.59 
hydroxysteroid dehydrogenase-2, 
delta<5>-3-β 
98531_g_at 1,026.0 (817.3 to 1,153.0) 162.0 (83.7 to 508.2) 6.33 growth arrest specific 5 
101532_g_at 1,345.7 (875.1 to 2,365.3) 304.7 (133.5 to 1,335.3) 4.42 aldolase 2, B isoform 
160799_at 444.6 (367.7 to 501.2 168.1 (64.9 to 315.1) 2.64 ESTs, Weakly similar to A47643 
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hypothetical protein - mouse 
(fragment) [M.musculus] 
103534_at 2,110.3 (862.9 to 4,953.2) 930.5 (349.5 to 1,526.3) 2.27 hemoglobin, β adult major chain 
102234_at 202.6 (172.1 to 260.1) 92.4 (87.9 to 98.2) 2.19 RIKEN cDNA 1810037I17 gene 
98525_f_at 
2,155.9 (1,893.8 to 
2,558.3) 
999.0 (681.2 to 1,388.4) 2.16 erythroid differentiation regulator 
161835_at 1,022.0 (914.1 to 1,197.9) 483.1 (362.1 to 776.2) 2.12 calbindin-D9K 
96215_f_at 614.8 (452.0 to 798.4) 297.6 (250.0 to 402.8) 2.07 
Mus musculus, clone 
IMAGE:3983821, mRNA, partial 
cds 
93435_at 104.9 (70.4 to 161.2) 52.1 (31.3 to 75.1) 2.01 
cytochrome P450, family 24, 
subfamily a, polypeptide 1 
95430_f_at 502.0 (418.6 to 565.1) 251.9 (135.9 to 421.1) 1.99 
DNA segment, Chr 9, Wayne 
State University 18, expressed 
99126_at 1,038.5 (748.4 to 1,281.1) 548.2 (358.4 to 712.0) 1.89 inactive X specific transcripts 
160375_at 812.6 (401.7 to 1,480.8) 453.3 (215.1 to 780.4) 1.79 carbonic anhydrase 3 
100443_at 578.0 (564.4 to 590.0) 331.2 (249.3 to 448.9) 1.75 
branched chain aminotransferase 
2, mitochondrial 
102049_at 425.8 (262.4 to 1,029.4) 250.4 (159.7 to 519.2) 1.70 
pyruvate dehydrogenase kinase, 
isoenzyme 4 
160918_at 
1,200.5 (1,148.5 to 
1,229.2) 
732.4 (511.2 to 990.4) 1.64 calbindin-D9K 
160306_at 665.2 (459.6 to 910.3) 408.0 (290.7 to 543.8) 1.63 
thyroid hormone responsive 
SPOT14 homolog (Rattus) 
101451_at 150.5 (105.6 to 227.9) 95.8 (80.4 to 133.0) 1.57 paternally expressed 3 
94224_s_at 299.1 (282.7 to 325.2) 190.6 (160.8 to 260.4) 1.57 interferon activated gene 205 
104445_at 190.3 (172.5 to 202.4) 124.4 (116.9 to 138.9) 1.53 RIKEN cDNA 4631408O11 gene 
99104_at 363.8 (194.3 to 580.2) 238.9 (132.6 to 321.7) 1.52 
adipocyte complement related 
protein 
94689_at 411.6 (351.0 to 537.0) 274.2 (257.8 to 303.7) 1.50 expressed sequence C79248 
101027_s_at 926.9 (867.0 to 1,003.1) 620.7 (589.9 to 670.4) 1.49 pituitary tumor-transforming 1 
104444_at 262.1 (173.0 to 362.9) 176.3 (163.6 to 187.2 1.49 RIKEN cDNA 9430098E02 gene 
98473_at 312.2 (240.2 to 402.8) 212.1 (172.7 to 268.5) 1.47 arginase type II 
104513_at 248.0 (180.9 to 298.7) 170.6 (145.1 to 188.7) 1.45 RIKEN cDNA 2410004N09 gene 
102108_f_at 727.9 (666.0 to 787.7) 509.6 (376.8 to 680.8) 1.43 myosin heavy chain IX 
93497_at 367.4 (328.9 to 454.2) 257.8 (177.7 to 483.1) 1.43 complement component 3 
99643_f_at 387.8 (326.5 to 529.7) 275.0 (194.4 to 458.5) 1.41 carboxypeptidase E 
 
Brain 





average and range 
CTMP1+/+ brain: 
normalized expression 




93059_at 134.4 (121.7 to 148.3) 398.8 (335.8 to 554.9) 0.34 
RIKEN cDNA 
2610204K14 gene 
98332_at 151.1 (149.8 to 153.0) 315.8 (266.1 to 370.6) 0.48 potassium inwardly-rectifying 
 67
channel, subfamily J, member 9 
94426_at 131.3 (98.2 to 221.9) 272.6 (232.5 to 370.1) 0.48 RIKEN cDNA 6330575P11 gene 
94767_at 
1,372.3 (1,230.5 to 
1,563.7) 
2,806.7 (2,421.0 to 
3,417.8) 
0.49 ribosomal protein S11 
96629_at 189.8 (174.1 to 200.6) 343.0 (209.8 to 510.8) 0.55 
DNA segment, Chr 7, Roswell 
Park 2 complex, expressed 
92943_at 556.1 (532.9 to 597.6) 890.3 (716.2 to 1,001.2) 0.62 
glutamate receptor, ionotropic, 
AMPA1 (alpha 1) 
98600_at 73.6 (67.5 to 76.9) 117.6 (110.5 to 125.0) 0.63 
S100 calcium binding protein A11 
(calizzarin) 
99608_at 296.9 (260.2 to 366.3) 427.7 (409.3 to 441.9) 0.69 peroxiredoxin 2 
93656_g_at 148.7 (141.7 to 154.8) 213.5 (180.5 to 250.3) 0.70 upstream transcription factor 1 
104343_f_at 524.0 (492.4 to 561.0) 744.9 (699.3 to 800.7) 0.70 phospholipase A2, group XII 
104598_at 407.5 (356.1 to 500.8) 579.0 (557.4 to 611.8) 0.70 dual specificity phosphatase 1 
160901_at 225.4 (206.1 to 239.9) 319.2 (305.5 to 340.6) 0.71 FBJ osteosarcoma oncogene 
100307_at 225.4 (207.6 to 260.7) 315.8 (247.9 to 370.4) 0.71 nuclear factor I/X 
Expression higher in CTMP1−/− 
98531_g_at 806.9 (783.9 to 854.6) 175.7 (97.3 to 476.4) 4.59 growth arrest specific 5 
102234_at 299.1 (242.0 to 414.5) 128.9 (119.4 to 141.5) 2.32 RIKEN cDNA 1810037I17 gene 
98525_f_at 1,109.8 (982.5 to 1,222.2) 523.8 (423.1 to 682.2) 2.12 erythroid differentiation regulator 
97752_at 267.4 (232.8 to 337.7) 135.8 (82.6 to 177.0) 1.97 
Mus musculus, clone 
IMAGE:4507176, mRNA 
99126_at 195.9 (145.5 to 247.4) 105.7 (82.9 to 120.4) 1.85 inactive X specific transcripts 
160173_at 
1,308.8 (1,144.0 to 
1,541.3) 
790.4 (536.9 to 1,076.2) 1.66 maternally expressed gene 3 
98946_at 170.3 (146.0 to 221.3) 107.9 (76.6 to 135.2) 1.58 
WD-40-repeat-containing protein 
with a SOCS box 1 
96215_f_at 255.3 (219.9 to 284.0) 169.5 (125.6 to 244.8) 1.51 
Mus musculus, clone 
IMAGE:3983821, mRNA, partial 
cds 
160172_at 807.7 (607.5 to 1,185.3) 537.2 (479.2 to 576.0) 1.50 maternally expressed gene 3 
102870_at 997.8 (844.7 to 1,325.1) 664.5 (597.4 to 705.7) 1.50 RIKEN cDNA 5930418K15 gene 
93274_at 594.6 (538.2 to 645.7) 398.2 (280.3 to 512.7) 1.49 CDC-like kinase 
160316_at 125.4 (112.1 to 150.2) 86.1 (72.3 to 95.1) 1.46 
heterogeneous nuclear 
ribonucleoprotein U 
RNA was extracted from whole brains and kidneys of 3-month-old female CTMP+/+ and CTMP−/− mice. Microarray analysis 
was performed on three individual organs per genotype using murine Affymetrix GeneChipsTM (U74). Changes ≤ 1.4-fold 
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The 90-kDa ribosomal S6 kinases (RSK1–3) are im-
portant mediators of growth factor stimulation of cel-
lular proliferation, survival, and differentiation and
are activated via coordinated phosphorylation by ERK
and 3-phosphoinositide-dependent protein kinase-1
(PDK1). Here we performed the functional characteriza-
tion of a predicted new humanRSK homologue, RSK4. We
showed that RSK4 is a predominantly cytosolic protein
with very low expression and several characteristics of
the RSK family kinases, including the presence of two
functional kinase domains and a C-terminal docking site
for ERK. Surprisingly, however, in all cell types analyzed,
endogenous RSK4 was maximally (constitutively) acti-
vated under serum-starved conditions where other RSKs
are inactive due to their requirement for growth factor
stimulation. Constitutive activation appeared to result
from constitutive phosphorylation of Ser232, Ser372, and
Ser389, and the low basal ERK activity in serum-starved
cells appeared to be sufficient for induction of50% of the
constitutive RSK4 activity. Finally experiments in mouse
embryonic stem cells with targeted deletion of the PDK1
gene suggested that PDK1 was not required for phospho-
rylation of Ser232, a key regulatory site in the activation
loop of the N-terminal kinase domain, that in other RSKs
is phosphorylated by PDK1. The unusual regulation and
growth factor-independent kinase activity indicate that
RSK4 is functionally distinct from other RSKs and may
help explain recent findings suggesting that RSK4 can
participate in non-growth factor signaling as for instance
p53-induced growth arrest.
The 90-kDa ribosomal S6 kinases (RSKs)1 are serine kinases
that are activated by growth factors and many polypeptide
hormones via the Ras-dependent mitogen-activated protein
(MAP) kinase cascade composed of Raf, MEK, and extracellular
signal-regulated kinase (ERK) (Refs. 1 and 2; for a review, see
Ref. 3). RSKs contain two functional protein kinase domains,
and in mammals three widely expressed homologues (RSK1,
RSK2, and RSK3) have been identified. Many studies suggest
that RSKs are central mediators of ERK in regulation of cellu-
lar division, survival, and differentiation via phosphorylation
of numerous intracellular proteins. For instance, RSK medi-
ates ERK-induced G2/M phase progression in meiosis I (4) and
metaphase arrest in meiosis II (5, 6) of Xenopus laevis oocytes,
which may in part occur via phosphorylation of the p34cdc2-
inhibitory kinase Myt1 (7) and the protein kinase Bub1 (8),
respectively. In somatic cell types, RSK may stimulate cell
division through phosphorylation of substrates like p27Kip1 (9)
and glycogen synthase kinase-3 (10–12); protein synthesis and
cell growth through substrates like elongation factor 2 kinase
(13), glycogen synthase kinase-3 (10–12), transcription initia-
tion factor IA (14), and tuberous sclerosis complex-2 protein
(15); cell survival through Bad (16); and transcription through
substrates like c-Fos (17) and estrogen receptor (18). Experi-
ments with PC12 cells suggest that RSK is a key mediator of
ERK in neurotrophin-induced neuronal differentiation (19). Fi-
nally genetic evidence from human and mouse has identified
an important role for RSK2 in osteoblast differentiation and
function through phosphorylation of activating transcription
factor-4 (20) and in stimulation of white adipose tissue mass
via an unknown mechanism (21). RSK is related to the mito-
gen- and stress-activated protein kinases (MSK1 and MSK2),
which also contain two kinase domains. MSK, however, is
activated by the ERK family as well as by p38 family MAP
kinases and thereby functions in signal transduction of growth
factors as well as of cellular stress stimuli like UV/radioactive
irradiation and proinflammatory cytokines (22, 23).
The substrates of RSK are phosphorylated by the N-terminal
kinase (NTK) domain (24–27) whose activity is regulated by
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the C-terminal kinase domain and a linker region between the
two kinase domains (Fig. 1). The activation mechanism of RSK
is complex and involves sequential phosphorylation of four
regulatory sites (28), which are Ser232, Ser372, Ser389, and
Thr581, using RSK4 numbering. First ERK, bound to a C-
terminal MAP kinase docking site (29, 30), phosphorylates
Ser372 in the linker and Thr581 in the activation loop of C-
terminal kinase (28, 31). Phosphorylation of Thr581 activates
C-terminal kinase, which thereafter autophosphorylates RSK
at Ser389, located in a so-called hydrophobic motif in the linker
(32). Phosphorylation of Ser389 in the hydrophobic motif gen-
erates a transient docking site that recruits as well as stimu-
lates the activity of 3-phosphoinositide-dependent protein ki-
nase-1 (PDK1) (25), which then phosphorylates Ser232 in the
activation loop of the NTK of RSK (33, 34). After dissociation of
PDK1 from RSK, the Ser386-phosphorylated hydrophobic motif
interacts with a binding pocket within the NTK domain and
thereby activates the NTK in synergy with phospho-Ser232 (35).
The phosphorylation of Ser372 enhances the activity of the NTK
by a yet unknown mechanism (28, 33). Apart from these four
activating sites, Thr368 is phosphorylated by ERK, but the site
has not been found to regulate kinase activity (28). Moreover
Ser742 appears to be phosphorylated by the activated NTK (28,
36), which results in decreased affinity of RSK for ERK, serving
as an intramolecular feedback inhibitory mechanism that op-
erates in RSK1 and RSK2 but not in RSK3 (36). The activation
mechanism of MSK is thought to be very similar to that of RSK
except for two features (22, 23, 37–39). First, the MAP kinase
docking site can interact with both ERK and p38 MAP kinase,
explaining why MSK is activated by two MAP kinase path-
ways. Second, the activation loop of the NTK is not phospho-
rylated by PDK1 but probably via autophosphorylation.
Recently a search for the mental retardation gene in a com-
plex disease locus at Xq21 resulted in the discovery of a gene
encoding a new RSK/MSK homologue (40), which contains all
the structural hallmarks of this kinase family (Fig. 1). Due to
highest amino acid sequence identity to RSKs, the kinase was
named RSK4 (gene symbol RPS6KA6), but no functional stud-
ies were performed to confirm the relationship. Although RSK4
was found to be deleted in several patients with alterations in
Xq21, a definitive link to mental retardation could not be
established. At present, the only characterization performed
with RSK4 is the demonstration of RSK4 mRNA expression in
various human (40) and fetal mouse (41) tissues. Very recently,
a short interfering RNA screen targeting 7,914 human genes
identified five genes, including RSK4, whose transcripts were
required for growth arrest induced by the p53 tumor suppres-
sor protein (42). This finding suggests that RSK4 has a function
in growth inhibition and opens the possibility that RSK4 is a
tumor suppressor protein. Moreover an expression screen with
mouse mRNAs in X. laevis embryos showed that RSK4 expres-
sion can disrupt mesoderm formation induced by the fibroblast
growth factor-Ras-ERK signaling pathway (43). RSK4 was
therefore proposed to be an inhibitor rather than a mediator of
growth factor signal transduction. However, the two recent
studies provided no characterization of the RSK4 protein, its
kinase activity, or regulation. Since RSK1–3 are activated by
growth factors it is currently enigmatic how RSK4 can be an
inhibitor of growth factor signal transduction and a mediator of
p53, which is a transcription factor.
In this study, we characterized RSK4 and demonstrated that
RSK4 is distinct from other RSKs by being constitutively acti-
vated in serum-starved cells in the absence of growth factor.
Our data suggested that constitutive activity was due to con-
stitutive phosphorylation of Ser232, Ser372, and Ser389 induced
in part by very low basal levels of ERK activity and in part by
less well defined mechanisms that may include enhanced au-
tophosphorylation ability of RSK4 compared with other RSKs.
The constitutive, growth factor-independent activity of RSK4
may help explain how RSK4 can participate in non-growth
factor signaling, such as p53-induced growth arrest.
EXPERIMENTAL PROCEDURES
Antibodies to RSK4 (sc-17178) were from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Two different lots, C112 and H152, were used,
and both were found to be specific as shown in the experiment depicted
in Fig. 2B. Antibodies to RSK2 (sc-1430), the PDK1 phosphorylation
site in RSK (sc-12445-R), MSK1 (sc-9392), lamin A/C (sc-7292), and the
influenza hemagglutinin (HA) epitope tag (sc-805, used for immunocy-
tochemistry and immunoblotting) were also from Santa Cruz Biotech-
nology, Inc. Antibodies to the phosphorylated hydrophobic motif (06-
826) and the regulatory ERK phosphorylation site in the linker (06-824)
of RSK were from Upstate Biotechnology (Lake Placid, NY). Antibody to
phospho-Thr581, raised against RSK2, is described in Ref. 44. Anti-HA
Ab used for immunoprecipitation was from the 12CA5 mouse hybri-
doma cell line. Antibody to p63/CLIMP-63 (45) was kindly provided by
Dr. Hans-Peter Hauri (Basel, Switzerland). Antibody to -tubulin was
from the YL1/2 mouse hybridoma cell line. Epidermal growth factor
(EGF) was from PreproTech Inc. (Rocky Hill, NJ). S6 peptide (RRLSS-
LRA) and cross-tide (GRPRTSSFAEG) were synthesized by K. J. Ross-
Petersen AS (Copenhagen, Denmark). U0126 was from Promega (Mad-
ison, WI). SB203580 was from Calbiochem. [-32P]ATP was from
Amersham Biosciences. Other chemicals were from Sigma.
Plamid Constructs—HA-RSK2 (mouse) and HA-RSK3 (human) in
the mammalian expression vector pMT2 (2) were kindly provided by Dr.
Christian Bjørbæk (Beth Israel Deaconess Medical Center, Boston,
MA). To generate pMT2-HA-RSK4, the entire human RSK4 coding
sequence was PCR-amplified using pTL10Flag-RSK4 (see below) as
template and primers introducing a 5 XhoI site just prior to the start
codon and a 3 KpnI site after the stop codon. RSK2 was excised from
pMT2-HA-RSK2 using XhoI and KpnI and replaced with the PCR
product digested with the same enzymes. HA-RSK1 (rat) in pMT2 (46)
was kindly provided by Dr. Joseph Avruch. HA-MSK1 in pMT2 is
described in Ref. 25. To generate pTL10-Flag-RSK4, Marathon Ready
human fetal brain cDNA (Clontech) was used as template to PCR-
amplify the human RSK4 coding region (amino acids 1–745) with prim-
ers introducing a 5 BamHI site just prior to the start codon and a 3
FIG. 1.Predicted structure and phosphorylation sites of RSK4.
RSK4 is predicted to contain two functional protein kinase domains
(NTK and C-terminal kinase (CTK)) connected by a regulatory linker
region. The black box indicates the hydrophobic motif, and the hatched
box indicates the MAPK docking site. The locations of six phosphoryl-
ation sites (P) are shown along with the kinases that appear to phos-
phorylate these sites in RSK family members as evidenced by the
present and previous studies. Amino acid alignment of all human RSK/
MSK family members shows conservation of the phosphorylated serine
or threonine residues (underlined) and the surrounding sequence. The
overall amino acid identity/similarity of RSK4 and RSK1–3 is 72/81,
76/85, and 73/83%, respectively.
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EcoRI site after the stop codon. The PCR product was cloned into the
pCR2.1 vector (Topo TA cloning kit, Invitrogen). RSK4 was then excised
from the pCR2.1 vector using BamHI and cloned into the BamHI site of
the mammalian expression vector pTL10Flag, modified from psG5 (47),
resulting in N-terminal fusion of the FLAG epitope tag. pMT2-HA-
RSK3* was generated by PCR amplification of the HA tag and residues
1–40 of RSK2 with a 3 primer introducing a SalI site and a 5 primer
annealing upstream of the PstI site in pMT2. The PCR product was
digested with PstI and SalI and used to replace the corresponding first
31 residues of RSK3 in pMT2 digested with PstI and XhoI. Point
mutations were introduced in RSK4 using the QuikChangeTM (Strat-
agene) mutagenesis procedure, and the entire coding region was se-
quenced to confirm that no other mutations were introduced. HA-RSK4-
(1–730) and HA-RSK2-(1–725) in pMT2 were generated by introducing
a stop codon after residues 730 and 725, respectively, in the wild-type
constructs using QuikChange. To generate wild-type and T581A HA-
RSK4-(371–745) in pMT2, the sequence encoding residues 371–745 of
RSK4 was PCR-amplified with primers introducing a 5 XhoI site just
prior to residue 371 and a 3 KpnI site after the stop codon using
wild-type RSK4 and RSK4-T581A, respectively, as a template. RSK2
was excised from pMT2-HA-RSK2 using XhoI and KpnI and replaced
with either of the two PCR products digested with the same enzymes.
To generate glutathione S-transferase (GST)-JNK22, the JNK22 (48)
coding sequence was amplified by PCR with primers introducing a 5
BamHI and a 3NotI site, and the digested PCR product was cloned into
the mammalian expression vector pEBG in-frame with GST. The ex-
pression construct for HA-c-Jun is described in Ref. 49.
Transfection, Stimulation, and Immunoprecipitation—All cell lines
were cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum at 37 °C in atmospheric air with 5% CO2.
Medium for wild-type and PDK1-deficient mouse embryonic stem (ES)
cells (37) also contained 10 ng/ml leukemia inhibitory factor and 0.1 mM
2-mercaptoethanol. For transfection, 90% confluent cells in 9.6-cm2
wells were incubated with 4 g of DNA and 11 l of Lipofectamine 2000
reagent (Invitrogen) as described in the manufacturer’s protocol. Trans-
fection of ES cells was scaled up to 56-cm2 culture dishes. Serum
starvation was performed by two washes with serum-free Dulbecco’s
modified Eagle’s medium, aspiration, and incubation in serum-free
Dulbecco’s modified Eagle’s medium. Phorbol 12-myristate 13-acetate
(PMA), anisomycin, U0126, and SB203580 were added from 1,000
stock solutions in Me2SO. Cells were harvested by washing with phos-
phate-buffered saline (PBS) and solubilization for 15 min in 500 l of
lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4),
1 mM Na3VO4, 5 mM EDTA, 25 mM sodium fluoride, 10 nM calyculin A,
1 mM phenylmethylsulfonyl fluoride, 10 M leupeptin, 10 M pepstatin,
and 200 kallikrein inhibitor units/ml aprotinin) on ice. Subsequent
manipulations were performed at 0–4 °C. Cell extracts were clarified
by centrifugation for 5 min at 14,000  g, and the supernatant was
incubated for 90 min with antibody with the addition of 20 l of 50%
protein G-agarose beads (Santa Cruz Biotechnology, Inc.) during the
final 30 min. For GST fusion protein pull-down assays, glutathione-
Sepharose 4B (Amersham Biosciences) was used. Agarose bead-anti-
body complexes were precipitated by centrifugation, washed five times
with lysis buffer, drained, and dissolved in SDS-PAGE sample buffer
(2% sodium dodecyl sulfate, 62 mM Tris (pH 6.8), 10% glycerol, 5%
2-mercaptoethanol, 0.1% bromphenol blue). For kinase assays, the final
two washes were with 1.5 kinase assay buffer (30 mM Tris-HCl (pH
7.4), 10 mM MgCl2, 1 mM dithiothreitol).
Kinase Assays—Agarose beads with immunoprecipitated kinase
were drained with a syringe and resuspended in 20 l of 1.5 kinase
assay buffer. The kinase reaction was initiated by the addition of 10 l
(final concentrations) of ATP (100 M, 0.5 Ci of [-32P]ATP) and 800
M S6 peptide (RSK assays) or 166 M cross-tide (MSK assays). After 10
min at 30 °C (the reaction was linear with time), 20 l of the superna-
tant was removed with a Hamilton syringe (leaving behind precipitated
kinase) and spotted onto phosphocellulose paper (Whatman p81) that
was washed four to five times with 150 mM orthophosphoric acid.
[32P]phosphate incorporated into protein substrate was quantified on a
STORMTM PhosphorImager using ImageQuantTM software (Amersham
Biosciences). Due to the low activity, a reaction blank (an assay per-
formed without antibody during immunoprecipitation) was performed
for all the conditions in endogenous RSK4 and MSK1 assays and sub-
tracted from the respective kinase assay values.
In Vitro Activation of RSK—Endogenous RSK4 or RSK2, immuno-
purified from 3  106 serum-starved embryonic kidney (HEK) 293
cells per assay point, were incubated for 30 min at 30 °C with 50 M
MgATP in the absence or presence of 50 ng of active ERK2 (Upstate
Biotechnology) and 50 ng of active PDK1 (35) in 20 l of 1.5 kinase
assay buffer. Thereafter the kinase activity of RSK4 and RSK2 was
determined as described under “Kinase Assays” except that in the
present assay the blank reaction contained ERK2 and PDK1.
Immunocytochemistry—Subconfluent cells cultured on gelatin-coated
glass coverslips were transfected with pMT2-HA-RSK4. One day after
transfection, cells were fixed in 4% (w/v) paraformaldehyde for 15 min
followed by permeabilization with 0.2% (v/v) Triton X-100 for 5 min and
blocking in 10% horse serum for 20 min. Cells were then incubated for 60
min at 37 °C with rabbit anti-HA antibody diluted 1:500 in PBS. After
washing with PBS, cells were incubated for 45 min at 37 °C with fluores-
cein isothiocyanate-conjugated anti-rabbit antibody (F0511, Sigma) di-
luted 1:300 in PBS. Coverslips were thenwashedwith PBS,mounted with
Vectashield mounting medium (Vector Laboratories Inc., Burlingame,
CA), and analyzed in a laser scanning confocal microscope (Leica).
Cell Fractionation—HEK293F cells were harvested in cold PBS,
pelleted, and resuspended in hypotonic RSB buffer (10 mM HEPES (pH
6.2), 10 mM NaCl, 1.5 mM MgCl2, inhibitors as for lysis buffer above).
The cell suspension was incubated for 30 min at 4 °C and then homog-
enized by 20 strokes in a tight fitting homogenizer. The homogenate
was centrifuged at 375  g (2 min), and the pellet was washed twice
with RSB buffer and then resuspended in lysis buffer (50 mM Tris (pH
8.0), 250 mM NaCl, 1% Triton X-100, inhibitors as for lysis buffer above)
to generate the nuclear fraction. The supernatant was centrifuged for
60 min at 150,000  g. The resulting pellet was washed once in RSB
buffer and then resuspended in lysis buffer to generate the membrane
fraction, whereas the supernatant of this centrifugation represented
the cytosolic fraction. All procedures were carried out at 4 °C.
Immunoblotting—Immunoblotting was performed as described previ-
ously (33) except that the membrane was blocked in Bailey’s Irish Cream
liquor in immunoblots using phosphospecific Abs or anti-RSK4 Ab.
RESULTS
We first cloned the predicted coding sequence of the human
RSK4 gene into the mammalian expression vector pMT2,
which resulted in fusion of the 9-amino acid HA epitope tag to
the N terminus of RSK4. In transiently transfected human
HEK293 cells, the RSK4 cDNA expressed a single protein
product that was of the same size as a putative endogenous
RSK4 protein immunoprecipitated from non-transfected
HEK293 cells with an antibody directed to the C-terminal
sequence of human RSK4 (Fig. 2A). To investigate the specific-
ity of the anti-RSK4 Ab, we tested its ability to precipitate each
of the four RSK homologues. To perform this experiment, we
first had to generate a soluble mutant of RSK3 because 95%
of wild-type RSK3 is lost to the insoluble fraction during clear-
ing of crude cell lysates before immunoprecipitation (Ref. 2 and
our data not shown). By constructing and analyzing RSK3-
RSK2 chimeras, an RSK3 mutant (RSK3*), in which the N-
terminal 40 amino acids derive from RSK2, was found to be
soluble and was used for the experiment. N-terminally HA-
tagged forms of the four RSKs were transiently expressed in
COS7 cells, and cell lysate from each transfection was split and
subjected to immunoprecipitation with anti-RSK4 Ab and an-
ti-HA Ab, respectively. Anti-HA immunoblotting on the precip-
itates showed that the anti-RSK4 Ab precipitated RSK4 only
(Fig. 2B). Similar experiments showed that the Ab also does not
interact with MSK1 or MSK2 (data not shown). Using the anti-
RSK4 Ab, we detected expression of RSK4 protein in lysates from
human U2OS osteosarcoma cells, BJ fibroblasts, Ln405 glioblas-
toma cells, and monkey COS7 kidney fibroblasts (Fig. 2C),
whereas no RSK4 was detected in HeLa and Chinese hamster
ovary (CHO) cells (data not shown). Immunoblotting on lysates of
adult mouse tissues showed RSK4 expression in whole brain,
heart, cerebellum, kidney, and skeletal muscle, whereas the re-
maining tissues analyzed showed no detectable RSK4 (Fig. 2C).
Typically 10 times more cells were required to perform an immu-
noprecipitation/immunoblot experiment with endogenous RSK4
compared with other endogenous RSKs, although we estimate
that the anti-RSK4 Ab has quite high avidity based on experi-
ments like the one depicted in Fig. 2B. RSK4 therefore appears to
be expressed at much lower levels than other RSKs.
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RSK4 immunoblotting on the nuclear, cytosolic, or mem-
brane fraction of HEK293 cells suggested that RSK4 is local-
ized to the cytoplasm (Fig. 2D). Control blots showed the ex-
pected distribution of the marker proteins lamin A/C,
-tubulin, and p63 in the various cell fractions. A predomi-
nantly cytosolic localization of RSK4 was confirmed by immu-
nocytochemistry and confocal microscopy to HA-RSK4 tran-
siently expressed in various cell types (Fig. 2E). However, a
weak nuclear RSK4 signal was also observed, suggesting that a
minor fraction of cellular RSK4 may be localized to the nucleus.
This fraction might have leaked to the cytoplasmic fraction
during the cell fractionation experiment depicted in Fig. 2D.
The subcellular distribution of transiently expressed RSK4 was
not affected by exposure of the cells to a variety of stimuli that
activate MAP kinase pathways. These stimuli included 20 nM
EGF or 150 nM PMA for 10, 20, 30, or 60 min; 120 J of UV
irradiation and analysis after 20, 40, or 60 min or 2, 4, 7, or
10 h; and 10 g/ml anisomycin for 30 or 60 min (data not
shown). We noted an optimal bipartite nuclear localization
signal in a loop within the N-terminal kinase domain of RSK4:
325KRHLFFANIDWDKLYKR341. Although this nuclear local-
ization signal is conserved in all RSKs, it does not appear to be
functional since the low nuclear RSK4 signal in transfected
cells was not affected by its mutation as in the triple mutant
RSK4-K325Q/R326A/K337A (data not shown).
To investigate how the kinase activity of RSK4 is regulated,
endogenous RSK4 was immunoprecipitated and assayed from
serum-starved HEK293 cells after exposure, or not, to EGF
and/or U0126, a specific inhibitor of MEK1 (50). The anti-RSK4
Ab precipitated RSK4 to the same extent under all the condi-
tions (Fig. 3A, lower left panel). Surprisingly the kinase activity
of RSK4 was only slightly stimulated by EGF (Fig. 3A, lower
left panel). In contrast, the activity of RSK2 precipitated from
the same cell lysates was stimulated 10-fold by EGF as ex-
pected (Fig. 3A, lower right panel) and as previously demon-
strated with RSK1, RSK2, and RSK3 in HEK293 cells (36).
Moreover ERK, assayed on the same cell lysates, was robustly
activated by EGF (Fig. 3A, upper panel). Incubation with
U0126 for 2 h reduced the basal and EGF-stimulated kinase
activity of RSK4 by 40–50%. This demonstrates the involve-
ment of the MEK-ERK pathway in activation of RSK4 and also
suggests that the very low level of ERK activity in unstimu-
lated cells is sufficient to induce significant activation of RSK4
but not of RSK2. Serum starvation for 18 h, instead of 4 h as in
Fig. 3, did not increase the responsiveness of RSK4 to growth
factor stimulation nor did incubation for 18 h with U0126 or
PD98059, another specific MEK1 inhibitor (51), decrease the
activity of RSK4 by more than 50% (data not shown). In agree-
ment with the activity measurements, EGF induced a profound
electrophoretic mobility shift in RSK2 (Fig. 3A, lower right
panel) most likely due to profound EGF-induced phosphoryla-
tion of RSK2. In contrast, EGF induced no significant mobility
shift in RSK4 (Fig. 3A, lower left panel), suggesting that no
significant phosphorylation was induced. Results identical to
those shown in Fig. 3A were obtained by exposure of HEK293
cells to PMA, which is another strong activator of the ERK
pathway in this and other cell types (data not shown). Intrigu-
ingly also in other cell types analyzed under serum-starved
conditions, the activity of endogenous RSK4 was not signifi-
cantly increased by EGF or PMA but was 30–50% inhibited by
U0126. In contrast, RSK2 precipitated from the same cell ly-
sates was robustly stimulated by EGF or PMA. Fig. 3, B–D,
shows the results of such experiments with U2OS osteosar-
coma cells, BJ fibroblasts, and COS7 cells. These experiments
indicate that RSK4 is constitutively activated in cells.
Control experiments showed that one single protein that was
reactive with the anti-RSK4 Ab was precipitated in the above
experiments, and this protein was competed out by incubation
of the anti-RSK4 Ab with the peptide used to raise the Ab
(blocking peptide) (Fig. 3E). Note that the band indicated by an
asterisk derives from the blocking peptide reagent and not from
the cell lysate since it is present in a precipitation performed
FIG. 2. Expression of endogenous and recombinant RSK4 pro-
tein in various cell lines and mouse tissues. A, anti-RSK4 immu-
noblot was performed on endogenous RSK4 immunoprecipitated from
107 HEK293 cells (lane 1) or on crude lysates from104 HEK293 cells
transfected with plasmid expressing HA-tagged RSK4 (lane 2) or with
empty plasmid (lane 3). B, COS7 cells were transfected with plasmid
expressing HA-tagged RSK1, RSK2, RSK3*, or RSK4. After 20 h, the
cells were lysed, and the lysates were split in two parts that were
subjected to immunoprecipitation with anti-RSK4 Ab (upper panel) or
with anti-HA Ab (lower panel). Thereafter all the precipitates were
subjected to immunoblotting with anti-HA Ab. To ensure higher
amounts of RSK1–3 compared with RSK4 in the precipitates, the
amounts of lysates were used in the ratio 3(RSK1):1(RSK2):1(RSK3*):
1(RSK4). C, anti-RSK4 immunoblot was performed on 50 g of total
protein from various cell lines (left panel) or from various adult mouse
tissues (right panel). The last lane in the right panel is lysate from
COS7 cells transfected with plasmid expressing HA-tagged RSK4. D,
lysates of the nuclear, cytosolic, or membrane fraction of HEK293 cells
were subjected to immunoblotting using antibody against RSK4 or
antibodies against marker proteins for the various fractions. E, U2OS
cells were transfected with plasmid expressing HA-RSK4. After 18 h,
including a final 4-h serum starvation period, the cells were fixed and
immunostained with Ab to the HA tag. A confocal micrograph is shown.
I.P., immunoprecipitate; I.B., immunoblot; IgL, Ig light; IgH, Ig heavy.
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with omission of cell lysate (Fig. 3E, lane 1). Moreover the S6
peptide kinase activity present in HEK293 immunoprecipi-
tates was reduced by 80–90% when the precipitations were
performed with anti-RSK4 Ab incubated with blocking peptide
or by omission of the anti-RSK4 Ab (Fig. 3F), confirming that
kinases other than RSK4 account for only a minor fraction of
the S6 peptide kinase activity. In fact, all the data with endog-
enous RSK4 kinase activity presented in this study have been
adjusted by subtraction of a reaction blank, which was deter-
mined by performing parallel immune complex kinase assays
with omission of the anti-RSK4 Ab in each experiment. We
therefore conclude that the kinase activity measured in the
experiments derives from RSK4.
To investigate the activity and regulation of RSK4 expressed
from the RSK4 cDNA clone, HEK293 cells were transiently
transfected with plasmid expressing HA-RSK4 or HA-RSK2 for
comparison. Exogenous RSK4 and RSK2 responded to EGF
and U0126 in basically the same way as the endogenous ki-
nases except that a 2-fold stimulation of exogenous RSK4 was
observed in response to EGF (Fig. 4A). To determine the spe-
cific kinase activity of RSK4 compared with that of RSK2,
immunoprecipitations for kinase assays were titrated to pre-
cipitate similar amounts of HA-RSK4 and HA-RSK2 from tran-
siently transfected COS7 cells. As shown in Fig. 4B, RSK4 has
in fact higher specific activity than RSK2 when measured
against S6 peptide, the most frequently used in vitro RSK
substrate, or against cross-tide, derived from glycogen syn-
thase kinase-3 and containing Ser9, which is a physiological
RSK phosphorylation site (37). Using full-length glycogen syn-
thase kinase-3 as a substrate, similar results were obtained
(data not shown). When correlating for RSK protein levels, the
specific activity of RSK4 was 10–20-fold higher than that of
RSK2 in serum-starved COS7 cells and 2–3-fold higher than
that of RSK2 in EGF-treated COS7 cells. As observed with
HEK293 cells, exogenous RSK4 could be stimulated 2–3-fold by
EGF in COS7 cells in contrast to the endogenous RSK4, which
was not stimulated by EGF in these cell types, as shown in Fig.
3. It should be noted that the above in vitro results do not imply
that S6 protein or glycogen synthase kinase-3 are physiological
substrates of RSK4 but only reflect that the proteins contain
FIG. 3. Endogenous RSK4 is consti-
tutively activated in many cell types
in a partly U0126-sensitive manner.
A, HEK293 cells were serum-starved for
2 h and then incubated for 2 h with 10 M
U0126 or vehicle. Thereafter the cells
were exposed, or not, for 20 min to 20 nM
EGF and lysed. Lower panels, the lysates
were split 8:1 and subjected to immuno-
precipitation with anti-RSK4 Ab and an-
ti-RSK2 Ab, respectively. The precipitates
were subjected to kinase assay using S6
peptide as a substrate or to immunoblot-
ting with the indicated Abs. Kinase activ-
ity is expressed as percent, and data are
means S.D. of three independent exper-
iments. Upper panel, aliquots of prepre-
cipitation lysates were subjected to im-
munoblotting with antibody to active
ERK or to ERK. B, RSK4 and RSK2 ac-
tivity in U2OS cells was analyzed as in A
except that cells were stimulated with
150 nM PMA or vehicle for 10 min. C,
RSK4 and RSK2 activity in BJ cells was
analyzed as in A except that cells were
stimulated with 150 nM PMA or vehicle
for 10 min. D, RSK4 and RSK2 activity in
COS7 cells was analyzed as in A. E, ly-
sates of HEK293, U2OS, BJ, or COS7
cells were subjected to immunoprecipita-
tion with anti-RSK4 Ab or with anti-
RSK4 Ab preadsorbed to the peptide used
to generate the Ab (blocking peptide). The
band indicated by an asterisk derives
from the blocking peptide reagent and not
from the cell lysate. F, RSK4 activity in
HEK293 cells was analyzed as in A except
that immunoprecipitations were also per-
formed with anti-RSK4 Ab preadsorbed to
blocking peptide as well as without any
Ab as indicated in the panel. IgH, Ig
heavy; I.P., immunoprecipitate.
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the minimal consensus sequence (Arg-X-X-Ser), which allows
in vitro phosphorylation by RSK family kinases as well as by
several other kinases related to RSKs.
We next investigated whether RSK4, like MSK, might be
regulated via stress-stimulated MAPK pathways. Endogenous
RSK4 was therefore immunoprecipitated from HEK293 cells
exposed to either of two distinct stress stimuli, anisomycin and
UV irradiation, that strongly activate p38 and JNK family
kinases. As shown in Fig. 5, A and B, the stress stimuli did not
increase the activity of RSK4. Moreover SB203580, a specific
inhibitor of p38 and - MAPKs (52), had no effect on the
kinase activity of RSK4. Serving as a control for the various
treatments, the kinase activity of MSK1 was strongly stimu-
lated by anisomycin or UV irradiation and was profoundly
inhibited by SB203580. Note that treatment with anisomycin
reduced precipitable RSK4 kinase activity apparently by de-
creasing the RSK4 protein level, which may be due to the
ability of anisomycin to inhibit protein synthesis. Also in U2OS
cells, the activity of RSK4 was not affected by UV irradiation or
SB203580 (data not shown).
The experiments depicted in Figs. 3–5 were performed with
cell cultures of 80–95% confluency that contained a mixture of
growing and contact-inhibited cells. To investigate whether the
activity of RSK4 varies as a function of growth status, RSK4
was immunoprecipitated from equal amounts of exponentially
growing or contact-inhibited HEK293 cells and assayed for
kinase activity. As shown in Fig. 6, RSK4 had similar activity
in growing and arrested HEK293 cells. Moreover RSK4 activity
was not affected by growth factor stimulation or by stress
stimulation of the growing or arrested cells. Similar results
were obtained in COS7 cells (data not shown).
The involvement of ERK in activation of RSK4 was sup-
ported by the finding that RSK4 can co-immunoprecipitate
ERK1 from lysates of transiently transfected COS7 cells (Fig.
7A). In contrast, the mutant RSK4-(1–730) with deletion of the
C-terminal 15 residues, which contain the predicted MAPK
docking site, did not precipitate ERK1, showing that the MAPK
docking site is functional. Interestingly RSK4 co-precipitated
from 2 to 3 times as much ERK1 as did similar amounts of
RSK2 (Fig. 7A). Finally RSK4 showed no ability to co-immu-
noprecipitate with p38 or JNK22 (Fig. 7, B and C). As con-
trols, p38 and JNK22 co-immunoprecipitated with MSK1
and c-Jun, respectively. Thus, these results provide further
evidence that RSK4 is regulated by ERK-type MAP kinases but
not by stress-activated MAP kinases.
The results presented in Figs. 3–7 support the intriguing
conclusion that endogenous RSK4 is maximally (constitutively)
activated in serum-starved cells and suggest that the low basal
ERK activity is responsible for inducing at least 30–50% of the
RSK4 activity under these conditions. RSK4 is thereby mark-
edly distinct from other RSKs, which require growth factor
stimulation to obtain significant kinase activity. To further
investigate the basis of constitutive RSK4 activity, endogenous
RSK4 and RSK2 were precipitated from HEK293 cells and
analyzed with phosphospecific antibodies to the three phospho-
rylation sites known from analysis of RSK1 (28) and RSK2 (33,
35) to directly stimulate catalytic activity, i.e. Ser232, Ser372,
and Ser389. This analysis revealed that RSK4 had a very sim-
ilar level of phosphorylation in serum-starved and EGF-stim-
ulated cells at all three sites (Fig. 8A). By contrast in RSK2,
EGF stimulated phosphorylation 2-fold at Ser232 and 10-fold
at Ser372 and Ser389 in a U0126-sensitive manner. The 40–50%
reduction of RSK4 kinase activity by U0126 (Fig. 3A) was not
paralleled by a 40–50% reduction of phosphorylation of one
particular site by U0126 in Fig. 8A. Conceivably U0126 induces
a small decrease of phosphorylation at perhaps all of the sites,
which is difficult to detect by immunoblotting but which to-
gether result in 50% reduction of kinase activity, which can
readily be measured by the very accurate kinase assay.
We next subjected endogenous RSK4 or RSK2, immunopre-
FIG. 4. Kinase activity of recombinant RSK4. HEK293 or COS7
cells were transfected with plasmid expressing HA-tagged RSK4 or
RSK2. After 20 h, the cells were serum-starved for 2 h and then
incubated for 2 h with 10 M U0126 or vehicle where indicated in the
panels. Thereafter the cells were exposed, or not, for 20 min to 20 nM
EGF and lysed. The lysates were subjected to immunoprecipitation
with anti-HA Ab, and the precipitates were subjected to kinase assay or
to immunoblotting with Ab to the HA tag. A, kinase activity, deter-
mined using S6 peptide as a substrate, is expressed as percent, and data
are meansS.D. of three independent experiments. B, to obtain similar
amounts of precipitated RSK2 and RSK4, 2.4-fold less cell lysate was
used for immunoprecipitation of RSK2 compared with that used for
RSK4. The precipitates were subjected to kinase assay using S6 peptide
or cross-tide as a substrate or to immunoblotting with Ab to the HA tag.
Kinase activity is expressed as percent of maximal RSK4 activity, and
data are means S.D. of triplicate determinations from one represent-
ative experiment of three. I.P., immunoprecipitate.
FIG. 5. RSK4 activity is not affected by activators or inhibitors
of stress-activated MAP kinase pathways. HEK293 cells were se-
rum-starved for 2 h and incubated for 2 h with 10 M SB203580 or
vehicle. Thereafter the cells were exposed, or not, for 60 min to 10 g/ml
anisomycin (A) or to 200 J of UV irradiation and lysed after 20 min (B).
The lysates were split 8:1 and subjected to immunoprecipitation with
anti-RSK4 Ab and anti-MSK1 Ab, respectively. The precipitates were
subjected to kinase assay using S6 peptide (for RSK4) or cross-tide (for
MSK1) as a substrate or to immunoblotting with Ab to RSK4 or MSK1.
Kinase activity is expressed as percent, and data are means  S.D. of
three independent experiments. I.P., immunoprecipitate.
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cipitated from serum-starved HEK293 cells, to in vitro phos-
phorylation by active ERK2 and PDK1 and thereafter meas-
ured the kinase activity of the two RSKs. The activity of RSK2
was increased 4-fold by incubation with ERK2 and PDK1,
whereas the activity of RSK4 was not affected (Fig. 8B). In
conclusion, the results presented in Fig. 8, A and B, strongly
suggest that endogenous RSK4 is constitutively activated in
serum-starved cells because it is maximally phosphorylated at
the key activating sites.
Phosphoblot analysis was also performed on exogenous
RSK4 and RSK2 transiently expressed in COS7 cells. RSK4
was phosphorylated at Ser232 to the same extent in starved and
EGF-stimulated cells, whereas RSK2 showed a 3–4-fold induc-
tion of this site in response to EGF (Fig. 8C, upper panel). RSK4
also showed high basal phosphorylation of Ser389 and Thr581 as
compared with RSK2. By contrast, RSK4 showed no basal
phosphorylation of Ser372. In exogenous RSK4, the phosphoryl-
ation of Ser372, Ser389, and Thr581 was induced or further
increased by EGF, probably explaining why the kinase activity
of exogenous RSK4 can be stimulated to a modest degree by
EGF in COS7 cells in contrast to the endogenous RSK4. How-
ever, exogenous RSK4 still showed high basal kinase activity in
COS7 cells that appears to result from high basal phosphoryl-
ation of Ser232 and Ser389.
Analysis of RSK4 point mutants surprisingly revealed that
phosphorylation of the predicted PDK1 site, Ser232, was not
affected by mutation of Ser389 in the predicted PDK1 docking
site (Fig. 8C, upper panel). By contrast in RSK2, mutation of
the corresponding serine in the PDK1 docking site (Ser386)
completely abolished phosphorylation of the PDK1 phosphoryl-
ation site (Fig. 8C, upper panel). Also unexpectedly, mutation
of Thr581 only slightly decreased the ability of EGF to induce
phosphorylation of Ser389. To investigate whether this is due to
an inability of the C-terminal kinase of RSK4 to be activated via
phosphorylation of Thr581, we analyzed EGF-induced activation
of the isolated C-terminal kinase domain with the linker includ-
ing the Ser389 site (RSK4-(371–745)). As shown in Fig. 8C (lower
panel), EGF promoted wild-type RSK4-(371–745), but not RSK4-
(371–745)-T581A, to autophosphorylate at Ser389. This shows
that the C-terminal kinase of RSK4 is functional. Kinase assays
showed that mutation of Ser389 profoundly decreased the kinase
activity of RSK4, suggesting that this phosphorylation site has a
major role in the basal as well as EGF-stimulated catalytic ac-
tivity of RSK4 (Fig. 8C). By contrast, kinase assays onmutants of
Thr581 and Ser372 suggested that these sites have no role in the
basal activity of exogenous RSK4 in COS7 cells but contribute to
the EGF-stimulated activity.
Only in one of eight cell lines tested did RSK4 show a low
basal activity compared with stimulated kinase activity. Thus,
in CHO cells stably transfected with the insulin receptor (IR)
(53), the activity of exogenous RSK4 was stimulated about
5-fold by insulin. No endogenous RSK4 protein could be de-
tected in CHO-IR cells (data not shown). Since endogenous
RSK4 was not stimulated in any cell type tested, the stimula-
tion in CHO-IR cells may not be physiological. However, this
cell line was considered suitable for further analysis of the role
of the individual phosphorylation sites in regulation of the
catalytic activity of RSK4 due to the low basal versus stimu-
lated activity. Wild-type RSK4 and mutants of the six phospho-
rylation sites identified in RSKs were expressed and assayed in
CHO-IR cells. Stimulation of RSK4 activity by insulin was
mediated by ERK since it was completely abolished by U0126
FIG. 6. Endogenous RSK4 is constitutively activated in expo-
nentially growing and contact-inhibited cells. Exponentially
growing HEK293 cells (used at 30–40% confluency) or contact-inhib-
ited HEK293 cells (used 2 days after reaching confluency) were exposed
for 20 min to 20 nM EGF or for 60 min to 10 g/ml anisomycin or left
untreated and then lysed. Cell lysates were normalized for protein and
subjected to immunoprecipitation with anti-RSK4 Ab. The precipitates
were subjected to kinase assay using S6 peptide as a substrate or to
immunoblotting using anti-RSK4 Ab. Kinase activity is expressed as
percent, and data are means  S.D. of three independent experiments.
I.P., immunoprecipitate.
FIG. 7. RSK4 can form a complex with ERK but not with p38 or
JNK in cells. COS7 cells were transfected with plasmid expressing
Myc-tagged ERK1 (A) or Myc-tagged p38 (B) together with plasmid
expressing wild type or deletion mutants of HA-RSK4, HA-RSK2, or
HA-MSK1 or with empty vector as indicated in the panels. After 20 h,
the cells were lysed, and cell lysates were subjected to immunoprecipi-
tation with Ab to the HA tag. Aliquots of the precipitates and the
preprecipitation lysates were subjected to immunoblotting with Ab as
indicated. To obtain equal amounts of precipitated RSK4 compared
with RSK2 and MSK1, 2.4- and 5-fold less cell lysate was used for
immunoprecipitation of RSK2 and MSK1, respectively, compared with
that used for RSK4. C, COS7 cells were transfected with plasmid
expressing HA-c-Jun or HA-RSK4 together with plasmid expressing
GST-JNK22 or empty vector. To obtain similar expression of HA-c-Jun
and HA-RSK4, HA-c-Jun plasmid was diluted 1:3 with empty vector.
After 20 h, the cells were lysed, and cell lysates were subjected to
precipitation of GST proteins using glutathione-agarose beads. Aliquots
of the precipitates and the preprecipitation lysates were subjected to
immunoblotting with Ab as indicated. All experiments were performed
three times with similar results. I.P., immunoprecipitate.
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(Fig. 9A, left panel) and insensitive to SB203580 (data not
shown). Mutation of Thr368 did not affect RSK4 kinase activity
as shown for the corresponding Thr in RSK1 (28) and RSK2.2
Individual mutation of Ser372 and Thr581 decreased the activity
of RSK4 by 30%, whereas the double mutant S372A/T581A
showed 80% reduced activity. Mutation of Ser389 most pro-
foundly reduced RSK4 activity, whereas mutation of Ser742 had
no effect. The RSK4-S232A mutant was not included in Fig. 9A
due to low expression, but the mutant was completely devoid of
kinase activity, indicating that Ser232 phosphorylation is
strictly required for activation of RSK4. Since individual mu-
tation of the sites corresponding to Ser372 and Thr581 were
previously shown to abolish PMA-induced activity of RSK1 in
COS1 cells (28), we analyzed these RSK1 mutants in CHO-IR
cells. Compared with RSK4, these two sites individually con-
tributed considerably more to activation of RSK1, although
their mutation did not abolish kinase activity (Fig. 9A, right
panel). Phosphoimmunoblot analysis of RSK4 from CHO-IR
cells showed that, as in COS7 cells, mutation of Ser389 did not
abolish phosphorylation of Ser232, although a 2-fold reduction
was observed (Fig. 9B). Also as in COS7 cells, mutation of
Thr581 had only a small effect on insulin-stimulated phospho-
rylation of Ser389, explaining why the T581Amutation had only
a small effect on kinase activity.
The finding that mutation of the PDK1 docking site in RSK4
did not significantly affect phosphorylation of Ser232 could in-
dicate that, unlike RSK1–3 (33, 34, 37), RSK4 does not require
PDK1 for activation. To address this question, RSK4 was tran-
siently expressed in wild-type mouse ES cells or in mouse ES
cells with targeted disruption of both PDK1 alleles (37) and
thereafter analyzed with respect to kinase activity and phos-
phorylation of Ser232. As shown in Fig 10A, exogenous RSK4
had similar activity in wild-type and PDK1-deficient ES cells
and showed similar phosphorylation of Ser232. In contrast,
endogenous RSK2 showed greatly decreased kinase activity
and phosphorylation at the PDK1 site in PDK1-deficient ES
cells (Fig. 10A). To obtain maximal RSK2 activity, the ES cells
were treated with PMA in these experiments, but RSK4 had
similar activity in PMA-treated and untreated cells (data not
shown). To investigate whether RSK4 may autophosphorylate
at Ser232, PDK1-deficient ES cells were transfected with RSK4
mutants (RSK4-K105A or RSK4-P242A/E243A) in which the
NTK had been inactivated by mutation of critical residues
conserved in virtually all kinases. These mutants had minimal
kinase activity and showed profoundly decreased phosphoryl-
ation at Ser232 compared with wild-type RSK4 (Fig 10B), sug-
gesting that RSK4 can autophosphorylate at Ser232. Finally,
like exogenous RSK4, endogenous RSK4 showed equal phos-
phorylation of Ser232 in wild-type and PDK1-deficient ES cells
(Fig. 10C). In conclusion, RSK4 is markedly distinct from other
RSKs in that it does not require PDK1 for phosphorylation of
Ser232 and activation.
DISCUSSION
We performed the first functional characterization of the
putative new RSK family member RSK4. Our data showed that
RSK4 is a functional protein kinase that belongs to the RSK,
rather than MSK, family since RSK4 interacts with and is
regulated by ERK, whereas no evidence for regulation by
stress-activated MAP kinases was obtained. However, our data
also showed that RSK4 has important features that clearly
distinguish it from other RSK proteins. Thus, RSK4 has growth
factor-independent, constitutive activity in many cell types and
does not require PDK1 for activation. These features imply that
RSK4 has different signaling properties and is functionally
distinct from other RSKs.
The constitutive activity of RSK4 appears to result from
constitutive phosphorylation of key activating sites. Thus, en-
dogenous RSK4 showed the same level of phosphorylation of
Ser232, Ser372, and Ser389 in starved and growth factor-stimu-
lated cells, and mutational analysis demonstrated that these
sites are important in stimulation of kinase activity. In a sim-
ple explanation for the constitutive activation, the expression
level (and/or the rate of dephosphorylation) of RSK4 is so low
that the basal activity of a highly expressed activating kinase is
sufficient to induce maximal phosphorylation of RSK4. This is2 C. J. Jensen and M. Fro¨din, unpublished observation.
FIG. 8. Constitutive activation of endogenous RSK4 in serum-
starved cells is due to constitutive phosphorylation. A, endoge-
nous RSK4 or RSK2 was immunoprecipitated from serum-starved
HEK293 cells treated as described in the legend to Fig. 3A and sub-
jected to immunoblotting with phosphospecific Abs to Ser232, Ser372, or
Ser389. The experiment was performed three times with similar results.
B, HEK293 cells were serum-starved for 4 h and then lysed. Endoge-
nous RSK4 or RSK2 was immunoprecipitated from the cell lysates and
incubated for 30 min with MgATP in the absence or presence of active
ERK2 and active PDK1. Thereafter the kinase activity of RSK4 and
RSK2 was determined using S6 peptide as a substrate and expressed as
percent of the activity after incubation with ERK2 and PDK1. C, COS7
cells were transfected with plasmid expressing wild-type or mutant
HA-RSK4 or HA-RSK2. After 20 h and a final 4-h serum starvation
period, cells were exposed, or not, for 20 min to 20 nM EGF and then
lysed. The lysates were subjected to immunoprecipitation with Ab to
the HA tag. Aliquots of the precipitates were subjected to immunoblot-
ting with the Abs indicated in the panel or to kinase assay using S6
peptide as a substrate. Kinase activity is expressed as percent of max-
imal RSK4 activity, and data are means  S.D. of three independent
experiments. pT, phosphothreonine; pS, phosphoserine.
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likely to be partly the case since the basal activity of ERK
contributed to at least 30–50% of the activity of endogenous
RSK4 as evidenced by U0126 sensitivity, although basal ERK
activity was very low, amounting to less than 5% of the EGF-
stimulated ERK activity (Fig. 3A and data not shown). In
addition, ERK is a very abundant kinase with an estimated
concentration of 1–3 M in mammalian cells (54), whereas
RSK4 has very low expression as discussed below. The above
explanation is also indirectly supported by the finding that, in
the case of overexpressed RSK4 in COS7 cells, the basal activ-
ity of endogenous ERK was not sufficient to induce maximal
phosphorylation of the ERK sites in RSK4 conceivably due to
high amounts of RSK4 relative to ERK.
The experiments with exogenous RSK4 in COS7 cells also
FIG. 9. Role of individual phospho-
rylation sites in regulation of RSK4
kinase activity. A, CHO-IR cells were
transfected with plasmid expressing wild-
type or mutant HA-RSK4 or HA-RSK1.
After 36 h and a final 4-h serum starva-
tion period, cells were exposed, or not, for
15 min to 150 nM insulin and then lysed.
The lysates were subjected to immuno-
precipitation with Ab to the HA tag. Ali-
quots of the precipitates were subjected to
kinase assay using S6 peptide as a sub-
strate or to immunoblotting with Ab to
the HA tag (only precipitates from
starved cells are shown). Kinase activity
is expressed as percent, and data are
means  S.D. of at least three independ-
ent experiments. B, wild-type and mutant
HA-RSK4 were expressed and purified
from CHO-IR cells as described in A and
subjected to immunoblotting with the Abs
indicated in the panel. The experiment
was performed three times with similar
results. I.P., immunoprecipitate; pT,
phosphothreonine; pS, phosphoserine.
FIG. 10.RSK4 does not require PDK1 for phosphorylation of Ser232 or activation. A, for RSK4, wild-type (/) or PDK1-deficient (/)
mouse ES cells were transfected with plasmid expressing FLAG-tagged RSK4. After 18 h, the cells were exposed to 150 nM PMA for 20 min and
then lysed. The lysates were subjected to immunoprecipitation with Ab to the FLAG tag. The precipitates were subjected to kinase assay using S6
peptide as a substrate followed by the addition of SDS-PAGE sample buffer to the precipitates and immunoblotting with Ab to Ser(P)232 or the
FLAG tag. To obtain equal amounts of precipitated RSK4 from the two ES cell lines, more lysate from / cells than from / cells was used for
immunoprecipitation since the / cells were transfected with low efficiency. Kinase activity is expressed as percent, and data are means  S.D.
of triplicate determinations. For RSK2, endogenous RSK2 was precipitated with anti-RSK2 Ab from 107 non-transfected PDK1(/) or
PDK1(/) ES cells exposed for 20 min to 150 nM PMA and then analyzed as described for RSK4. The experiments were performed four times with
similar results. B, PDK1-deficient (/) ES cells were transfected with plasmid expressing wild-type or mutant HA-tagged RSK4. HA-RSK4 was
precipitated using anti-HA Ab and analyzed as described in A. To obtain similar amounts of precipitated RSK4, 5-fold less cell lysate was used for
immunoprecipitation of wild-type compared with mutant RSK4 as the mutants showed decreased expression. Kinase activity is expressed as
percent, and data are means range of two independent experiments. C, approximately 107 wild-type (/) or PDK1-deficient (/) ES cells were
exposed to 150 nM PMA for 20 min and then lysed. Endogenous RSK4 was precipitated with anti-RSK4 Ab and subjected to immunoblotting with
Ab to Ser(P)232 or to RSK4. The experiment was performed twice with similar results. pS, phosphoserine; WT, wild type.
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suggested that the U0126-insensitive (i.e. apparently ERK-
independent) RSK4 activity derives from phosphorylation of
Ser232 and Ser389 since the RSK4-S372A/T581A mutant with
all regulatory ERK sites mutated showed considerable basal
phosphorylation of Ser232 and Ser389 as well as considerable
basal kinase activity. Mutational analysis furthermore con-
firmed that Ser232 and Ser389 are the most important phospho-
rylation sites in stimulation of RSK4 catalytic activity. This is
not surprising since the two sites are conserved in many ki-
nases of the so-called AGC kinase superfamily, which includes
RSK, MSK, protein kinase B (PKB), p70 S6 kinase, and serum-
and glucocorticoid-inducible kinase, where the two sites have
an essential and synergistic effect on kinase activation (35). An
absolute requirement for PDK1 in phosphorylation of the acti-
vation loop in the NTK of RSK1–3 has been demonstrated
biochemically (33, 34) and genetically (37, 55). It is therefore
surprising that PDK1 is not required for Ser232 phosphoryla-
tion and activation of RSK4 as demonstrated here genetically
in PDK1-deficient ES cells. Instead RSK4 may autophospho-
rylate at Ser232 as indicated by the reduced Ser232 phosphoryl-
ation observed in the catalytically inactive RSK4 mutants in
PDK1-deficient ES cells. Our results, however, do not exclude
that PDK1 may contribute to phosphorylation of Ser232 in
PDK1 wild-type cells.
Mutational analysis also suggested that phosphorylation of
Ser372 and Thr581 plays a more modest role in stimulation of
RSK4 kinase activity than does phosphorylation of Ser232 and
Ser389. In insulin-stimulated CHO-IR cells, double mutation of
Ser372 and Thr581 had a much greater effect on RSK4 kinase
activity than did the single mutations, suggesting that the sites
can compensate for each other. It is possible that the unex-
pected phospho-Thr581-independent phosphorylation of Ser389
induced by insulin in the T581A mutant (Fig. 9B) could con-
tribute to the apparent compensating function of the two sites,
but the mechanism behind this observation is unknown.
Based on this and previous studies on the RSK activation
mechanism, a model for constitutive activation of endogenous
RSK4 in serum-starved cells is proposed. Constitutive activa-
tion is due to maximal phosphorylation of Ser232, Ser372, and
Ser389 of which Ser232 and Ser389 synergize to stabilize the
NTK in the active conformation thereby inducing about 80% of
the RSK4 activity. The low basal ERK activity is responsible
for induction of at least 50% of the RSK4 activity via maximal
phosphorylation of Ser372 and Thr581. Phosphorylation of
Ser372 directly stimulates the activity of the NTK, whereas
phosphorylation of Thr581 stimulates NTK by promoting par-
tial phosphorylation of Ser389, and this event may possibly
enhance autophosphorylation of Ser232. The remaining 50%,
apparently ERK-independent, RSK4 activity derives from
phosphorylation of Ser232 and Ser386, which may be catalyzed
by autophosphorylation by the NTK and the C-terminal kinase,
respectively, although a contribution from additional kinases
cannot be excluded.
Two recent studies suggest that RSK4 may have unique
cellular functions compared with RSK1–3. In the first study, a
short interfering RNA screen was carried out to identify medi-
ators of p53-induced growth arrest, and it was discovered that
knock-down of RSK4 abolishes p53-dependent G1 cell cycle
arrest induced either by conditional activation of p53 or by
DNA damage via ionizing irradiation (42). It was also demon-
strated that RSK4 knock-down strongly suppressed expression
of mRNA for the cyclin-dependent kinase inhibitor p21cip1, a
major component of the antiproliferative response to p53. How-
ever, the regulation and mechanism of action of RSK4 in the
p53 response was not addressed. In the present study, we found
no regulation of RSK4 by UV irradiation, which also induces
DNA damage and p53 activation, or by p53 transfection in
U2OS or BJ cells, the two cell types analyzed in the study
mentioned above. Thus, no change in RSK4 activity or subcel-
lular distribution was detected within 8 h after UV irradiation
nor did UV irradiation or transfection with p53 plasmid in-
crease the RSK4 protein level within 24 h, although a robust
growth arrest was observed (data not shown). It is therefore
possible that RSK4 may function as an indirect mediator of p53
in induction of downstream effectors for instance by phospho-
rylating a protein in the p53 transcriptional activation complex
on the p21cip1 promotor or by stimulating p21cip1 mRNA sta-
bility in the cytoplasm. The constitutive activity of RSK4 dem-
onstrated here would enable RSK4 to function as such an
indirect mediator of p53 signaling.
In the second study, a functional screen of mouse mRNAs
showed that injection of RSK4, but not RSK1–3, transcripts
into X. laevis one-cell embryos disrupted the subsequent for-
mation of mesoderm, which is induced by the fibroblast growth
factor-Ras-ERK pathway (43). The mechanism of inhibition
was not resolved, but the inhibitory action appeared to take
place at a level downstream of Ras, resulting in reduced phos-
phorylation of MEK and ERK at the activating sites. In early
mouse development, RSK4 shows particularly high mRNA ex-
pression in extraembryonic tissue, and RSK4 expression is
inversely correlated with the presence of active ERK as de-
tected by anti-active ERK immunostaining. The authors pro-
posed that RSK4 is an inhibitor, rather than a mediator, of
growth factor signal transduction via the Ras-ERK pathway in
selected cellular contexts. This hypothesis would require that
activation of RSK4 can occur in a growth factor-independent
manner. In the present study, we found evidence for growth
factor-independent activation of RSK4 that may occur via low
basal levels of ERK activity and/or autophosphorylation.
Although a quantitative analysis was not performed, the low
signal in kinase assays and immunoblots of endogenous RSK4
suggests that RSK4 may be expressed at 10–20 times lower
levels than other RSKs in most cell types. This conclusion is
supported by the extraordinarily low number of human RSK4
expressed sequence tags (ESTs) in the public data bases. Thus,
as of January 2005, Unigene listed 16 RSK4 ESTs, 289 RSK1
ESTs, 282 RSK2 ESTs, and 351 RSK3 ESTs (www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db	unigene), indicating that low
RSK4 protein expression is due to low RSK4 mRNA levels. In
agreement with this conclusion, Kohn et al. (41) noted that
RSK4 shows relatively broad but low expression compared with
RSK2 in fetal mouse tissues. Since RSK4 appears to be consti-
tutively activated in cells and may function to suppress Ras-
ERK signal transduction and cell proliferation, the expression
level of RSK4 may be low in most cell types to allow cell growth.
Conversely up-regulation of RSK4 expression may be one
mechanism to restrict cell growth. It can further be speculated
that the biological activity of RSK4 is regulated primarily at
the level of expression rather than at the level of catalytic
activity, the major level of regulation of RSK1–3.
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Viele neue Erkenntnisse aus der Grundlagenforschung haben in den 
letzten Jahren zu konkreten Erfolgen im Bereich der Krebsbehandlung 
geführt. Unser zunehmendes Wissen darüber, wie aus gesunden Zellen 
Krebszellen entstehen können, ermöglicht die Entwicklung von 
spezifischen Medikamenten, welche weniger Nebenwirkungen zeigen als 
herkömmliche Chemotherapien. Mehrere neue Techniken, die in 
Forschungslaboratorien entstanden sind, werden nun im klinischen 
Bereich der Diagnostik eingesetzt. 
Mit der Entschlüsselung des menschlichen Erbguts stehen erstmals 
Informationen über die Genstruktur aller menschlichen Gene zur Verfügung. 
Durch so genannte Hochdurchsatztechnologien kann diese immense 
Datenmenge für die molekulare Analyse von Krankheiten nutzbar gemacht 
werden. In einem einzigen Experiment kann in einem Gewebe oder einer 
Blutprobe die Expression von hunderten von Proteinen oder tausenden von 
Genen untersucht werden. Die Verfügbarkeit solcher Technologien hat die 
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biomedizinische Forschung fundamental verändert. Im Prinzip ist es heute 
möglich, präzise zu analysieren, welche Gene oder Proteine in einer Zelle 
eines bestimmten Typs oder Zustandes exprimiert werden, und welche nicht. 
Diese Information wird als "Expressionsprofil" des Zelltyps bezeichnet. Ein 
Bereich der Krebsforschung, in welchem diese Technologien intensiv genutzt 
werden, ist die Suche nach neuen Tumormarkern. 
Tumormarker sind Stoffe, hauptsächlich Proteine, die sich bei der Entstehung 
und dem Wachstum von bösartigen Tumoren bilden. Indem man die 
Expressionsprofile von Krebszellen mit denjenigen von gesunden Zellen 
vergleicht, können viele solche potenzielle Marker identifiziert werden. Durch 
den spezifischen Nachweis eines verlässlichen Markermoleküls, zum Beispiel 
im Serum des Patienten oder in entsprechenden Gewebebiopsien, ist eine 
Diagnose in einem frühen Krebsstadium möglich. Neben verbesserter 
Diagnostik erlauben Hochdurchsatzverfahren aber auch eine zunehmend auf 
den einzelnen Patienten zugeschnittene Behandlung. Auf Grund von 
genetischen Unterschieden können zum Beispiel gewisse Medikamente bei 
einem Patienten wirkungsvoll sein, bei einem anderen jedoch keine oder eine 
unerwünschte Wirkung zeigen. So genannte Gentests können bei Patienten 
Verträglichkeit und Wirksamkeit für gewisse Medikamente im vornherein 
abklären. 
Die Entwicklung effizienterer und besser verträglicher Krebsmedikamenten ist 
ein weiterer Forschungsschwerpunkt. Toxische Nebenwirkungen treten unter 
anderem bei allen Medikamenten auf, welche nicht nur Krebszellen, sondern 
auch das gesunde Gewebe angreifen. In den letzten Jahren wurden selektive 
Krebsmedikamente entwickelt, die ein höheres Potenzial zur Unterscheidung 
von Tumor- und Nichttumorzellen besitzen. Ein solcher neuer therapeutischer 
Ansatz ist der zielgerichtete Transport eines therapeutisch wirkenden Stoffes 
ins Tumorgewebe, zum Beispiel mit Hilfe von tumorspezifischen Antikörpern. 
Ein anderer innovativer Therapieansatz ist die selektive Inhibierung von 
Signaltransduktionswege innerhalb der Krebszellen. Fortschritte in der 
Grundlagenforschung haben hier zur Identifikation zahlreicher molekularer 
Angriffspunkte ('drug targets') geführt, für welche selektive Wirkstoffe entwickelt 
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werden können. Solche Angriffspunkte sind Proteine, die zum Beispiel an der 
Vermehrung der Krebszellen oder an der Entwicklung neuer Blutgefässe 
(Angiogenese) im Tumorgewebe beteiligt sind. 
In diesem Beitrag möchten wir an einigen Beispielen erläutern, wie Ergebnisse 
aus der Grundlagenforschung Eingang in die klinische Praxis finden und damit 
den Patienten zugute kommen. 
 
Früherkennung durch Tumormarker and Proteinmuster 
Bei Krebs spielt das frühe Erkennen der Erkrankung eine entscheidende Rolle. 
Bisher basierte eine Diagnose hauptsächlich auf der mikroskopischen 
Untersuchung von Gewebeproben. Manche Krebserkrankungen sind jedoch 
bis zu dem Zeitpunkt, an dem ein solcher Nachweis möglich ist, schon weit 
fortgeschritten und können häufig nicht mehr erfolgreich behandelt werden. In 
der Grundlagenforschung werden deshalb grosse Anstrengungen 
unternommen, um verlässliche Tumormarker zu identifizieren. Tumormarker 
sind Substanzen, meist Proteine, die bei Krebserkrankungen im Blut oder in 
anderen Körperflüssigkeiten erstmals oder in größerer Menge nachweisbar 
sind. In der klinischen Praxis können Serumproben von Patienten auf solche 
Tumormarker untersucht werden, um Krebserkrankungen frühzeitig zu 
erkennen. 
Konzeptionell stützt sich dieses diagnostische Verfahren auf die veränderte 
Expression von Genen und Proteinen, die mit der Krebsentstehung 
einhergehen. Über solche molekularen Veränderungen weiss man in der 
Grundlagenforschung immer besser Bescheid. Zudem können mittels neuer 
Hochdurchsatzverfahren zahlreiche im Erkrankungszustand unterschiedlich 
exprimierte Proteine identifiziert werden. Diese Fortschritte haben zur 
Aufdeckung einer Reihe neuer Tumormarker-Kandidaten geführt (1,2). 
Prostataspezifisches Antigen (PSA) ist ein gutes Beispiel für einen etablierten 
Tumormarker. PSA ist ein Protein das von der Prostata sezerniert wird. Die 
Entdeckung, dass die Serumkonzentration von PSA bei Prostatakrebs erhöht 
ist, hat die Diagnostik von Prostatakrebs drastisch verbessert. Seit über zehn 
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Jahren werden nun Messungen der Serumkonzentration von PSA 
routinemässig für die Früherkennung und Überwachung von Prostatakrebs 
genutzt. Ausserdem sind einige neue Tumormarker identifiziert worden, welche 
die Diagnose von Prostatakrebs weiter verbessern könnten, zum Beispiel 
humanes Kallikrein 2 (hK2) (3) und Prostataspezifisches Membran Antigen 
(PSMA) (4). 
Eine weitere vielversprechende Perspektive für die klinische Diagnostik bietet 
die Untersuchung von Proteinmustern ('proteomic pattern analysis'). Diese 
Methode fokussiert nicht auf die Identifikation eines einzelnen Tumormarkers, 
sondern erfasst das Gesamtbild der Veränderungen in den Protein- und 
Peptidzusammensetzungen (6). Mit einer auf Massenspektrometrie 
basierenden Technologie kann beispielsweise eine Abbildung des 
Proteinmusters einer Serumprobe aufgezeichnet werden. Für diese Methode 
ist keine Identifikation der einzelnen Komponenten notwendig. Vielmehr wird 
ein für "Krebserkrankung" charakteristisches Proteinmuster etabliert, welches 
dann mit dem Proteinmuster der Serumprobe eines Patienten verglichen wird. 
Eine kürzlich publizierte Pilotstudie benutzte dieses neuartige diagnostische 
Verfahren zur Erkennung von Tumoren in Eierstöcken (7). Bei dieser Krebsart 
ist eine Frühdiagnose besonders dringlich. Tumore der Eierstöcke werden oft 
zu spät erkannt und haben dann nur noch geringe Heilungschancen. Bei 
rechtzeitiger Erkennung könnten jedoch die meisten Patienten durch einen 
operativen Eingriff geheilt werden. In der erwähnten Pilotstudie wurden durch 
Proteinmuster-Analysen Tumore der Eierstöcke mit einer Effizienz von über 
90% erkannt. Die Proteinmuster-Analysen in der Tumordiagnostik steckt zwar 
noch in den Anfängen, sie könnte sich aber in naher Zukunft zu einer 
effizienten diagnostischen Methode entwickeln.  
 
Gentests und Massgeschneiderte Behandlungen 
Warum reagieren Patienten unterschiedlich auf eine Behandlung? Und wie 
finden wir die optimale Behandlung für den einzelnen Patienten? Die Antwort 
liegt zu einem grossen Teil in der Genetik. Kleine genetische Unterschiede 
 74
können nicht nur das Risiko, an Krebs zu erkranken, und den klinischen Verlauf 
der Krebserkrankung beeinflussen, sondern können auch dramatische 
Auswirkung auf die Wirksamkeit und Verträglichkeit von Medikamenten haben 
(8). Der Einbezug der Genetik in die Krebsbehandlung fördert eine individuell 
angepasste Medizin, welche eine Maximierung der Effizienz und Minimierung 
von toxischen Nebenwirkungen erlaubt. Dabei sollten sowohl der genetisch 
Hintergrund des Patienten, als auch die genetische Klassifizierung des Tumors 
berücksichtigt werden. 
Gentests können das Erbgut von Patienten auf häufige Mutationen (so 
genannte Polymorphismen) in Genen überprüfen, welche zum Beispiel die 
Verstoffwechselung der Medikamente regulieren. Solche Tests stehen vor 
allem dann zur Diskussion, wenn ein Medikament verordnet werden soll, bei 
dem gravierende Nebenwirkungen auftreten können. Ein gutes Beispiel für eine 
solche Situation ist die Behandlung mit 6-Mercaptopurin (6MP). Dies ist ein 
effizientes Medikament um Leukämie bei Kindern zu behandeln. Die 
Behandlung mit 6MP ist jedoch bei Patienten mit vererbten Mutationen in 
TPMT, einem Gen, das die Verstoffwechselung von 6MP beeinflusst, extrem 
toxisch. Für Patienten, welche in beiden Genkopien von TPMT eine Mutation 
tragen, ist die Einnahme von 6MP lebensgefährlich (9). Es ist relativ einfach, 
Patienten auf eine Mutation in einem einzelnen Gen zu überprüfen. Schwieriger 
wird es, wenn wie für die meisten Krebsmedikamente, zahlreiche genetische 
Polymorphismen die Wirksamkeit und Verträglichkeit beeinflussen.  
Ein neues Verfahren, welches die parallele Analyse von zahlreichen Genen 
ermöglicht, ist die Microarray Technologie. Microarray Chips, auch Genchips 
genannt, bestehen aus einer soliden Oberfläche, beispielsweise aus Glas, auf 
der tausende von verschiedenen DNA Molekülen (so genannte DNA- oder 
Oligonukleotid-Proben) in einer systematische Anordnung platziert sind (Abb. 
1). Jede einzelne Probe besteht aus einem einmaligen genau definierten 
Genabschnitt. Anhand eines solchen Microarrays kann untersucht werden. 
welche Gene in einer Zelle transkribiert werden. Microarray Technologie kann 
unter anderem (mit auf diesen Zweck angepassten DNA Proben) dazu benutzt 
werden,  genetische Polymorphismen im Erbgut eines Patienten abzuklären. 
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Abb. 1. Microarray Technologie. Microarray Chips ermöglichen die simultane Expressionsanalyse von 
zehntausenden von Genen in einem einzigen Assay. Als erster Schritt wird RNA aus biologischem 
Material (z.B. Blut oder Gewebe) extrahiert. Diese RNA wird danach über mehrere Zwischenschritte 
markiert (z.B. mit Biotin) und in kürzere Fragmente zerstückelt. Die RNA Fragmente werden dann mit dem 
Microarray Chip inkubiert. Ein Microarray Chip enthält sogenannte DNA Proben, kurze Gensequenzen 
von tausenden von verschiedenen Genen, welche auf einem Träger immobilisiert sind. Ein einziger 
Microarray Chip kann heute mit bis zu 450'000 verschiedenen DNA Proben bestückt werden, wobei jede 
Probe auf dem Chip eine genau bekannte Sequenz und Lokalisation hat. Oft ist so ein Chip nicht viel 
grösser als 1 cm2. Die Anordnung und Zusammensetzung der Proben auf solchen Chips können bei der 
Herstellung dem Verwendungszweck angepasst werden. Die markierten RNA Fragmente hybridisieren 
während der Inkubation an komplementäre DNA Proben auf dem Microarray. Die gebundene RNA kann 
z.B. mit einem an Streptavidin-gekoppelten Fluoreszenzfarbstoff detektiert werden. Für jede Probe wird 
mit einem Scanner die Lichtintensität des Fluoreszenzfarbstoffes gemessen. Diese ist proportional zur 
Anzahl gebundener RNA Transkripte und es ist damit möglich die relative Menge der Transkripte eines 
spezifischen Gens zu bestimmen. 
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Eine andere Anwendung für Microarray Technologie ist die genetische 
Klassifizierung von Tumoren. Neben genetischen Polymorphismen im Erbgut 
der Patienten ist die molekulare Heterogenität der Tumore ein weiterer 
Hauptgrund für die interindividuelle Variation in der Arzneimittelwirkung. 
Tumorentwicklung ist ein komplexer Prozess, und auch wenn Tumore, die aus 
demselben Zelltyp entstanden sind, gewisse gemeinsame Charakteristika 
haben, gibt es dennoch grosse Variationen auf der molekularen und 
genetischen Ebene. Bis jetzt ist die mikroskopische Untersuchung von 
Tumorbiopsien der goldene Standard für Diagnose und Klassifizierung. Sie 
beruht ausschliesslich auf dem morphologischen Erscheinungsbild des Tumors. 
Morphologisch ähnliche Tumore können jedoch unterschiedliche molekulare 
Veränderungen aufweisen, die den klinischen Prozess und die Ansprechbarkeit 
auf Medikamente wesentlich bestimmen. Mit Microarray Technologie ist eine 
molekulare Tumorklassifizierung anhand von Genexpressionsprofilen möglich, 
welche die herkömmlichen Diagnoseverfahren komplementieren kann (10). Die 
prognostische und therapeutische Beurteilung eines Tumors wird dadurch 
signifikant verbessert und ermöglicht eine Behandlung die besser auf den 
individuellen Patienten abgestimmt ist.  
 
Molekulare Angriffspunkte und tumorspezifische Antikörper in der 
Krebsbehandlung 
Zwar hat sich die Chemotherapie bei bestimmten Krebsarten als 
ausserordentlich wirkungsvoll erwiesen, doch wird ihre Effizienz häufig durch 
erhebliche Nebenwirkungen behindert. Die meisten zytotoxischen Wirkstoffe, 
die in der Chemotherapie eingesetzt werden, wirken auf DNA und Tubulin, das 
heisst, ihre Wirkung beschränkt sich nicht auf Krebszellen, sondern sie greifen 
alle sich häufig teilenden Zellen im Körper an. Eine neue 
Behandlungsmöglichkeit hat sich nun mit der Entwicklung von zielgerichteten 
Wirkstoffen eröffnet, welche spezifisch bestimmte zelluläre Proteine blockieren, 
die an der Tumorentstehung beteiligt sind. Solche Proteine können 
Plasmamembranrezeptoren sein, Komponenten von intrazellulären 
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Signaltransduktionswegen, Zellzyklus-regulierende Proteine, oder auch 
Proteine und Signalstoffe, welche in der Angiogenese wichtig sind. 
Eine wichtige Klasse von Proteinen, auf welche viele der neuen Wirkstoffe 
ausgerichtet sind, bilden die Proteintyrosinkinasen (PTKs) (Tabelle 1).  
 
Tabelle 1 
Proteinkinase-Hemmer in klinischer Entwicklung 
Hemmer Firma Zielkinase(n) 
Flavopiridol Aventis Cdks 
PD184352 (CI 1040) Pfizer MEK 
RAD001 Novartis mTOR 
CCI779 Wyeth-Ayerst mTOR 
E7070 Eisai Cdks 
Cyc202 Cyclacel Cdks 
Bryostatin-I Bristol Myers Squibb PKC 
PKC412 Novartis PKC, VEGFR2, PDGFR, Flt-
3 
UCN-01 NCI PKC and Chk1 
ISIS 3521 (antisense) ISIS PKC-α 
GEM231 (antisense) Hybridon PKA 
BIRB0796 Boehringer Ingelheim p38 
SCIO-469 Scios p38 
BAY 43-9006 Bayer c-raf 
CEP-1347 Cephalon Jun 
LY-333531 Eli Lilly PKC-β 
Gleevec (Glivec, Imatinib, STI571) Novartis ABL, KIT, PDGFR 
PTK787/ZK222584 Novartis/Schering AG VEGFR2, KIT, PDGFR 
PKI166 Novartis EGFR and HER-2 
AG013726 Agouron VEGFR2, PDGF-R 
KRN633 Kirin VEGFR1/2, KIT 
CHIR 200131 Chiron VEGFR1/2, FGFR, PDGFR 
Tarceva (Erlotinib, OSI-774) Roche/Genentech/OSI EGFR 
CI-1033 (PD183805)  Pfizer/Warner-Lambert EGFR and HER-2 
CP-547632 Pfizer VEGFR2, FGFR 
EKB-569 Wyeth-Ayerst EGFR and HER-2  
GW-2016 GlaxoSmithKline EGFR and HER-2 
SU5416 SUGEN/Pharmacia VEGFR2 
SU6668 SUGEN/Pharmacia VEGFR2 (PDGFR, FGFR) 
SU11248 SUGEN/Pharmacia VEGFR, PDGFR, KIT, Flt-3 
ZD 6474 AstraZeneca VEGFR2 and EGFR 
Iressa (Gefitinib, ZD 1839) AstraZeneca EGFR 
CEP-701 Cephalon Trk 
Angiozyme ® Ribozyme VEGFR1 (Flt-1) 
Abkürzungen: ABL: Abelson; Cdk: cyclin-dependent kinase; Chk1: checkpoint kinase 1; EGFR: 
Epidermal growth factor receptor; FGFR: fibroblast growth factor receptor; Flt: FMS-like tyrosine 
kinase; MEK: mitogen-activated protein kinase kinase; PDGFR: platelet-derived growth factor receptor; 
PKA: protein kinase A; PKC: protein kinase C; VEGF-R: vascular endothelial growth factor receptor. 
  
  
PTKs sind Enzyme, welche andere Proteine modifizieren, indem sie 
Phosphatgruppen auf deren Tyrosin-Reste übertragen (Phosphorylierung). 
 78
Durch solche Phosphorylierungen können PTKs die Funktion anderer Proteine 
aktivieren oder deaktivieren. Häufig belegen PTKs deshalb eine 
Schlüsselposition innerhalb intrazellulärer Signaltransduktionswege und 
kontrollieren zahlreiche zelluläre Prozesse wie Wachstum, Stoffwechsel, 




Abb. 2. Signaltransduktionswege von Rezeptor-Tyrosinkinasen. Receptor-Tyrosinkinasen wie z.B. 
PDGFR (platelet-derived growth factor receptor), EGFR (epidermal growth factor receptor) und HER-2, 
enthalten eine extrazelluläre Rezeptor-Domäne, welche den Ligand bindet, und eine intrazelluläre 
Tyrosinkinase-Domäne (TK). Beim Binden eines Liganden dimerisieren die Rezeptoren, und ihre 
intrazelluläre Tyrosinkinase-Domänen werden aktiviert durch Phosphorylierung (P). Spezifische 
intrazelluläre Signalproteine werden darauf zu den aktivierten Rezeptoren rekrutiert und induzieren 
verschiedene Signaltransduktionswege. Zwei wichtige solche Signaltransduktionswege sind hier illustriert: 
der RAS/ERK Signalweg (links) und der PI3K/PKB Signalweg (rechts). Viele Proteine in diesen 
Signalwegen sind Proteinkinasen (z.B. RAF, MEK, ERK, PDK1, and PKB). Abhängig vom zellulären 
Zusammenhang und dem Ligand-Rezeptor-Paar, definieren diese Signaltransduktionswege 
verschiedenste physiologische Vorgänge wie Zellproliferation, Differenzierung, Migration oder Apoptose. 
Wird dieses abgestimmte Netzwerk durch Überexpression oder Genmutationen in wichtigen 
Signalmolekülen gestört, kann dies zu pathophysiologischen Veränderungen wie beispielsweise Krebs 
führen. (Abkürzungen: ERK: extracellular signal-regulated kinase; GAP: GTPase activating protein; MEK: 
Mitogen-activated protein kinase kinase; PDK1: 3-phosphoinositide-dependent kinase; PI3K: 
phosphoinositol 3-kinase; PIP3: phosphatidylinositol 3,4,5-trisphosphate; PKB: Protein kinase B; PTEN: 
Phosphatase and tensin homolog deleted on chromosome 10; SOS: son of sevenless). 
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In einer gesunden Zelle wird genau kontrolliert, wo und für wie lange eine 
solche Schlüsselposition-PTK aktiv ist. In Krebszellen ist die Aktivität von PTKs 
jedoch aufgrund von Mutationen oder anderen genetischen Veränderungen oft 
ausser Kontrolle. Die Konsequenz ist ein deregulierter Signaltransduktionsweg, 
der zur unkontrollierter Vermehrung der Zelle und zur Entstehung maligner 
Tumore führen kann. Im menschlichen Genom sind über 90 PTKs bekannt und 
viele von diesen sind bei Krebserkrankungen als Onkogene identifiziert worden 
(11). Das Verständnis der physiologischen Regulation von PTKs und der 
molekularen Mechanismen, welche eine onkogene Aktivierung von PTKs 
bewirken, ist ein wichtiges Anliegen der Grundlagenforschung- und die 
Voraussetzung für die Entwicklung von auf PTKs ausgerichteten 
Medikamenten. 
Zahlreiche niedermolekulare synthetische Wirkstoffe, welche PTKs hemmen, 
sind zur Zeit in der klinischen Entwicklung (Tabelle 1) (12,13). Das 
Krebsmedikament Gleevec (Glivec, imatinib mesylate, vorher STI571) ist ein 
beeindruckendes Beispiel für die erfolgreiche Therapie von Krebserkrankungen 
mit einem Tyrosinkinase-Hemmer (14). Gleevec wird für die Behandlung von 
chronisch myeloischer Leukämie (CML), einer Form von Blutkrebs, bei dem es 
zu exzessiver Vermehrung von weissen Blutkörperchen kommt, verewendet. 
Die leukämischen Zellen fast aller CLM Patienten weisen eine spezifische 
chromosomale Anomalie auf: eine reziproke Translokation von genomischer 
DNA zwischen den Chromosomen 9 und 22 (das dadurch veränderte 
Chromosom 22 ist bekannt als Philadelphia-Chromosom). Durch diese 
Umlagerung geraten auf Chromosom 22 zwei Gene - das Gen für die 
Proteintyrosinkinase Abelson (ABL) und das Gen für break-point cluster region 
(BCR) - in unmittelbare Nachbarschaft,. Als Produkt entsteht ein abnormes 
BCR-ABL Fusionsprotein mit erhöhter Tyrosinkinase-Aktivität, welches die 
Blutzellen dazu antreibt, sich ungebremst zu teilen. Diese Erkenntnisse aus der 
Grundlagenforschung, die BCR-ABL als zentralen Verursacher von CML 
identifizierten, lieferten der medizinischen Forschung einen molekularen 
Angriffspunkt für den nun gezielt ein Wirkstoff entworfen werden konnte. 
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Die Entwicklung des Medikaments Gleevec begann mit einem willkürlichen 
Screen für Tyrosinkinasehemmer. Dabei wurde eine erste geeignete Prototyp-
Substanz gefunden, die mehrere Tyrosinkinasen hemmte, darunter auch BCR-
ABL. Die gefundene Substanz wurde daraufhin durch chemische 
Veränderungen optimiert und daraus entstand der Wirkstoff Gleevec, ein 
spezifischer und potenter Hemmer von drei Kinasen, nämlich (BCR-)ABL, 
platelet-derived growth factor receptor (PDGFR) und c-KIT. Tests in 
Zellkulturen und Mausmodellen zeigten, dass Gleevec gezielt BCR-ABL 
induzierte Zellproliferation hemmen kann, ohne gesunde Zellen anzugreifen 
(15,16). Solche Experimente führten zu ersten klinischen Tests, welche die 
Wirksamkeit von Gleevec in der Behandlung von CML bestätigen konnten. In 
der Schweiz erhielt das Medikament schliesslich im April 2002 die Zulassung 
(17). Gleevec setzt neue Standards für Krebstherapien, die gezielt molekulare 
Signaltransduktionswege hemmen. Es wurde seither nicht nur für die 
Behandlung von CML gebraucht, sondern hat sich auch bei bestimmten 
anderen Krebserkrankungen, bei welchen ABL, c-KIT oder PDGFR eine 
kritische Rolle in der Pathogenese spielen, bewährt (18). 
Ein anderer Therapieansatz für einen zielgerichteten Angriff auf Krebszellen ist 
der Gebrauch von tumorspezifischen monoklonalen Antikörpern (19). Eine 
erste Herausforderung war hier die Entwicklung von verträglichen Antikörpern. 
Erste Antikörperkonstrukte stammten von Mäusen und verursachten teilweise 
starke Abstossungsreaktionen, da das menschliche Immunsystem diese als 
Fremdproteine erkennt. Durch die Entwicklung von genetisch veränderten 
Mäusen und anderen Technologien wurde es möglich, so genannte 
"humanisierte" Maus-Antikörper (zu 95% human und zu 5% murin) oder sogar 
vollständig humane Antikörper zu produzieren. Diese sind gut verträglich und 
für den therapeutischen Gebrauch geeignet. Im Gegensatz zu den oben 
erwähnten niedermolekularen synthetischen Wirkstoffen, können Antikörper 
jedoch nicht ins Zellinnere eindringen und deshalb nur solche tumorspezifische 
Zielproteine angreifen, die an der Zelloberfläche zugängliche sind. 
Therapeutische Antikörper haben einen einzigartigen Wirkungsmechanismus 
um Tumorzellen zu bekämpfen: sie mobilisieren körpereigene Abwehrzellen 
(natürliche Killerzellen) und Komplement-Proteine des Immunsystems, welche 
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vom gebundenen Antikörper dazu aktiviert werden die Tumorzelle abzutöten. In 
den Fällen, in denen das Zielprotein des Antikörpers ein Wachstumsfaktor-
Rezeptor ist, kann die Bindung des Antikörpers auch dessen 
Signaltransduktion blockieren oder verändern. Therapeutische Antikörper 
können zudem auch mit einer zytotoxischen Substanz (z.B. Radioisotope oder 
Toxine) gekoppelt werden, welche dann spezifisch dem Tumor zugeführt wird. 
 
Tabelle 2 
Therapeutische Antikörper in klinischer Entwicklung 
Antikörper Firma Zielkinase(n) 
Cetuximab (Erbitux, IMC-225) ImClone & Merck KgaA chimeric mAb against EGFR 
Herceptin (Trastuzumab) Genentech humanized mAb against HER-2 
Bevacizumab (Avastin, RhuMAb) Genentech humanized mAb against VEGF 
ABX-EGF Abgenix/Immunex humanized mAb against EGFR 
MDX-447 (EMD 82633) MEdarex humanized mAb against EGFR 
MV833 EORTC humanized mAb against VEGFR 
IMC-1C11 ImCone chimeric mAb against VEGFR 
CDP 860 Celltech humanized mAb against PDGFR 
 
Mehrere therapeutische Antikörper für verschiedene Krebserkrankungen 
befindend sich zur Zeit in klinischen Testphasen oder sind bereits zugelassen 
(Tabelle 2). Ein Beispiel für einen zugelassenen therapeutischen Antikörper, 
welcher ebenfalls eine PTK als Zielprotein hat, ist Herceptin (Trastuzumab). 
Herceptin wird in der Behandlung von Brustkrebs verwendet (20,21). Die 
Suche nach genetischen Veränderungen bei Brustkrebs, wies in den Tumoren 
von 25-30% der Patientinnen eine Überexpression des Wachstumsfaktor-
Rezeptors HER-2  (human epidermal growth factor receptor-2, ErbB2/Neu) 
nach. 
HER-2 ist ein Transmembranprotein mit einer extrazellulären Rezeptordomäne 
und einer intrazellulären Domäne mit Tyrosinkinase-Aktivität, durch welche 
Proliferationssignale an den Zellkern weitergeleitet werden können (Abb. 2). 
Überexpression von HER-2 führt in Zellen zu unkontrollierter Proliferation und 
ist bei Brustkrebs mit einem aggressiveren Tumorphänotyp und schlechteren 
Heilungschancen verbunden (22). 
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Es wurden deshalb viele Wirkstoffe entwickelt, die spezifisch auf HER-2 
ausgerichtet sind (Tabelle 1 und 2). Im Gegensatz zu BCR-ABL, ist HER-2 an 
der Zelloberfläche zugänglich und kann von therapeutischen Antikörpern 
erreicht werden. Herceptin, ein humanisierter monoklonaler Antikörper ist 
gegen die extrazelluläre Komponente des HER-2 Proteins gerichtet und zeigt 
effiziente Wirkung in der Behandlung von HER-2-überexprimierenden 
Brusttumoren. 
Zielgerichtete Therapien mit niedermolekularen synthetischen Hemmern oder 
therapeutischen Antikörpern haben ein grosses Potenzial für die 
Krebsbehandlung. Die Grundlagenforschung ist hier essenziell, um geeignete, 
mit der Krebsentstehung und –ausbreitung relevante Proteine zu identifizieren.  
 
Schlussfolgerung 
Innerhalb weniger Jahre wurden sowohl in der Diagnostik als auch im 
Therapiebereich grosse Fortschritte erzielt. Innovative Technologien und das 
zunehmend bessere Verständnis der molekularen Mechanismen, die der 
Entstehung eines Tumors zugrunde liegen, haben zur Entdeckung zahlreicher 
Tumormarker und molekularer Angriffspunkte für zielgerichtete therapeutische 
Wirkstoffe geführt. Eine neue Generation von antineoplastischen Wirkstoffen 
wurde entwickelt, welche die molekulare Basis von Krebs bekämpft. In den 
nächsten paar Jahren wird die Entwicklung hochspezifischer 
Krebsmedikamente voraussichtlich exponentiell ansteigen. PTKs und 
Signaltransduktions-Kinasen im Allgemeinen bilden eine wichtige Gruppe von 
Zielproteinen für spezifische Krebsmedikamente. Die klinische Wirksamkeit von 
Gleevec belegt eindrucksvoll den Nutzen und das Potenzial von 
Kinasehemmern in der Krebsbehandlung. Pharmazeutische Unternehmen 
fokussieren deshalb über ein Drittel ihrer Medikamentenforschung im Bereich 
der Krebsbehandlung auf Kinasehemmer. 
Die Behandlung mit hochspezifischen Krebsmedikamenten setzt jedoch eine 
sorgfältige Abklärung beim Patienten voraus. So muss geprüft werden, ob es 
wahrscheinlich ist, dass der betreffende Patient auf ein spezifisches 
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Medikament anspricht (oder schädigende Nebenwirkungen erleiden müsste). 
Eine solche Abklärung erfordert eine genetische und molekulare Analyse des 
Tumors und des Patienten. Ansatzweise ist dies zum Beispiel schon Praxis bei 
Herceptin: Das Medikament wird nur an solche Brustkrebs-Patientinnen 
abgegeben, bei welchen eine Überexpression von HER-2 in den Tumoren 
nachgewiesen wurde. Zukünftige Therapien könnten aus 
Kombinationsbehandlungen von mehreren zielgerichteten Medikamenten 
bestehen, die in Krebszellen komplementär den selben Signaltransduktionsweg 
blockieren. Fortgesetzte intensive Grundlagenforschung ist notwendig um die 
zellulären Signalnetzwerke, welche die Krebsentwicklung antreiben, weiter zu 
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